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CHAPTER 1 
INTRODUCTION 
1.1 Biology of the Nervous System 
The nervous system can be broken down into two parts, the central nervous system (CNS) 
which is composed of the brain and spinal cord, and the peripheral nervous system (PNS), 
consisting of nerves, ganglia, and the enteric nervous system which controls the gastrointestinal 
system (Chapman & Silkwood-Sherer 2000).  These two parts of the nervous system come 
together where nerves enter and exit the spinal cord and the brain, in spinal and cranial nerves 
respectively.  Spinal nerves enter and exit the spinal cord through openings between adjacent 
vertebrae and correspond roughly to segments of the vertebral column.  Figure 1.1.1 (A) shows 
how the spinal cord is encased in the vertebral column and where spinal nerves join the 
periphery.  Sensory information comes into the spinal cord from the periphery through nerves 
entering dorsal roots, while motor information leaves the spinal cord through nerves exiting 
ventral roots, sending motor signals to the periphery (Chapman & Silkwood-Sherer 2000; Squire 
et al 2008).  Spinal nerves handle sensory and motor information from the limbs and trunk.  
Figure 1.1.1 (B) shows the basic structure of the spinal cord and how dorsal and ventral roots 
leave the spinal cord and come together to form spinal nerves.  Cranial nerves, which emerge 
from the brain directly, deal with sensory and motor information from the head and neck 
(Chapman & Silkwood-Sherer 2000; McNeill 1997). 
 
 
 
 
 
2 
 
 
Figure 1.1.1  Overview of spinal cord structure and spinal nerves. 
A. The general structure of the spinal column.  The spinal cord is encased by the vertebrae with 
spinal nerves roughly corresponing to each vertebrae, entering the periphery through spaces 
between them.  B.  The general structure of the spinal cord.  Grey matter is found in the center 
of the spinal cord and consists of neuronal cell bodies that receive sensory information that 
enters through dorsal roots.  Motor information exits the spinal cord through ventral roots.  White 
matter surrounds the grey matter and consists of tracts of myelinated axons that send 
information up and down the spinal cord. 
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Both the CNS and the PNS are composed of a variety of cell types that work cooperatively 
to maintain homeostasis and allow for intercellular communication through electrochemical 
signaling.  There are two main types of cells that make up the nervous system, neurons and 
glial cells. 
Neurons are polarized cells that can be divided into distinct sub cellular regions, each of 
which carries out a different set of functions (Cooper et al 2003; Nestler et al 2001; Squire et al 
2008).  They come in a variety of shapes and sizes but can be broken down into a basic 
morphology consisting of three regions:  1) the soma (cell body), containing the nucleus and 
cytoplasmic organelles; 2) dendrites, which branch from the soma and vary in size, shape, and 
number depending upon the type of neuron; and 3) a single axon, which is rich in 
neurofilaments, extending a distance from the cell body to make contacts with other neurons 
(Cooper et al 2003; Nestler et al 2001; Squire et al 2008).  These three basic compartments of a 
neuron can be seen in Figure 1.1.2.  Dendrites, neuronal cell bodies, and unmyelinated axons 
make up grey matter.  
Dendrites receive electrochemical signals from other neurons, which are integrated at the 
cell body and passed down the axon in the form of action potentials to signal other neurons or 
organs.  In order to send these signals, neurons express a variety of ion channels and pumps to 
maintain an electrochemical gradient across the membrane.  They also express a variety of 
neurotransmitter receptors coupled to ion channels, which alter the electrochemical gradient for 
signaling.  The connections between pre- and post-synaptic neurons are dynamic, with the 
formation of new synapses and the removal of unused synapses occurring constantly.  
Maintaining and resetting electrochemical gradients after an action potential, and synaptic 
restructuring both require a significant amount of energy which is provided by supporting cells.   
Glial cells are a broad category of cells that serve structural and supportive functions in the 
nervous system.  In the CNS there are three main types of glia, oligodendrocytes, astrocytes,  
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Figure 1.1.2 Basic cellular interactions in the central nervous system. 
There is a complex set of interactions that occur between neurons, astrocytes, and 
oligodendrocytes in the central nervous system.  Astrocytes can make several connections with 
neurons - at the soma, at nodes of Ranvier (between myelin sheaths), and at synapses – while 
also making connections with blood vessels and other astrocytes.  Oligodendrocytes (OL) send 
out several processes to myelinate multiple axons.   
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and microglia, whereas the PNS has only one major type of glial cell, Schwann cells (Chapman 
& Silkwood-Sherer 2000; Squire et al 2008).  Both oligodendrocytes and Schwann cells 
synthesize myelin, a fatty substance that wraps around axons to accelerate the propagation of 
action potentials.  Although they are similar in function, oligodendrocytes and Schwann cells 
have very different morphological features.  Oligodendrocytes have a cell body that gives rise to 
several processes, each of which is composed of a long, extremely thin layer of plasma 
membrane that wraps around a portion of an axon to produce myelin.  A single oligodendrocyte 
produces and maintains several myelin sheaths, myelinating segments of multiple axons.  
Figure 1.1.2 illustrates an oligodendrocyte myelinating an axon in the CNS.  Schwann cells, on 
the other hand, are very thin, pancake-shaped cells that wrap their entire cell body around a 
single axon segment to produce myelin.  As a result, it takes multiple Schwann cells to 
myelinate a single axon in the PNS.  Axons are myelinated in small segments, with gaps called 
nodes of Ranvier between segments of myelin (Chapman & Silkwood-Sherer 2000; Nestler et al 
2001; Squire et al 2008).   Myelinated axons have a characteristic white color and make up the 
portion of the CNS referred to as white matter.   
Astrocytes and microglia are two very different types of cells that also serve supporting 
roles in the CNS.  In most areas of the brain, astrocytes make up 20-50% of the volume (Squire 
et al 2008).  They are star-shaped cells, and like oligodendrocytes, extend several processes 
from their cell bodies.  These processes branch out and serve a variety of structural and 
supportive functions throughout the CNS, and are extremely important in maintaining 
homeostasis and supporting neuron function (Squire et al 2008).  They help form barriers within 
the CNS, the glia limitans (Squire et al 2008) as well as the blood-brain, blood-cerebrospinal 
fluid, and blood-spinal cord barriers (BBB, BCSFB, and BSCB respectively), providing protection 
from pathogens and other types of insults (Abbott 2002; Engelhardt & Coisne 2011).  They also 
extend processes to nodes of Ranvier, synapses, dendrites, and neuronal cell bodies where 
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they help to buffer ion fluxes during action potentials, remove excess neurotransmitters, and 
provide much needed metabolic intermediates to active neurons (Fields & Stevens-Graham 
2002; Prebil et al 2011; Squire et al 2008; Turner & Adamson 2011).  Astrocytes are connected 
to one another by gap junctions, which allows for the movement of small molecules and ions 
across the brain parenchyma.  Figure 1.1.2 shows some of the interactions that astrocytes can 
make within the CNS.  Astrocytes also produce growth factors and extracellular matrix proteins 
which act to regulate survival, proliferation, differentiation, and the morphology of other cell 
types in the nervous system.  In addition, astrocytes have the potential to become activated and 
produce cytokines during injury and infection playing an immunological role as well (Dong & 
Benveniste 2001; Squire et al 2008). 
Microglia are considered to be the resident macrophages of the CNS, which has 
traditionally been thought of as an immunologically privileged tissue (Murphy et al 2008).  The 
physical barriers produced by astrocytes make it difficult for antibodies and peripheral immune 
cells, such as natural killer cells, T-cells, and macrophages, to infiltrate the CNS to fight 
infection.  Microglia, which develop from monocytes derived from bone-marrow, have the ability 
to phagocytose apoptotic cells (Murphy et al 2008; Nicklin et al 2009) and provide the first line of 
defense during infection.  In the case of injury or infection, microglia become reactive, changing 
their morphology and upregulating molecules involved in immune responses. They can divide 
and behave like macrophages, secrete cytokines and growth factors, and present antigens to T-
cells (Murphy et al 2008; Squire et al 2008; Town et al 2005).  Microglia react quickly in 
response to alterations in their environment and can act in conjunction with astrocytes to regain 
homeostasis.          
In the healthy nervous system, there is a delicate interplay between all of the various cell 
types which allows for rapid transmission of signals between neurons and a quick response of 
the person to environmental factors.  Astrocytes maintain barriers which separate the CNS from 
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the circulating blood, selectively allowing the entry of nutrients and peripheral immune cells and 
the exit of waste, while blocking the entry of pathogens (Abbott 2002; Engelhardt & Coisne 
2011; Fields & Stevens-Graham 2002; Redzic 2011; Squire et al 2008).  Neurons with 
myelinated axons communicate quickly with each other through electrochemical signals, which 
are regulated by astrocytes.  During neuronal signaling, astrocytes maintain ion homeostasis at 
the nodes of Ranvier and at synapses, where they also aid in the removal of excess 
neurotransmitter to prevent over-signaling (Nestler et al 2001; Squire et al 2008).  They are 
capable of interacting with neurons by expressing neurotransmitter receptors that detect signals 
from neurons, allowing them to adjust their metabolism accordingly to keep active neurons 
functioning efficiently (Nestler et al 2001; Prebil et al 2011).  Astrocytes, with the help of 
microglia, monitor the environment and respond accordingly to maintain homeostasis.  Neurons 
are delicate cells and when this homeostasis is disrupted by chemical insult, pathogen 
infiltration, or other injuries, a cascade of events can occur that result in neuron death, 
inflammation, and overall dysfunction within the nervous system. 
1.2 Amyotrophic Lateral Sclerosis 
1.2.1 Amyotrophic Lateral Sclerosis in General 
Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease in which 
the primary target is the motor neuron.  Amyotrophy refers to the atrophy of skeletal muscle 
fibers that occurs when motor neurons die and muscle innervation is lost.  Lateral sclerosis 
refers to the degeneration of neurons in the anterior horn and lateral corticospinal tracts and the 
gliosis that accompanies this (Wijesekera & Leigh 2009).  The disease is commonly referred to 
as Lou Gehrig’s disease after New York Yankee, Lou Gherig, who died of the disease in 1941. 
The axons of motor neurons gradually die back from the skeletal muscles they innervate, 
leading to a loss of neuromuscular connections and muscle atrophy.  Patients experience 
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muscle weakness which rapidly turns into paralysis, and eventually succumb to respiratory 
complications within one to five years of disease onset (Bruijn et al 2004).    
ALS is a relatively rare disease, with an overall incidence of about 2 in 100,000 people per 
year (Alonso et al 2009; Logroscino et al 2008) and a prevalence of about 5 in 100,000 people 
(Haverkamp et al 1995).  The low incidence rate makes it difficult to collect epidemiological data 
from large numbers of patients, but with better diagnostic and communication technologies, data 
collection is improving.  The incidence of the disease increases after age 40 and peaks 
somewhere between the late 60s and early 70s, after which the incidence seems to decline 
(Logroscino et al 2008).  The typical age of onset of ALS is between 50 and 60 years of age 
(Bruijn et al 2004), but there are some rare forms with juvenile onset (Beghi et al 2007).  There 
tends to be a slight male prevalence in the disease, with a male to female ratio of about 3:2 
(Wijesekera & Leigh 2009).  This gender difference decreases with increasing age and 
approaches a ratio of 1:1 after age 60 (Haverkamp et al 1995). 
The phenotypic characterization of ALS is inconsistent across patients (Logroscino et al 
2008).  The symptoms of the disease vary, depending upon the area in which motor neurons 
are affected.  Most patients, about 75%, develop early symptoms in the limbs in what is referred 
to as limb or spinal onset ALS.  This can begin in the arms or legs, with the most common 
symptoms being muscle weakness and wasting.  Involuntary muscle twitching and cramping 
can occur prior to muscle weakness (Wijesekera & Leigh 2009).  When symptoms begin in the 
leg patients may experience some problems walking, whereas patients with arm symptoms 
have difficulty performing tasks requiring manual dexterity.  Typically symptom onset is 
asymmetrical, affecting only one side of the body, however most patients eventually experience 
symptoms in other limbs (Wijesekera & Leigh 2009).  The remaining 25% of patients have 
symptom onset occurring in the head or neck, which is referred to as bulbar onset ALS.  These 
symptoms typically present themselves as difficulty swallowing or speaking, due to problems 
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with tongue mobility, and may progress to include facial weakness (Wijesekera & Leigh 2009).  
Patients with bulbar onset ALS may experience limb symptoms simultaneously, and most 
patients with limb onset eventually develop bulbar symptoms as well.  It is important to note that 
there is significant heterogeneity in the symptoms of ALS (Beghi et al 2007), which makes the 
disease difficult to diagnose. 
 Patients with ALS suffer from degeneration of both upper and lower motor neurons.  
Upper motor neurons are neurons whose cell bodies reside in the primary motor cortex of the 
brain, sending their axons down the spinal cord.  Lower motor neurons have axons that project 
into the ventral root and through a spinal nerve to innervate skeletal muscle, with their cell 
bodies remaining in the ventral horn of the spinal cord (Chapman & Silkwood-Sherer 2000).  
Upper motor neurons in the primary cortex send signals down the spinal cord and synapse on 
lower motor neurons, which then send signals to skeletal muscles in the periphery (Chapman & 
Silkwood-Sherer 2000).  When either type of motor neuron is affected by the disease, there is a 
loss of trophic factor signaling between synapsing neurons, which can result in dying back of all 
of the motor neurons in the pathway leading to paralysis. 
1.2.2 Causes of ALS 
ALS is a heterogeneous disorder with a variety of factors, both genetic and 
environmental, believed to play a role in pathogenesis of the disease.  Patients with ALS can be 
broken down into two groups, those with a hereditary form of ALS, Familial ALS (FALS), and 
those with no known family history of ALS, referred to as Sporadic ALS (SALS).  SALS is much 
more common, accounting for the majority of ALS cases, while FALS accounts for only 5-10% 
of all cases of the disease (Bruijn et al 2004; Wijesekera & Leigh 2009).    The pathological and 
clinical characteristics of FALS and SALS are strikingly similar, making it very difficult to 
distinguish between the two (Beghi et al 2007).  Genetic forms of ALS show a great deal of 
heterogeneity, with a variety of gene mutations implicated in the cause.   
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Mutations in 13 genes have been found to be associated with FALS (Table 1.2.2.1).  All 
of these genes are inherited in an autosomal dominant fashion, with the exception of three that 
are recessive and two with unknown inheritance patterns. The  genetic loci of all of these 
mutations have been determined, however only seven gene products have been positively 
identified in ALS: 1) superoxide dismutase-1 (SOD1); 2) alsin; 3) senataxin (SETX); 4) vesicle 
associated protein B (VAPB); 5) angiogenin (ANG); 6) TAR-DNA binding protein-43 (TDP43); 
and 7) fused in sarcoma (FUS) (Beghi et al 2007; Belzil et al 2009; Bruijn et al 2004; Pasinelli & 
Brown 2006; Wijesekera & Leigh 2009).  Two genes, with unknown products, produce a form of 
ALS that is associated with frontotemporal dementia (FTD) (Beghi et al 2007; Wijesekera & 
Leigh 2009).  Mutations in chromatin-modifying protein 2B (CHMP2B; also called charged 
multivesicular body protein 2B) have been found in two ALS patients and seem to be primarily 
associated with a form of FTD accompanied by ALS, however more research must be done in 
order to characterize the  inheritance pattern of these mutations and their involvement in the 
disease (Beghi et al 2007; Parkinson et al 2006).  Mutations in dynactin (DCTN1), a protein 
involved in axonal transport, have been associated with a form of lower motor neuron disease 
and their presence in the genome may increase a person’s susceptibility to motor neuron 
degeneration and the development of ALS (Beghi et al 2007; Wijesekera & Leigh 2009).  
Another axonal protein, microtubule-associated protein tau (MAPT), is commonly associated 
with FTD and may also increase the risk of developing ALS.    
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Table 1.2.2.1 List of genetic mutations associated with ALS 
 
 
AD = autosomal dominant 
AR = autosomal recessive 
* The SOD1 D90A mutation is the only recessive mutation (Al-Chalabi et al 1998). 
GEF = guanine nucleotide exchange factor 
ESCRT-III = endosomal sorting complex required for transport-III 
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Of the seven positively identified genes involved in FALS, superoxide dismutase-1 
(SOD1) is probably the most well studied protein, although its involvement in neurodegeneration 
is still a mystery.  SOD1 is a ubiquitously expressed copper/zinc-binding protein that is involved 
in scavenging reactive oxygen species (ROS) produced during oxidative phosphorylation.  
Superoxide dismutase catalyzes the reaction between two molecules of superoxide and two 
protons to produce hydrogen peroxide and oxygen, preventing oxidative damage within the cell 
(Nelson & Cox 2008).  Approximately 15-20% of FALS cases are associated with mutations in 
the gene encoding SOD1, accounting for only a small portion of all cases of ALS (Beghi et al 
2007; Bruijn et al 2004; Orrell et al 1996; Wijesekera & Leigh 2009; Zoccolella et al 2006).  Over 
100 different ALS-associated mutations have been found in the gene encoding SOD1, most of 
which are autosomal dominant (Beghi et al 2007; Wijesekera & Leigh 2009).  These mutations 
result in a variety of alterations to the protein, most of which are single-amino acid substitutions 
that may alter the protein structure to decrease metal binding and increase protein aggregation 
(Hayward et al 2002; Johnston et al 2000; Rumfeldt et al 2009; Shinder et al 2001; Tiwari & 
Hayward 2005).  Figure 1.2.2.1 shows the amino acid sequence of the SOD1 protein, with the 
amino acids that can undergo mutations highlighted in green.  The enzyme can be mutated in 
several locations throughout its sequence, including introns (Turner & Talbot 2008).  The 
mechanism by which mutations in the SOD1 protein lead to motor neuron death remain unclear, 
since the enzyme appears to retain its normal function with most mutations, but are believed to 
involve a toxic gain of function (Harraz et al 2008; Mali & Zisapels 2008) and the combined 
effects of its expression in neurons, microglia, and astrocytes (Boillee et al 2006; Yamanaka et 
al 2008a).   
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Figure 1.2.2.1 Amino acid sequence of the SOD1 protein. 
SOD1 mRNA consists of five exons and four introns and the final protein-product is 153 amino 
acids in length.  The protein can undergo a wide variety of mutations and the amino acids that 
can be mutated are highlighted in green with the substitutions listed below them.  Amino acids 
involved in Cu/Zn binding are indicated with red lines and the cysteine residues involved in 
disulfide bond formation are indicated with blue lines.  Introns and the 3’ untranslated region are 
shown in purple and the asterisks indicate those that can contain mutations.   
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The remaining six genes involved in ALS encode an array of proteins involved in a 
variety of cellular processes.  Alsin, a protein containing three guanine nucleotide exchange 
factor domains (Yang et al 2001), is a cytosolic protein capable of associating with membrane 
structures believed to be involved with actin cytoskeleton remodeling and vesicular trafficking 
(Topp et al 2004).  Senataxin, which has been linked to an early onset form of ALS (Chance et 
al 1998), was discovered to be the ortholog of a yeast RNA helicase (Moreira et al 2004) and is 
believed to play a role in RNA processing in humans (Beghi et al 2007).  Vesicle associated 
protein B (VAPB) is an integral membrane protein found on the membrane of the endoplasmic 
reticulum, which is believed to exert its negative effects in ALS by promoting protein aggregation 
and ER stress  (Langou et al 2010; Moumen et al 2011; Nachreiner et al 2010).  Angiogenin is a 
protein involved in angiogenesis that plays a variety of roles within the cell.  Under normal 
conditions angiogenin acts as a ribonuclease, regulating rRNA transcription (Li & Hu 2010), 
attenuates apoptotic signals (Li et al 2012), and can bind to actin to alter polymerization 
(Pyatibratov & Kostyukova 2012; Pyatibratov et al 2010).  TDP43 is a DNA/RNA-binding protein 
found in glia and neurons (Swarup et al 2011b) that plays a role in the maintenance of 
autophagy (Bose et al 2011), regulation of splicing RNA transcripts and the production of micro 
RNAs (Lee et al 2012a), and may associate with mutant forms of VAPB in ALS (Suzuki & 
Matsuoka 2011).    Like TDP43, FUS (also called TLS for translocated in liposarcoma) is also a 
DNA/RNA-binding protein.  It is found primarily in the nucleus of normal cells but is transported 
to dendritic spines and is involved in transcription, splicing, and mRNA transport from the 
nucleus to the cytoplasm (Fujii et al 2005; Wang et al 2008; Yang et al 1998; Zinszner et al 
1997). Despite its rare occurrence and the variety of genetic factors involved, studies of FALS 
have offered insight into the molecular mechanisms underlying motor neuron death and 
provided potential therapeutic targets and biomarkers of the disease.   
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FALS research has been able to shed some light on SALS, as some of the mutations 
involved in hereditary forms of the disease have also been identified in sporadic ALS patients.  
Table 1.2.2.1 lists the cellular function of the proteins SOD1, ANG, TDP43, and FUS that have 
been found to undergo mutations and become involved in some cases of SALS.  In addition to 
these, mutations in APEX1 (Hayward et al 1999), HFE (Goodall et al 2005; He et al 2011; 
Sutedja et al 2007a; Wang et al 2004b), PON (Cronin et al 2007; Slowik et al 2006; Ticozzi et al 
2010; Valdmanis et al 2008), PRPH (Corrado et al 2011; Gros-Louis et al 2004; Leung et al 
2004), and PGRN (Sleegers et al 2008; Talbot & Ansorge 2006) have also been found to be 
associated with SALS (Table 1.2.2.2).  It is unknown as to whether or not these mutations cause 
the disease, or if their presence increases the risk of developing ALS (Schymick et al 2007).  
The association of certain genes with SALS provides some hope that there may be a genetic 
component to sporadic forms of the disease.   
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Table 1.2.2.2 List of genes found to have SALS-associated mutations. 
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There are a large number of genetic mutations associated with FALS that have the 
ability to alter a variety of proteins with roles in a multitude of cellular processes which lead to a 
significant amount of heterogeneity in the disease.  To complicate matters further, the 
inheritance patterns of FALS genes are not strictly followed in all cases and multiple mutations 
can occur within the same individual (Andersen 2006; Andersen et al 1996; Orrell et al 1996).  
This had led to the belief that ALS develops through a complex interaction between genetic and 
environmental factors. 
  Since most cases of ALS are sporadic and have no known genetic component, exposure 
to environmental toxins and head injuries are believed to be potential risk factors for developing 
ALS.  Examining patients’ occupations has typically been used as a way to evaluate exposure 
to toxins that may be associated with development of the disease.  Workplace exposure to lead, 
with elevated lead levels found in bone and blood of ALS patients, has been suggested to play a 
role in the etiology of ALS (Kamel et al 2005; Kamel et al 2002).  People exposed to other 
chemicals commonly associated with construction work, such as paint strippers, lubricating oils, 
coolants, metals and metal fumes, also show an increased risk in developing ALS (Binazzi et al 
2009; Fang et al 2009).  One study conducted in Italy showed that professional soccer players 
had an increased risk of developing the disease (Chio et al 2005), suggesting that head injuries 
lead to an increased risk of ALS.  Patients who had experienced multiple head injuries or who 
had been injured within a ten year period prior to diagnosis were found to have a threefold 
higher risk of developing ALS.  It was also found that people with head injuries were more likely 
to have bulbar onset ALS and an earlier age of diagnosis (Chen et al 2007).      
Most often the types of studies used to evaluate chemical exposures and injuries 
associated with ALS involve the use of questionnaires, which also take into consideration other 
means of exposure to toxins, such as smoking and diet.  Several studies have found that 
smokers have an increased risk in developing ALS (Binazzi et al 2009; Nelson et al 2000; 
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Sutedja et al 2007b; Weisskopf et al 2004).  One study determined that female smokers have a 
greater risk of developing ALS than male smokers (Weisskopf et al 2004), while another study 
detected a link between cigarette smoking and bulbar onset ALS (Binazzi et al 2009).  
Interestingly, an interaction between cigarette smoking and chemical exposure was also 
observed (Fang et al 2009).  This increased risk in ALS with smoking could be directly due to 
the chemicals found within cigarettes, or chemicals in the cigarettes could induce the expression 
of metabolic enzymes that alter metabolism in such a way that smokers become more sensitive 
to other chemicals.    With respect to diet, it was found that bulbar onset patients showed an 
increase in the consumption of cold cuts and a decrease in the consumption of vegetables 
(Binazzi et al 2009).  In a small population of people in Guam, where the incidence of ALS is 
higher than that of Europe and North America, β-methyl-amino-L-alanine is found in low levels 
in the diet and has been found in brain tissue of ALS patients and is believed to play a role in 
the disease (Banack & Murch 2009).    
1.2.3 Molecular Mechanisms Underlying ALS Pathogenesis 
Genetic analyses of patients with both hereditary and sporadic forms of ALS have 
identified a wide variety of genes that can be involved in the development of the disease.  These 
genes encode proteins that are involved in several different cellular processes and implicate an 
array of cellular mechanisms that may become dysfunctional during the disease.  
Understanding the molecular mechanisms behind the disease is the primary goal of ALS 
research, as it will aid in the development of pharmacological treatments and possibly uncover 
biomarkers that may allow for early detection of the disease.  There are believed to be six major 
mechanisms underlying ALS pathogenesis:  glutamate excitotoxicity; mitochondrial dysfunction 
and oxidative stress; dysfunctional protein quality control mechanisms; aberrant RNA 
processing; neurotrophic factor dysregulation; and neuroinflammation.  These mechanisms 
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overlap to some extent and involve several different cell types.  Experimental evidence suggests 
that these mechanisms may converge at some point to initiate the programmed cell death 
pathway, as the final mechanism of cell death seems to resemble apoptosis. 
1.2.3.1 Glutamate Excitotoxicity   
The amino acid glutamate acts as the major excitatory neurotransmitter in the central 
nervous system where it is released from electrically stimulated neurons in a calcium-dependent 
fashion (Cooper et al 2003; Nestler et al 2001; Squire et al 2008).  Upon stimulation, glutamate 
is released from the pre-synaptic nerve terminal into the synaptic cleft where it:  1) stimulates 
the post-synaptic neuron by binding to glutamate receptors; 2) is taken up by astrocytes; and 3) 
may be taken back up by the pre-synaptic neuron for recycling  (Figure 1.2.3.1).  In healthy 
individuals, glutamate binds to a variety of glutamate receptors on post-synaptic neurons, some 
of which are coupled to ion channels that when stimulated, allow for an influx of calcium to 
induce an action potential.  Since overstimulation of these receptors can lead to a massive influx 
of calcium resulting in apoptosis, there are mechanisms in place to remove glutamate from the 
synapse.  Both pre-synaptic neurons and astrocytes express excitatory amino acid transporters 
(EAATs) which remove excess glutamate from the synapse.  Glutamate taken up by pre-
synaptic neurons can be repackaged into vesicles for later use or converted to aspartate by the 
mitochondrial enzyme aspartate transaminase (Nestler et al 2001).  The majority of the 
glutamate in the synapse is taken up by astrocytes where it is converted to glutamine by the 
enzyme glutamine synthetase (GS) (Cooper et al 2003; Nestler et al 2001; Squire et al 2008).  
GS plays an extremely important role in the central nervous system as it not only detoxifies 
glutamate, but it removes ammonia as well.  The glutamine produced in astrocytes is then 
passed back to neurons where it is converted to glutamate by mitochondrial glutaminase and 
then packaged into vesicles for later use.  This process of astrocytic removal of glutamate, its 
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conversion to glutamine by GS, and the transport of glutamine back to neurons is referred to as 
the glutamate-glutamine cycle and its importance in the CNS is illustrated in Figure 1.2.3.1. 
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Figure 1.2.3.1.1 Glutamatergic signaling in the central nervous system. 
Once released from the pre-synaptic neuron, there are three possible fates of glutamate in the 
synapse.  A.  Glutamate can interact with ionotropic glutamate receptors (NMDA, AMPA, or 
kainate receptors) on the post-synaptic neuron, which are coupled to ion channels and allow 
calcium to flow into the cell.  Glutamate can also bind to metabotropic receptors which are 
coupled to g-proteins and produce their effects more slowly.  B.  Glutamate can be taken up by 
the pre-synaptic cell where it is recycled for subsequent action potentials.  C.  The majority of 
the glutamate is taken up by astrocytes, where glutamine synthetase (GS) converts it to 
glutamine.  The glutamine is then transported back to the pre-synaptic neuron through SN1 
transporters where it is converted back to glutamate by mitochondrial glutaminase and 
packaged into vesicles. 
 
 
EAAT = excitatory amino acid transporter 
SN1 = glutamine transporter 
AMPA = α-amino-3-hydroxy-5-methyl-4-isoxazole 
NMDA = N-methyl-D-aspartate 
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Experimental evidence suggests that the glutamate-glutamine cycle is disrupted in ALS.  
Glutamate levels were found to be elevated in the cerebrospinal fluid (CSF) of ALS patients 
(Rothstein et al 1990) and glutamate signaling defects were found in neuronal tissue from 
patients who had died of ALS (Rothstein et al 1992).  Western blot analysis of post-mortem 
motor cortex tissue  indicated that the major astrocytic glutamate transporter EAAT2 was 
significantly decreased in patients with ALS, and that a splice variant of this transporter, 
EAAT2b, was increased when compared to controls (Maragakis et al 2004).  
Immunohistochemical analysis of lumbar spinal cord samples from patients with motor neuron 
disease showed a decrease in EAAT2 density in the grey matter (Fray et al 1998).  In a rat 
model of ALS, immunohistochemical analysis of spinal cord sections showed a focal loss of 
EAAT2 in the ventral horn region that coincided with gliosis but occurred prior to motor neuron 
degeneration.  As the disease progressed the loss of EAAT2 and reactive gliosis increased, 
suggesting that these processes worsen with disease progression (Howland et al 2002).   
Studies in which excitatory amino acid transporters were selectively knocked down, in 
both cell culture and animal models, showed that glutamate uptake was impaired and that 
animals developed a motor neuron syndrome that resulted in paralysis similar to ALS (Rothstein 
et al 1996).  In mouse models of ALS, it was shown that overexpression of EAAT2 was able to 
slow motor neuron loss and grip strength decline (Guo et al 2003) and treatment with drugs that 
increase the expression of glutamate transporters also slow disease progression and increase 
survival (Rothstein et al 1995).  Taken together, these results suggest that there may be a 
decrease in glutamate uptake by astrocytes due to down-regulation of transporters which in turn 
leads to an increase in glutamate in the CSF.  Excessive glutamate in the synapse may lead to 
increased calcium influx into motor neurons, resulting in caspase activation and apoptosis.  
Caspase activation has been observed in mouse models of ALS (Li et al 2000; Pasinelli et al 
2000), lending support for this method of motor neuron death.  However, the order in which 
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these mechanisms occur during pathogenesis remains unclear as the dysfunction of other 
cellular mechanisms may play a role in glutamate transporter expression.  For example, 
analysis of post-mortem spinal cord tissue collected from ALS patients indicated that mRNA 
levels of EAAT2 were normal (Bristol & Rothstein 1996) and aberrant EAAT2 mRNA has been 
detected in affected areas in ALS patients (Lin et al 1998), indicating that dysfunctional mRNA 
processing may lead to a decrease in transporter expression.  Caspase-3 has also been shown 
to cleave and inhibit EAAT2 function (Boston-Howes et al 2006), suggesting that decreased 
transporter function may occur secondary to excitotoxic mechanisms.      
1.2.3.2 Mitochondrial Dysfunction and Oxidative Stress   
Mitochondria are mobile, plastic organelles that occupy a significant volume of 
eukaryotic cells.  They are capable of associating with microtubules, which carry them to 
different locations within a cell and allow the mitochondria to take on unique distributions and 
orientations depending upon the cell type (Alberts et al 2002).  Mitochondria play many roles 
within the cell, but they primarily function as energy producing organelles.  Glycolysis alone is 
not sufficient to meet the energy demands of most animals and the pyruvate produced is taken 
up by the mitochondria (along with the carbon skeletons of fatty acids and amino acids) where it 
is oxidized by molecular oxygen (Alberts et al 2002; Nelson & Cox 2008).  High energy 
electrons are produced which drive the electron transport chain to form the ATP that fuels the 
cell (Nelson & Cox 2008).  If not channeled properly these electrons can become involved in 
aberrant reactions and damage cellular components, but healthy cells have mechanisms in 
place to help prevent oxidative damage.   
In addition to their role as energy producers, mitochondria play an extensive role in 
calcium signaling and homeostasis.  Mitochondria can store calcium and take it up from the 
cytosol to maintain intracellular calcium concentrations and modulate calcium signaling.  They 
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can also interact directly with endoplasmic reticulum (ER) membranes through a structure called 
the mitochondria-associated ER membrane (MAM), which is involved in phospholipid exchange 
(Vance 1990), may play a role in the secretory pathway (Rusinol et al 1994), and also plays a 
role in calcium signaling (Rizzuto et al 2009).  Through this interaction the ER can send calcium 
directly to the mitochondria to stimulate oxidative metabolism, allowing the cell to integrate 
signal transduction and metabolic pathways (Hayashi et al 2009).  Regardless of how the 
calcium enters mitochondria, it can increase the production of ROS and once a calcium 
threshold is surpassed the intrinsic apoptotic pathway can be initiated resulting in cell death 
(Green 1998).   
In patients with ALS, as well as in cell culture and animal models of the disease, 
experimental evidence suggests that at some point during disease pathogenesis mitochondria 
become dysfunctional and cells experience and increase in oxidative stress.  In mouse models 
of ALS morphological abnormalities in motor neuron mitochondria, such as swelling and 
vacuolization, can be seen as early as two weeks of age, well before symptom onset (Bendotti 
et al 2001).  These abnormal mitochondria can be found in the dendrites and axons of motor 
neurons and appear to be undergoing degeneration (Wong et al 1995).  Mitochondrial 
vacuolization is associated with an increase in immunoreactivity for mutatant SOD1 (Bendotti et 
al 2001; Jaarsma et al 2000), which appears to associate with the outer mitochondrial 
membrane, the intermembrane space and the matrix (Higgins et al 2003; Mattiazzi et al 2002; 
Vijayvergiya et al 2005).  Mitochondrial accumulation in the axon terminals of motor neurons is 
associated with an increase in ROS and RNS, and these mitochondrial show an accumulation 
of nitrated proteins (Martin et al 2007).  Single-stranded, followed by double-stranded, DNA 
breaks in nuclear and mitochondrial DNA accompany morphological changes in mitochondria 
(Martin et al 2007).  Abnormalities in mitochondrial DNA, such as alterations in gene copy 
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number as well as gene deletions, have been seen in spinal motor neurons of ALS patients 
(Keeney & Bennett 2010).   
In addition to morphological changes in mitochondria, alterations in mitochondrial 
proteins and enzyme activities have been associated with disease pathogenesis.  Mitochondria 
isolated from the brain and spinal cord of mouse models of ALS show an overall decrease in 
state three respiration, suggesting a decrease in the rate at which oxygen can be utilized for 
ATP synthesis in symptomatic animals (Mattiazzi et al 2002).  While mitochondria isolated from 
the spinal cords of ALS patients showed an overall decrease in activity of all of the enzymes of 
the respiratory chain (Wiedemann et al 2002).  When oxygen consumed by the whole animal 
was measured in mouse models, there was an increase in the total oxygen consumption as well 
as energy expenditure at rest, which was attributed to greater energy usage by the muscle 
(Dupuis et al 2004).  These results were preceded by alterations in leptin, insulin, and 
corticosterone signaling prior to the development of symptoms (Dupuis et al 2004).  In addition, 
presymptomatic mice have shown depletion of ATP in the cortex along with impaired glucose 
utilization in bulbospinal and corticospinal motor tracts (Browne et al 2006).  Mutant SOD1 
protein has been shown to interact with cytosolic malate dehydrogenase, an enzyme involved in 
the malate-aspartate shuttle important for transporting electrons produced during glycolysis 
across the mitochondrial inner membrane, in neuronal cell culture experiments (Mali & Zisapels 
2008).  Neuron-like cells stably expressing mutant SOD1 have shown an overall decrease in 
glutathione levels (D'Alessandro et al 2011), with a corresponding decrease in mitochondrial 
glutathione pools which make these cells more susceptible to oxidative stress (Muyderman et al 
2009).  In post-mortem brain tissue of SALS patients, an increase in the level of protein carbonyl 
groups was found suggesting an increase in oxidative damage to proteins (Bowling et al 1993).  
Similar results were found in mouse models of the disease, in which increased levels of 
oxidative damage were found in mitochondrial proteins and lipids (Mattiazzi et al 2002).   
26 
 
 
It is important to note that these alterations to mitochondria and mitochondrial proteins in 
ALS are not limited to motor neurons, but have been seen in liver, lymphocytes, muscle, and 
astrocytes.  Hepatocytes from liver biopsy samples collected from ALS patients have shown 
defects in mitochondrial morphology, exhibiting enlarged mitochondria containing protein 
inclusions, that were associated with liver dysfunction (Nakano et al 1987).  Mouse models of 
the disease also show a decrease in liver mitochondrial respiration and oxidative damage to 
proteins and lipids within the mitochondria at the time of symptom onset (Mattiazzi et al 2002).  
In circulating lymphocytes isolated from SALS patients, mitochondria showed a decrease in 
complex I activity and an increase in free cytosolic calcium levels (Curti et al 1996).  
Abnormalities in muscle mitochondrial DNA from SALS patients have been associated with 
decreased activity in NADH dehydrogenase and cytochrome c oxidase (Vielhaber et al 2000).  
In astrocytes isolated from a rat model of ALS, mitochondria showed defective respiratory 
function, a decrease in membrane potential, and an increase in ROS production and protein 
nitration.  When these cells were co-cultured with motor neurons and preincubated with 
antioxidants and nitric oxide synthase inhibitors, motor neuron loss was prevented suggesting 
that dysfunctions in other cell types contribute to motor neuron death (Cassina et al 2008).          
1.2.3.3 Dysfunctional Protein Quality Control Mechanisms   
In healthy cells there are several quality control mechanisms in place to aid in the 
refolding of misfolded proteins, and quickly degrade misfolded proteins that cannot be repaired 
to prevent their accumulation and stress on cells.  Often times when proteins are misfolded, 
hydrophobic amino acid residues, which are normally found inside of proteins, are exposed and 
signal quality control machinery to aid in protein refolding or removal.  Chaperon proteins, like 
the heat shock protein families hsp60 and hsp70, can be found in the cytosol, mitochondria, and 
the ER to aid in proper protein folding (Alberts et al 2002).  When proper folding cannot be 
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accomplished proteins are degraded through two major mechanisms, ER associated 
degradation and the ubiquitin-proteosome pathway, which function cooperatively to maintain 
homeostasis within the cell.      
The endoplasmic reticulum is found in two forms within the cell, a smooth form 
containing a variety of enzymes and proteins which is involved in the secretory pathway and 
calcium homeostasis; and a rough form containing ribosomes on the cytosolic side of the 
membrane and different types of proteins and enzymes inside which are involved in protein 
synthesis, folding, post-translational modification, and transport (Alberts et al 2002).  When new 
proteins are misfolded and accumulate within the ER, the unfolded protein response (UPR) is 
initiated and there is an increase in ER chaperones and enzymes that degrade misfolded 
proteins within the ER (Alberts et al 2002).  When refolding within the ER fails, proteins can be 
transported back into the cytosol for degradation through the ubiquitin-proteosome pathway.  
Dysfunction or overloading of ER associated protein degradation machinery can lead to ER 
stress, disruption of protein synthesis and transport, and calcium homeostasis, resulting in 
mitochondrial dependent or independent forms of cell death.   
There is evidence to suggest that the UPR is activated during ALS and that there are 
abnormalities in ER associated degradation of misfolded proteins.  Spinal cords from patients 
with SALS also show signs of the UPR, with induction of kinases, chaperones, and other 
proteins involved in ER stress (Atkin et al 2008; Ilieva et al 2007; Sasaki 2010).  Transgenic 
mouse models of ALS in which mutant SOD1 protein is overexpressed show early upregulation 
of ER stress markers well before symptom onset, and an ER-stress protective agent has been 
shown to slow progression of the disease in these animals (Saxena et al 2009).  Studies using 
ALS mice have shown that mutant forms of SOD1 accumulate in ER lumen to form high 
molecular weight aggregates that interact with immunoglobulin-binding protein (BiP), an ER 
chaperone, in affected spinal cord regions (Kikuchi et al 2006).  Mutant forms of SOD1 have 
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also been shown to directly interact with derlin-1, a protein component of ERAD machinery, 
which causes ER stress in motor neurons and leads to activation of the apoptosis-signal 
regulating 1 (ASK1) cell death pathway (Nishitoh et al 2008).  Mutant forms of VAPB, an ER 
protein which has recently been associated with ALS, also show the ability to trigger ER stress 
and activate the UPR.  In cell culture models, mutant forms of VAPB form aggregates that co-
localize with other ER proteins, initiating upregulation of ER stress related proteins (Moumen et 
al 2011).  Viral-mediated expression of mutant forms of VAPB in primary mouse motor neuron 
cultures also showed evidence of ER stress, as well as impaired calcium homeostasis, 
providing further support for ER stress in ALS pathogenesis (Langou et al 2010).   
The proteosome is an ATP-dependent protease that works to degrade proteins in the 
cytoplasm and aids the ER in removal of improperly assembled proteins.  The proteosome is a 
large, multisubunit complex that specifically targets, with a few exceptions, proteins that have 
been tagged with ubiquitin.  Once inside the active site, proteins are cleaved into several short 
peptide fragments about seven to eight amino acids long that can then go on to be degraded 
further into individual amino acids.  In addition to the removal of misfolded proteins, the 
proteosome also degrades normal proteins to regulate their concentrations within the cell and 
maintain homeostasis.  As with ERAD, dysfunction or overloading of the proteosome can lead to 
increased cellular stress and result in cell death. 
The presence of cytosolic protein aggregates, as well as ubiquitin-positive protein 
aggregates, in the spinal cords of ALS patients has provided evidence suggesting that protein 
aggregation and dysfunction of the proteosome play a role in disease pathogenesis (Redler & 
Dokholyan 2012; Wijesekera & Leigh 2009).  Several different proteins have been found to 
aggregate in motor neurons during ALS, such as neurofilaments, mutant SOD1 protein, and 
TDP43.  Mutations in the KSP region of the neurofilament heavy chain, a region involved in 
neurofilament cross-linking, have been found in patients with sporadic and familial ALS (Al-
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Chalabi et al 1999; Figlewicz et al 1994; Tomkins et al 1998).  In addition, peripherin, an 
intermediate filament found primarily in motor neurons, has been found in axonal aggregates in 
ALS patients and mouse models of the disease (Corbo & Hays 1992; Robertson et al 2003).  
The aggregation of neurofilaments in the axons of motor neurons may slow anterograde and 
retrograde transport of proteins and organelles, disrupt homeostasis, and alter the neuron’s 
ability to send signals to other cells.  As previously mentioned, mitochondria have been found to 
accumulate in axon terminals in mouse models of ALS (Martin et al 2007).  This accumulation 
may be due to neurofilament aggregates which block the axon and prevent retrograde transport 
back to the cell body.  In the same respect, blockage of axons may impair anterograde transport 
of proteins to the axon terminal and may play a role in the dysregulation of neurotrophic factor 
signaling.  Both retrograde and anterograde transport along axons have been shown to be 
slowed in mouse models of ALS (Borchelt et al 1998; De Vos et al 2008; Murakami et al 2001; 
Williamson & Cleveland 1999).   
In addition to neurofilaments, mutant forms of the SOD1 protein have been found in 
protein aggregates in ALS patients, mouse models, and cell culture models of the disease 
(Deng et al 2006; Gruzman et al 2007; Johnston et al 2000; Matsumoto et al 1996; Shibata et al 
1996a; Shibata et al 1994; Shibata et al 1996b).  Several studies have been conducted to 
examine changes in stability of the SOD1 protein with the various mutations it can undergo 
(Furukawa & O'Halloran 2005; Hough et al 2004; Khare et al 2006; Rodriguez et al 2005; Shaw 
& Valentine 2007).  It has been shown that not all of the mutations that can occur within SOD1 
disrupt the protein’s stability (Rodriguez et al 2005), which suggests that the different mutations 
promote SOD1 aggregation by different mechanisms (Shaw & Valentine 2007).  However, there 
are over 100 different mutations that can occur in SOD1 and many of them have been shown to 
disrupt protein stability, increase its dissociation, and increase its ability to form aggregates 
(Furukawa & O'Halloran 2005; Hough et al 2004; Khare et al 2006).   Interestingly, mouse 
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models of ALS show SOD1 aggregation as early as birth and these aggregates are enriched in 
motor neurons (Jonsson et al 2004; Rakhit et al 2007; Zetterstrom et al 2007).  Co-expression 
of wild-type SOD1 with certain mutant forms of the protein in animal models actually increases 
its ability to aggregate and exacerbates ALS phenotypes (Deng et al 2006; Fukada et al 2001; 
Jaarsma et al 2000; Wang et al 2009).   
Aggregation of mutant SOD1 protein within motor neurons has also provided support for 
the hypothesis that the ubiquitin-proteosome system becomes dysfunctional during ALS 
pathogenesis.  It has been determined that misfolded SOD1 undergoes degradation through the 
proteosome system (Di Noto et al 2005), and inhibition of the proteosome leads to increased 
aggregation of mutant SOD1 and cell death (Hoffman et al 1996; Hyun et al 2003; Puttaparthi et 
al 2003).  Mutant forms of SOD1 have been shown to sequester proteosomal subunits, as well 
as ubiquitin ligases and some chaperone proteins (Hyun et al 2003; Niwa et al 2002; Watanabe 
et al 2001; Zetterstrom et al 2011b), and proteosomal dysfunction has been seen in animal and 
cell culture models of the disease (Cheroni et al 2009; Sau et al 2007).   Spinal cord samples 
from mouse models of FALS and ALS patients test positive for ubiquitin and ubiquitin-ligase 
immunoreactive aggregates (Bendotti et al 2004; Leigh et al 1991; Mendonca et al 2006; 
Watanabe et al 2001), suggesting that proteosomal dysfunction or overloading prevents 
degradation of tagged proteins.  These ubiquitin positive aggregates are typically found in the 
anterior horn of the spinal cord (Leigh et al 1991) and have been found in astrocytes as well as 
motor neurons (Mendonca et al 2006).  TDP43 has also been found in these inclusions in 
affected regions in ALS patients (Arai et al 2006; Neumann et al 2006), but TDP43 positive 
aggregates seem to be specific to SALS patients (Tan et al 2007). 
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1.2.3.4 Aberrant mRNA Processing   
The discovery of ALS-associated mutations in DNA/RNA-binding proteins, TDP43 and 
FUS, has lead to new ideas involving alterations in mRNA processing playing a role in the 
progression of the disease.  This area of ALS research is relatively new and the normal roles of 
these proteins have yet to be fully characterized.  TDP43 protein aggregates were first 
discovered in tissue from patients with FTD, and in 2006, TDP43 was identified as a major 
constituent of protein aggregates in tissue from patients with ALS (Arai et al 2006; Neumann et 
al 2006).  Since then there has been an increase in research to identify mutations in the gene 
encoding TDP43, understand the normal cellular functions of the protein, as well as elucidate 
the mechanisms underlying its aggregation in ALS and FTD.  Starting in 2008, several ALS-
specific mutations in the gene encoding TDP43 were identified in both FALS and SALS patients 
(Kabashi et al 2008; Lagier-Tourenne et al 2010; Sreedharan et al 2008).  During this time, 
mutations in the gene encoding FUS, which is functionally and structurally similar to TDP43, 
were also identified and associated with ALS (Kwiatkowski et al 2009; Vance et al 2009). 
 Under normal conditions both TDP43 and FUS are found primarily in the nucleus, with 
lower levels of both proteins detectable in the cytoplasm (Andersson et al 2008; Lagier-
Tourenne et al 2010).  Both proteins are widely expressed, capable of binding DNA and RNA 
and have several similarities in their sequences.  TDP43 is 414 amino acids in length and 
consists of two RNA recognition motifs and a glycine-rich region at the C-terminus (Ayala et al 
2005; Ou et al 1995; Wang et al 2004a).  The first RNA recognition motif is required for RNA 
binding (Ayala et al 2005), but the second is not and is believed to play a role in the 
reorganization of chromatin (Ayala et al 2008; Buratti et al 2001).  The C-terminal glycine-rich 
region is required for TDP43 to interact with other proteins (Ayala et al 2005; D'Ambrogio et al 
2009; Wang et al 2004a) and is the primary site for ALS-associated mutations.  In addition, 
TDP43 also contains a predicted nuclear localization sequence closer to the N-terminus and a 
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nuclear export sequence within the second RNA recognition motif (Lagier-Tourenne et al 2010).  
These sequences are believed to be involved in the shuttling of the protein between the nucleus 
and the cytoplasm.  The FUS protein is 526 amino acids in length and consists of an N-terminal 
sequence rich in glutamine, glycine, serine and tyrosine residues (called the QGSY-region), a 
region of multiple arginine-glycine-glycine repeats, a zinc-finger motif at the C-terminus, and like 
TDP43, a glycine-rich region and an RNA recognition motif (Crozat et al 1993; Iko et al 2004; 
Morohoshi et al 1998; Prasad et al 1994).  Most of the FUS mutations that are associated with 
ALS are found clustered in the glycine-rich region of the protein, however the C-terminal portion 
of the protein, which is believed to contain a nuclear localization sequence, can also become 
mutated (Lagier-Tourenne et al 2010).  Like TDP43, FUS also contains a predicted nuclear 
export sequence in the RNA recognition sequence.    
 The exact roles of these two proteins have yet to be elucidated and there is no evidence 
to suggest that TDP43 and FUS interact with each other directly despite their structural 
similarities (Lagier-Tourenne et al 2010), but they may have roles in the same pathway (Kabashi 
et al 2011).  Under normal conditions, TDP43 is involved in the regulation of transcription, 
alternative RNA splicing, RNA stabilization, and plays a role in the metabolism of micro RNA 
(Buratti & Baralle 2008; Buratti et al 2010).  TDP43 is capable of regulating its own mRNA levels 
by binding to its own transcript (in an intron found in the 3’-untranslated region) and enhancing 
splicing (Ayala et al 2011; Polymenidou et al 2011).  Variations have been found in the 
sequence of the 3’-UTR in patients with FTD (Gitcho et al 2009) corresponding with increased 
TDP43 protein expression (Gitcho et al 2009; Mishra et al 2007), suggesting that mutations in 
this region of the protein lead to enhanced splicing and increased protein levels during disease 
progression.  TDP43 has been found to be abnormally truncated in tissue collected from 
patients, with C-terminal fragments found in brain and both N- and C-terminal fragments found 
in spinal cord samples of FTD and ALS patients (Igaz et al 2008).  In addition to truncation, 
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TDP43 has found to be hyperphosphorylated and ubiquitinated (Arai et al 2006; Neumann et al 
2006).  Most of the TDP43 aggregates found in patients occur within the cytoplasm or neurites 
of affected cells and correspond with an overall depletion of nuclear TDP43 (Arai et al 2006; 
Cairns et al 2007; Neumann et al 2006).  This mislocalization is a pathological hallmark of the 
disease in patients with TDP43 mutations and it is unclear if it is due to mutations in the nuclear 
localization sequence itself or mutations in the C-terminal glycine rich region which is involved in 
interactions with other proteins.  Several models of the disease, including mouse, D. 
melanogaster, and C. elegans, all show severe motor symptoms upon overexpression of wild-
type and mutant forms of TDP43, with wild-type TDP43 found mainly in nuclei and mutant 
TDP43 accumulating in the cytoplasm (Ash et al 2010; Hanson et al 2010; Kabashi et al 2010; 
Li et al 2010b; Shan et al 2010; Swarup et al 2011a; Voigt et al 2010; Wils et al 2010; Xu et al 
2010).  However, mouse models of ALS that overexpress wild-type human TDP43 containing 
mutations in the predicted nuclear localization sequence do not show reduced levels of human 
or mouse TDP43 in the nucleus when compared to controls (Igaz et al 2011), suggesting that 
TDP43 pathology in mouse models may differ from that of ALS patients.     
 The fused in sarcoma (FUS) protein, also called translocation in liposarcoma (TLS), was 
originally identified in cancer patients where the gene encoding FUS had undergone a 
chromosomal translocation leading to the production of fusion proteins (Crozat et al 1993; 
Rabbitts et al 1993).  The gene encoding FUS is constitutively activated and ubiquitously 
expressed in almost all human tissues and cell lines under normal conditions (Aman et al 1996; 
Andersson et al 2008; Morohoshi et al 1996).  Expression levels of the protein vary between 
tissues, but expression seems to be downregulated in differentiated cells and upregulated in 
certain cancers suggesting it may play a role in proliferation (Andersson et al 2008; Mills et al 
2000).  FUS is primarily nuclear, except in hepatocytes where it is found in the cytosol, and 
when cells are exposed to environmental stressors it can be found in cytoplasmic aggregates 
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that localize with stress granules containing translationally silenced mRNA and micro RNAs 
(Andersson et al 2008).  Neurons and glial cells contain cytoplasmic aggregates that stain 
positive for FUS in postmortem CNS tissue isolated from patients with mutations in the gene 
(Corrado et al 2010; Kwiatkowski et al 2009; Vance et al 2009).  FUS can interact with a variety 
of molecules as it has two functional domains, an N-terminal domain rich in glutamine, glycine, 
serine, and tyrosine residues that functions as a transcriptional activation domain and a domain 
near the C-terminus for DNA/RNA binding (Yang et al 2010).   
FUS binds to pre-mRNA as a component of the heterogeneous nuclear 
ribonucleoprotein (hnRNP) H complex (Calvio et al 1995) and it takes part in pre-mRNA splicing 
by forming a complex with other hnRNPs, specifically A1 and C1/C2 (Zinszner et al 1994).  FUS 
is also believed to form a complex with RNA that interacts with RNA polymerase II, as it 
accumulates in the cytoplasm upon inhibition of RNA polymerase II (Zinszner et al 1997).  It has 
also been found to be part of the Drosha complex and may have a role in micro RNA processing 
(Strong 2010).  In neurons FUS is believed to play a role in the reformation of actin and 
maintenance of dendritic spine shape, as it has been found localized with a protein complex 
involved in transporting actin-related mRNA to dendrites (Fujii et al 2005; Fujii & Takumi 2005).  
In addition to its role in RNA processing, FUS is believed to play a role in maintaining the 
integrity of the genome through its ability to promote annealing of DNA (Baechtold et al 1999) 
and acts as a transcriptional regulator through its interactions with DNA, nuclear receptors, and 
transcription factors (Amoresano et al 2010; Kaczynski et al 2003; Law et al 2006; Li et al 
2010a).  Exactly how ALS associated mutations in FUS disrupt its normal function and lead to 
its aggregation are not entirely clear, however mutations have been found in exons that make 
up the N-terminal QGSY and glycine-rich regions, as well as in the C-terminal region involved in 
DNA/RNA binding (Lagier-Tourenne et al 2010).  Due to the locations of these mutations, it is 
not unreasonable to believe that they may disrupt protein transport (shuttling of FUS to and from 
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the nucleus), DNA/RNA binding, and some of the interactions between FUS and other proteins 
involved in forming the various complexes that take part in RNA processing and transcriptional 
regulation. 
1.2.3.5 Neurotrophic Factor Dysregulation   
Neural networks are dynamic entities that are capable of changing over time in response 
to molecular cues secreted by cells within the nervous system and by skeletal muscle.  
Neurotrophic factors are peptides that act as these molecular cues, and when secreted, 
influence the cell cycle, growth, differentiation, and survival of neurons and glia (Nestler et al 
2001).  They are produced in the cell body and sent to areas where they will be secreted.  It has 
been suggested that neurotrophic factor signaling is dysfunctional in ALS and that motor neuron 
death results from withdrawal of these molecules.  Studies with mouse models have supported 
this idea by showing that knocking out ciliary neurotrophic factor (CNTF) resulted in motor 
neuron death and loss of muscular strength (Masu et al 1993).  ALS mouse models in which 
CNTF had been knocked out showed earlier onset of symptoms, which correlated with early 
onset seen in human FALS patients expressing mutations in the gene for CNTF, in addition to 
mutations in SOD1 (Giess et al 2002).  Despite these findings, neurotrophic factor deficits have 
not been seen in human ALS patients.  CNTF, hepatocyte growth factor (HGF), and gial-cell 
derived neurotrophic factor (GDNF) were found to be upregulated in spinal cord samples of ALS 
patients (Jiang et al 2005), and GDNF levels in CSF and GDNF mRNA levels in muscle 
biopsies were found to be elevated in ALS patients (Grundstrom et al 1999; Grundstrom et al 
2000; Yamamoto et al 1999).  The upregulation of these factors in ALS patients may be 
secondary to other dysfunctional cellular processes and reflect a defense mechanism 
attempting to aid in motor neuron survival.   
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 Vascular endothelial growth factor (VEGF) and angiogenin (ANG) are proteins involved 
in vasculogenesis and angiogenesis that have been found to play roles in the CNS and have 
been implicated in ALS.  VEGF has been found to act as a neurotrophic factor, promoting 
neurite outgrowth and increasing neuron survival in cell culture (Sondell et al 1999) and 
decreased expression in mice leads to neurodegeneration (Oosthuyse et al 2001).  VEGF levels 
have been found to be decreased in the CSF of ALS patients (Devos et al 2004).  ANG has 
been found to play a role in directing the path of neurite outgrowth (Subramanian & Feng 2007), 
and expression of ALS-associated ANG mutants leads to compromised neurite outgrowth and 
cytotoxicity in neuron cultures (Subramanian et al 2008).  The roles of VEGF and ANG in the 
pathogenesis of ALS remain unclear, as their primary roles in the body are to promote de novo 
blood vessel formation, as well as blood vessel formation from pre-existing vessels.  In addition 
to motor neuron degeneration, ALS patients exhibit decreased cerebral blood flow (Kobari et al 
1996; Waldemar et al 1992) and mouse models of ALS show breakdown of the blood-spinal 
cord barrier (Zhong et al 2008), suggesting that VEGF and ANG may actually play roles 
vascular growth.         
1.2.3.6 Neuroinflammation   
Motor neurons are the primary cell target of ALS, but in many ALS models in which 
mutant proteins are overexpressed, such as SOD1, these proteins are not expressed solely in 
motor neurons, but in all cells of the CNS as well as other organs.    So why do motor neurons 
undergo selective cell death?  Several studies of ALS suggest that the disease is non-cell 
autonomous, involving a variety of cell types both within and outside of the CNS.  Animal 
models suggest that motor neuron-specific expression of mutatant SOD1 is not sufficient to 
cause neurodegeneration (Pramatarova et al 2001), suggesting that aberrant interactions with 
other cell types are necessary to cause motor neuron death.  The CNS is set up in such a 
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manner that even though neurons may appear to be the most important cell type (as their rapid 
signaling abilities play a vital role in all life processes), they cannot function without the aid of a 
variety of supporting cells.  Astrocytes, oligodendrocytes/Schwann cells, and microglia are 
indispensable pieces of the nervous system, each of which play an important role in maintaining 
homeostasis and proper neuronal function.   
During the pathogenesis of ALS, inflammatory processes occur that involve supportive 
cells within the CNS, as well as peripheral immune cells that infiltrate the CNS, resulting in a 
variety of cellular interactions that lead to motor neuron death.  Studies of postmortem tissue 
from ALS patients suggest that neuroinflammation is an important part of the disease, however 
the progression of these processes are difficult to study in human patients as most human data 
comes from end stage patients.  As a result, several studies have focused on animal models of 
ALS where early events in neuroinflammatory processes can be monitored.  Both human and 
animal models of ALS show that astrocytes become activated, microglia become reactive, and 
peripheral immune cells enter the CNS to take part in inflammation.  Although data are not 
necessarily consistent across animal and human studies of the disease, research also shows 
that a variety of cytokines and chemokines are released by activated cells within the nervous 
system, and can be beneficial or deleterious to the disease process. 
It is not fully understood how myelinating cells (oligodendrocytes in the CNS and 
Schwann cells in the PNS) contribute to the pathogenesis of ALS, but studies aimed at 
characterizing other roles of these cells, suggest that they may be important players in disease 
progression.  When mitochondrial cytochrome C oxidase is conditionally knocked down in 
oligodendrocytes and Schwann cells of mice, animals undergo severe neuropathy that includes 
defective myelination, muscle atrophy, and paralysis and a corresponding increase in brain 
lactate concentrations compared to control animals (Funfschilling et al 2012).  These results 
suggest that there is some kind of metabolic coupling between myelinating cells and axons and 
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that myelinating cells, much like astrocytes, may play multiple roles in the nervous system.  
Further experimental evidence supports this idea, as it has been shown that disruption of 
monocarboxylate transporter 1 (MCT1; the major lactate transporter in the brain which is 
enriched in oligodendrocytes) leads to axonal damage and neuron death in cell culture and 
animal models (Lee et al 2012b).  Tissue from ALS patients shows a reduction in the expression 
of this transporter and SOD1 mouse models support these data, showing transporter down 
regulation in spinal cord tissue of early symptomatic and end stage mice (Lee et al 2012b).  It is 
possible that expression of the mutant SOD1 protein disrupts cell processes within myelinating 
cells, as well as neurons, leading to a decline in metabolic support.  Mutant misfolded SOD1 
protein aggregates have been found in the nuclei of oligodendrocytes (Forsberg et al 2011) and 
the complement proteins C3d and C4d have been found associated with oligodendrocytes 
(Kawamata et al 1992) in CNS tissue from ALS patients.  Studies focusing on Schwann cell 
involvement in ALS progression have produced conflicting results.  When Schwann cell 
expression of mutant SOD1 protein was reduced in transgenic mice, disease onset was not 
affected but disease progression was accelerated and the average lifespan was decreased 
(Lobsiger et al 2009).  However, when mutant SOD1 protein expression was targeted to 
Schwann cells of mice, animals did not develop paralysis and no motor neuron degeneration 
was observed.  In addition, further increasing the expression of mutant SOD1 protein in 
Schwann cells of transgenic mice did not accelerate disease progression (Turner et al 2010).      
Astrocytes, which also provide neurons with metabolic support and maintain an 
environment suitable for synaptic signaling, become activated during the course of ALS, 
increasing in size and the number of processes extending from the cell body (Boillee et al 
2006).  Postmortem tissue from ALS patients shows increased glial fibrillary acidic protein 
(GFAP) and phosphotungstic acid hematoxylin (PTAH) reactivity suggestive of astrocyte 
activation and the number of reactive astrocytes near sites of neuron loss is inversely 
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proportional to the number of motor neurons remaining (Schiffer et al 1996).   Astrocytes in 
tissue from mouse models of the disease show similar characteristics upon activation 
(Garbuzova-Davis et al 2007b) and those near capillaries in the brainstem show swollen end-
foot processes that may contribute to the breakdown of the BBB (Garbuzova-Davis et al 2007a).  
Although reactivity may be a normal response to pathogens or stress within the CNS, normal 
homeostatic functions of astrocytes may become impaired upon activation and ultimately impair 
neuron function.   
In cell culture models, normal and mutant SOD1-expressing motor neurons plated on an 
astrocyte monolayer expressing mutant SOD1 protein showed an increase in motor neuron 
death, suggesting a toxic interaction between the two cell types that involves mutant protein 
expression in astrocytes (Nagai et al 2007).  Culturing normal and mutant SOD1-expressing 
neurons in conditioned cell culture media obtained from astrocytes expressing mutant SOD1 
protein also resulted in motor neuron death, suggesting that astrocytes secrete a factor that is 
toxic to motor neurons (Nagai et al 2007).  However, motor neurons have been found to release 
factors that may contribute to activation of astrocytes and their own demise.  Fibroblast growth 
factor 1 (FGF-1), which is highly expressed in motor neurons, has been shown to be released 
from stressed motor neurons expressing mutant SOD1 protein in culture.  When these cells are 
co-cultured with astrocytes, the astrocytes become activated and motor neuron survival 
decreases (Cassina et al 2005).  Chemically activated astrocytes isolated from ALS rats show 
increased expression of mGluR5 (Vermeiren et al 2006), a metabotropic glutamate receptor 
involved in regulation of astrocyte activity and proliferation (Miller et al 1995), and modulation of 
excitatory synaptic transmission (Aronica et al 2003).  These cells also show impaired glutamate 
uptake (Vermeiren et al 2006), suggesting that reactive astrocytes may be less capable of 
carrying out their normal supportive roles.  It is not clear as to when astrocytes become reactive 
and ALS pathogenesis cannot be explained solely by aberrant interactions between motor 
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neurons and astrocytes.  In an ALS mouse model utilizing an astrocyte-specific deletable 
mutant SOD1 gene, the removal of mutant SOD1 from astrocytes did not affect the onset of the 
disease, but progression was slowed and microglial activation was delayed (Yamanaka et al 
2008b).  These results suggest a more complex interaction of cells in the CNS and that 
astrocytes may become activated first and contribute to microglial activation.   
Microglia, which interact closely with both astrocytes and neurons, are considered to be 
the resident macrophages of the nervous system, providing the first line of defense against 
insults to the CNS.  Although they are typically regarded as macrophage-like cells, they can be 
activated by a variety of signals to produce an array of activated phenotypes.  These 
phenotypes range from phagocytic activity characteristic of innate immunity to antigen 
presentation characteristic of adaptive immunity (Town et al 2005).  Once activated, microglial 
morphology changes and these cells become more mobile in order to travel to sites of infection.  
In addition to gaining mobility, microglia secrete a variety of pro-inflammatory molecules 
including nitric oxide and superoxide to kill pathogens, and interferon  and tumor necrosis 
factor  to continue stimulating an immune response (Philips & Robberecht 2011).  Microglia 
can also release anti-inflammatory cytokines (interleukins 4 and 10), as well as trophic factors 
(insulin-like growth factor 1), to help stop inflammatory responses and initiate repair.  The 
factors secreted are influenced by surrounding cells and the local environment, resulting in 
either deleterious or benign effects of microglial activation.   
 Experimental evidence from both ALS patients and animal models of the disease 
indicates that microglial activation is part of the disease process.  Activated microglia have been 
found in both brain and spinal cord tissue of ALS patients, specifically in areas undergoing 
significant motor neuron death (Kawamata et al 1992; Moisse & Strong 2006).  The exact time 
point at which microglia become activated during the progression of ALS is unclear, but studies 
using animal models of the disease suggest that it occurs near the end stage of the disease 
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succeeding astrocyte activation (Hall et al 1998).  However, some studies using animal models 
of ALS have found microglial activation to occur in presymptomatic mice as early as 60 days of 
age (Dibaj et al 2011), suggesting that microglial activation may have an early and a late phase 
or it may be model-specific.  New techniques utilizing a specific ligand of the peripheral 
benzodiazepine binding site expressed by mitochondria of activated microglia and positron 
emission tomography allow for the in vivo detection of activated cerebral microglia in ALS 
patients (Turner et al 2004) and may become a useful tool for studying the time course of 
microglial activation in humans, provided the discovery of earlier methods of disease detection 
and diagnosis.   
 The phenotype of activated microglia in animal models and human ALS patients appears 
to be primarily pro-inflammatory in nature.  In human studies, monocyte chemoattractant 
protein-1 (MCP-1), a chemokine involved in the recruitment of peripheral immune cells, was 
found to be elevated in both the serum and CSF of ALS patients.  However, its expression was 
not limited to microglia, but was also detected in neurons and astrocytes in post-mortem spinal 
cord tissue (Baron et al 2005).  Primary microglia cultures prepared from ALS mice show 
increased release of MCP-1 upon stimulation with lipopolysaccharide (LPS) compared 
nontransgenic primary microglia cultures (Sargsyan et al 2009), supporting human data.  
Studies using animal models of ALS have also found mRNA levels of TNF, IFN, and TGF-1 
and 2 are elevated in spinal cord tissue with a corresponding increase in protein levels of TNF, 
IL-6, IFN, and some chemokines (Hensley et al 2003).  TNF mRNA expression has been 
shown to occur prior to symptom onset and increase until the end stage of the disease (Elliott 
2001), suggesting that it may be the main cytokine driving neuroinflammation and possibly 
motor neuron death. Microglia have been shown to express neurotransmitter receptors, such as 
ionotropic and metabotropic glutamate receptors, that under normal conditions may help them 
monitor their local environment.  These receptors, however, may also play a role in modulating 
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the release of certain cytokines from activated microglia when neurons become stressed 
(Pocock & Kettenmann 2007).  Animal models of the disease in which mutant SOD1 protein 
expression was reduced in microglia have shown no changes in disease onset; however 
disease progression was slowed (Boillee et al 2006).  In mice where reactive microglia have 
been significantly reduced, motor neuron degeneration continues at the same rate (Gowing et al 
2008), suggesting that microglia alone are not responsible for motor neuron death.   
In mouse models of ALS, it has been shown that both the blood-brain and blood-spinal 
cord barriers begin to break down early in the disease (Garbuzova-Davis et al 2007a; 
Garbuzova-Davis et al 2007b).   Data from ALS patients corroborate these findings as albumin, 
immunoglobulin G (IgG), and the complement component C3c have been detected in 
cerebrospinal fluid (CSF), and IgG has been found in motor neurons of the spinal cord 
(Annunziata & Volpi 1985; Engelhardt et al 2005; Leonardi et al 1984; Meucci et al 1993).  In 
addition, both human patients and animal models of the disease show peripheral immune cell 
infiltration into the CNS, further supporting the evidence that the barriers of the CNS are 
compromised during the disease (Beers et al 2008; Chiu et al 2008; Troost et al 1989).    
Astrocytes and microglia work together to create an environment that allows for the 
infiltration of peripheral immune cells into the CNS.  Astrocytes help form the blood-brain barrier 
and the blood-spinal cord barrier, which are compromised during ALS and both astrocytes and 
microglia release MCP-1 to attract circulating immune cells to sites of injury.  As a result, a 
variety of immune cells which normally cannot enter the nervous system, have been detected in 
the CNS of ALS patients and animal models.  Cytotoxic (CD8+) and helper (CD4+) T cells have 
been found lining the walls of capillaries and venules and extending into affected areas 
(corticospinal tracts, motor nuclei of the brainstem, and the primary motor cortex) of the CNS in 
postmortem tissue from ALS patients (Kawamata et al 1992).  Animal models of ALS show a 
similar pattern of peripheral immune cell infiltration, with CD4+ and CD8+ T cells, and natural 
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killer cell populations found in spinal cord tissue prior to symptom onset (Chiu et al 2008).   
Peripheral macrophages have also been shown to enter the spinal cords of ALS patients, 
surrounding and possibly engulfing motor neurons (Graves et al 2004).  It is unclear as to 
whether or not these T cells are attracted to areas of motor neuron degeneration by chemokines 
or if they are part of an antigen-driven immune response (Holmoy 2008).  In animal models of 
ALS in which the primary T cell receptor was knocked out disease progression was accelerated, 
suggesting a potentially protective role for T cells in the disease process (Chiu et al 2008).  
Specifically, helper (CD4+) T cells have been shown to have a neuroprotective effect in mouse 
models of ALS (Beers et al 2008).    
 It has been suggested that a toxic form of SOD1 may be involved in triggering an 
immune response in ALS and may possibly act as an antigen to activate immune cells 
(Brotherton et al 2012).  Misfolded SOD1 protein has been found in the CSF of ALS patients 
suffering from both sporadic and familial ALS (Frutiger et al 2008; Zetterstrom et al 2011a) and 
an antibody that can differentiate between pathologically affected cells in tissue from human and 
animal models carrying SOD1 mutations has been discovered (Brotherton et al 2012) providing 
evidence for the presence of a toxic form of the protein.  The presence of misfolded SOD1 
protein in CSF, in the absence of disease-causing SOD1 mutations, suggests that there is 
probably something else going on in patients leading to motor neuron degeneration.  There is a 
clear immune component to ALS and more work needs to be done to characterize the immune 
response and identify potential antigens that may activate immune cells and exacerbate disease 
progression. 
Several studies have identified a range of cellular processes that become dysfunctional 
during the progression of ALS – glutamate excitotoxicity, mitochondrial dysfunction and 
oxidative stress, dysfunctional protein quality control, aberrant mRNA processing, neurotrophic 
factor dysregulation, and neuroinflammation – and all of these mechanisms may contribute to 
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the development of the disease.  It is clear that certain mutations contribute to the disease, but 
the overlap of dysfunctional cellular processes in transgenic animal models suggests that ALS 
pathogenesis is much more complex than a single gene mutation can account for.  Although 
these studies help to identify potential therapeutic targets by dissecting out specific disease-
associated mechanisms, treating the disease still remains a hurdle due to its difficulty to 
diagnose and its rapid progression.   
1.2.4 Diagnosis and Treatment of ALS 
ALS is an extremely difficult disease to diagnose.  There is no individual test or 
procedure that can lead to a definitive diagnosis of the disease and no diagnostic biomarkers for 
the disease have been identified (Turner et al 2009).  Part of the difficulty in diagnosing the 
disease is due to the wide range of symptoms exhibited by ALS patients and the overlap of 
these symptoms with those of other motor neuron diseases, such as spinal muscular atrophy.  
Clinicians carefully monitor symptoms and typically conduct a range of diagnostic tests to rule 
out other diseases in order to diagnose patients with ALS.  As a result it can take a significant 
amount of time, up to a year from symptom onset, to obtain a positive diagnosis of ALS (Turner 
et al 2009).  By the time symptoms become apparent, a significant number of the motor neurons 
in the anterior horn of the spinal cord are thought to have died and these cells do not have the 
ability to proliferate and replace themselves.  To be able to effectively treat ALS patients and 
prevent motor neuron damage, early diagnosis is critical.   
The difficulty in diagnosing ALS and the need for early diagnosis lead clinicians and 
scientists to convene at a workshop in 1990 where a set of diagnostic criteria were drafted.  In 
1994 the first set of internationally acceptable criteria for the diagnosis of ALS, resulting from 
this meeting, were published in the Journal of the Neurological Sciences (Brooks 1994).  The El 
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Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral 
Sclerosis read as follows: 
The diagnosis of ALS requires the presence of  
(1) signs of lower motor neuron (LMN) degeneratioin by clinical, 
electrophysiological or neuropathologic examination, 
(2) signs of upper motor neuron (UMN) degeneration by clinical 
examination, and 
(3) progressive spread of signs within a region or to other regions, 
together with the absence of 
(1) electrophysiological evidence of other disease processes that might 
explain the signs of LMN and/or UMN degeneration, and 
(2) neuroimaging evidence of other disease processes that might explain 
the observed clinical and electrophysiological signs. (Brooks 1994) 
 
In addition to basic diagnostic criteria for ALS, this guide also provided a list of steps for 
clinicians to follow to diagnose the disease which read as follows: 
The diagnosis of ALS is made possible by 
(1) history, physical and appropriate neurological examinations to 
ascertain clinical findings which may suggest suspected, possible, 
probable or definite ALS, 
(2) electrophysiological examinations to ascertain findings which confirm 
LMN degeneration in clinically involved regions, identify LMN 
degeneration in clinically uninvolved regions and exclude other 
disorders, 
(3) neuroimaging examinations to ascertain findings which may exclude 
other disease processes, 
(4) clinical laboratory examinations, determined by clinical judgment, to 
ascertain possible ALS-related syndromes, 
(5) neuropathologic examinations, where appropriate to ascertain findings 
which may confirm or exclude sporadic ALS, coexistent sporadic 
ALS, ALS-related syndromes or ALS variants, 
(6) repetition of clinical and electrophysiological examinations at least six 
months apart to ascertain evidence of progression.  (Brooks 1994) 
 
The El Escorial World Federation of Neurology Criteria for the Diagnosis of Amyotrophic Lateral 
Sclerosis also included a thorough description of clinical signs of the disease, a list of disorders 
related to ALS, and defined the different types of ALS.  Developing a set of internationally 
acceptable diagnostic criteria for ALS was a breakthrough for diagnosing the disease, and these 
criteria have been built upon over the years to accommodate new technologies and to include 
guidelines for clinical trials.   
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 Despite the continual evolution of diagnostic criteria for ALS, as well as an increased 
understanding in molecular mechanisms underlying disease progression, there is still a need for 
drugs that can slow progression of the disease and help increase patients’ quality of life.   
Currently, the only drug approved to treat ALS in most countries is riluzole, which has a modest 
effect on the lifespan of patients (Miller et al 2007).  Riluzole is believed to target excitotoxicity in 
ALS patients, as it has been found to prevent the release of neurotransmitters stimulated by 
excitatory amino acids, like glutamate (Barbeito et al 1990; Benavides et al 1985; Hubert & 
Doble 1989).  Riluzole has been shown to block NMDA and kainic acid initiated currents in 
Xenopus oocytes (Debono et al 1993), but radioligand binding studies failed to demonstrate its 
ability to bind with glutamate receptors (Benavides et al 1985; Debono et al 1993), suggesting 
that riluzole targets excitotoxicity in an indirect fashion.  The drug has also been shown to inhibit 
basal and synaptically stimulated glutamate release (Cheramy et al 1992; Hubert & Doble 1989; 
Martin et al 1993) and appears to exhibit its indirect effects on excitotoxicity through its ability to 
block tetrodotoxin-sensitive sodium channels expressed on damaged neurons, preventing 
glutamate release by reducing calcium influx into the presynaptic neuron (Song et al 1997).  
Riluzole has also been shown to enhance the Wnt pathway (Biechele et al 2010), which has 
recently been implicated in ALS (Chen et al 2012).   Even though riluzole has been shown to 
target multiple pathways involved in ALS it only extends the median survival by about two to 
three months (Miller et al 2007), and by the time it is administered motor neurons have 
undergone a significant amount of damage that cannot be reversed.  The issues with 
diagnosing the disease combined with a lack of treatment options, makes slowing the 
progression of ALS with early treatment a serious problem.   
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1.3 Models of ALS 
ALS is a complicated disease that is not fully understood.  A wide array of gene 
mutations have been implicated as causative factors for developing the disease, and a number 
of molecular mechanisms are believed to play a role in the death of motor neurons.  Much has 
been learned about the pathogenesis of the disease due to the development of ALS animal 
models. However, it has been difficult to link all of the molecular mechanisms with gene 
mutations to gain a full understanding of the initial steps leading to motor neuron death, creating 
the need to continue studying ALS and developing better disease models. There are a variety of 
ways in which ALS can be modeled in the laboratory, from single-cell systems to whole animal 
models, each of which have a variety of advantages and disadvantages.   
 Single-cell models of ALS, such as Saccharomyces cerevisiae and mammalian cell 
cultures of neurons, astrocytes, and microglia, are easily manipulated genetically and 
pharmacologically and allow for rapid data collection.  S. cerevisiae is a simple eukaryotic 
organism that shares several protein quality control mechanisms with many higher eukaryotes 
and is a useful system for studying the protein misfolding that occurs as a consequence of 
expressing mutations in proteins such as SOD1, TDP43, and FUS (Bastow et al 2011).  In 
addition, S. cerevisiae can be used to study oxidative stress associated with SOD1 mutations, 
as well as a variety of different protein-protein interactions (heat shock and chaperone proteins, 
and DNA/RNA binding proteins) that may occur during ALS pathogenesis (Bastow et al 2011).  
Like yeast, mammalian cell culture models can also be used to gain insight into the molecular 
mechanisms behind ALS, however, these cells can provide a clearer picture of exactly what is 
happening in a single cell type during the disease.  For example, fluorescently-tagged proteins 
can be expressed in these systems and intracellular trafficking can be monitored directly using 
live cell imaging, to gain a greater understanding of ER stress or aggregation of mutant proteins.  
In addition, co-culturing of neurons and other cell types such as astrocytes can provide insight 
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into cell-cell interactions that may become toxic during the progression of ALS.  These single-
cell model systems of ALS are valuable tools for understanding the molecular mechanisms 
behind the disease, but they only tell a small part of the story.  S. cerevisiae may have some 
similarities to human cells, but they are not human and therefore do not express all of the same 
proteins, nor do they mimic the cell-cell interactions that occur within higher organisms.  
Mammalian cell culture systems may model the molecular mechanisms of ALS more accurately 
than yeast, but these cells do not behave in culture exactly as they do in the body.  In single cell 
culture systems cell-cell interactions that occur in the body (neuron-astrocyte, neuron-muscle, 
and neuron-oligodendrocyte) are lost, while in co-culture systems interactions may be regained 
to some extent, but again are not the same as in the human body.   
 Small, multicellular organisms provide a slightly better model of the disease, as these 
systems maintain the cellular interactions that are lost in single-cell systems.  Caenorhabditis 
elegans, Drosophilia melanogaster, and zebrafish have all been used as small model systems 
to study ALS (Joyce et al 2011).  C. elegans and D. melanogaster are small multicellular 
organisms that are easy to manipulate genetically and grow in the lab. Both organisms have a 
short life cycle and are capable of rapidly reproducing in large numbers, which allows for rapid 
collection of data.  C. elegans is a simple organism that has been studied extensively.  It is a 
transparent nematode containing less than 1000 cells, the lineage of which can be traced back 
to the egg (Muller & Grossniklaus 2010).  The adult nematode contains 302 neurons that can be 
broken down into classes based on their function – chemosensory, mechanosensory, and 
thermosensory.  C. elegans has been so thoroughly studied that the complete pattern of 
synaptic connections within its nervous system has been mapped and all of the neuronal 
subtypes have been identified down to the neurotransmitter secreted and the area innervated 
(Gama Sosa et al 2012).  The transparent nature of C. elegans allows for proteins to be 
fluorescently tagged, and specific cells and intracellular processes can then be visualized within 
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living nematodes.  In addition, genetic manipulations in which genes are targeted to specific 
cells or turned on at specific times can be performed in C. elegans.  Several proteins involved in 
vesicle formation, trafficking, and release at the synapse, are highly conserved, which allows C. 
elegans to be used as a model for neurodegenerative diseases (Teschendorf & Link 2009).  In 
ALS research C. elegans has been used to examine the effects of neuron-specific expression of 
various human SOD1 and TDP43 mutations, as well as the effects of muscle-specific 
expression of human SOD1 mutations, on protein aggregation, movement, and lifespan (Joyce 
et al 2011). 
D. melanogaster is slightly more complex than C. elegans, but the adult fly brain and the 
eye have been utilized extensively to study mechanisms of neurodegeneration (Jeibmann & 
Paulus 2009).  D. melanogaster expresses both neurons and glial cells in the developing CNS, 
that grow to produce the adult brain which contains association areas used for olfactory learning 
and memory called mushroom bodies (Gama Sosa et al 2012).  Neurons in the complex eye 
develop in a stereotypical fashion with sequential differentiation of photoreceptors.  Like C. 
elegans, the fruit fly has some mammalian homologs and can be used to understand the normal 
biological functions of genes, as well as dysfunctions that lead to neuronal death upon mutation 
(Bonini & Fortini 2003; Gama Sosa et al 2012; Muqit & Feany 2002).  D. melanogaster can be 
manipulated in such a way that gene expression can be targeted to specific regions of the body 
(such as the eye or mushroom bodies) or induced at specific times using hormone inducible 
gene expression, or Tet-On/Tet-Off inducible systems (Gama Sosa et al 2012).  The beauty of 
the fruit fly as a model system is that it can be used to perform forward genetic screens in which 
phenotypes are assessed and selected for through breeding to identify the genes responsible 
for causing certain traits.  As a result, large-scale genetic screens can be performed in a 
relatively short period of time and used to dissect out the cell-signaling pathways involved in 
disease.  D. melanogaster has been used to examine the effects of tissue-specific expression of 
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human wild-type and mutated forms of SOD1 and TDP43 on protein aggregation, glial cell 
stress, motor dysfunction, cell death, and lifespan (Joyce et al 2011). 
The zebrafish (Danio rerio), an inexpensive vertebrate, has increased in popularity as a 
model organism.  It is somewhat more difficult to work with in the lab than fruit flies and 
nematodes, as it requires more space (for aquariums) and has a longer life cycle, but it can 
reproduce rapidly and is fairly easy to breed and maintain (Gama Sosa et al 2012).  Zebrafish 
share a close evolutionary relationship with mammals and the overall organization of the brain is 
similar to that of humans.  The zebrafish brain consists of a forebrain, a midbrain, and a 
hindbrain which contains a diencephalon, telencephalon, and a cerebellum.  Their peripheral 
nervous system has motor and sensory components, similar to humans, and they exhibit higher 
order behaviors that are not present in invertebrate systems (Gama Sosa et al 2012; Lieschke & 
Currie 2007).  Zebrafish are easy to manipulate genetically and there are a variety of techniques 
that can be employed to generate transgenic zebrafish models of disease.  Plasmid DNA can be 
inserted into the cytoplasm of fertilized eggs through microinjection or electroporation,  sperm 
can be genetically modified, retroviral systems can be used to deliver genetic material, and 
genes can be knocked down using morpholino technology (Gama Sosa et al 2012).  Gene 
expression can be regulated in a cell type-specific manner or temporally using similar systems 
utilized in fruit fly models.  During the larval stage of development, the brain and skull of the 
zebrafish are transparent which allows for fluorescence imaging of cells in vivo (Cheng et al 
2011).   Dyes can be injected into cells, and transgenic fish expressing genetically coded 
calcium indicators in specific neurons have been developed, allowing for the imaging of neural 
activity by monitoring calcium changes that occur during action potentials (Wilms & Hausser 
2009).  The adult zebrafish develops stripes and is no longer transparent making in vivo imaging 
in the adult fish difficult, however cancer researchers recently developed a new strain of the 
species (called Casper) that remains transparent as an adult (White et al 2008), which may be 
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used to visualize cells involved in neurodegeneration.   In addition to the ease with which cells 
can be visualized in zebrafish, this model can also be used to perform forward genetic screens, 
as well as reverse genetic screens in which genes are manipulated (mutated, inserted, or 
knocked down) and corresponding phenotypes assessed to identify genes with the potential to 
cause neurodegeneration.  Mutations in the zebrafish SOD1 gene have been used to study 
motor neuron loss and muscle atrophy, and the motor defects that accompany these 
phenomena during ALS.  Human wild-type and mutant TDP43 mRNA have also been 
expressed in zebrafish embryos as a model for ALS (Joyce et al 2011). 
C. elegans, D. melanogaster, and D. rerio, have been useful models in gaining an 
understanding of the molecular mechanisms behind the pathogenesis of neurodegenerative 
disorders, but they are not the best models for human diseases.  Both C. elegans and D. 
melanogaster lack an immune system, which is a major disadvantage when studying 
neurodegeneration.  These organisms also lack mylenated axons and as a result are missing an 
important cell-cell interaction (that of neurons and oligodendrocytes or Schwann cells), as the 
motor neurons undergoing degeneration in human ALS are myelinated (Gama Sosa et al 2012).  
Microglial activation, peripheral immune cell infiltration into the CNS, and interactions between 
neurons and myelinating cells play significant roles in the progression of ALS, as previously 
discussed, and the inability of these organisms to mimic these processes limits the usefulness 
of data collected from invertebrate models.  Zebrafish are a slightly more useful model of ALS 
because they have an immune system that functions similar to that of humans, and have even 
been used as models for immune function during other types of infection.  In addition, this model 
also expresses many of the same CNS cell types seen in humans and mimics human anatomy 
and physiology better than invertebrate models.  The use of fish as a model system does have 
its disadvantages.  The gene targeting technology available for the zebrafish model is limited 
and a greater range of gene targeting exists for mouse models (Gama Sosa et al 2012).  
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Zebrafish also live in a very different environment than humans, which may be a disadvantage 
when studying diseases like ALS that may have an environmental component.            
The best organisms for models of human diseases are those that most closely resemble 
humans (with respect to organ structure and function, and genetics) and can mimic human 
diseases.  Several mammalian models of ALS are currently being used to study the disease, 
and research is ongoing to produce better mammalian models that exhibit the same hallmarks 
of the disease seen in humans.  Currently there are a wide variety of mouse models of ALS and 
there are a few rat models of the disease.  There is even a naturally occurring SOD1 mutation 
that produces a neurodegenerative disorder in dogs that can be used as a model for ALS 
(Awano et al 2009; Joyce et al 2011).  All of these models have been invaluable tools for 
studying the disease, but they do not exhibit the same symptoms and they do not always show 
the same pathological hallmarks of the disease as human patients.  As a result, researchers 
have been working on better models of the disease and have recently produced a non-human 
primate model of ALS (Uchida et al 2012). 
The mouse is probably the most common and well-studied mammalian model of human 
disease.  The first genetically modified mouse was created in 1974 when DNA inserted into a 
mouse embryo showed that the gene insert was present in all of the animal’s cel ls, but was 
unable to be passed to offspring (Jaenisch & Mintz 1974).  The first transgenic mice capable of 
passing exogenous DNA to offspring were later produced in 1981.  This was accomplished by 
injecting purified DNA into a single-cell mouse embryo (Costantini & Lacy 1981; Gordon & 
Ruddle 1981).  Since then, the technology used to genetically manipulate mice has been vastly 
improved and applied to other animals creating an entire industry devoted to transgenic animal 
models of human disease. 
  The first transgenic mouse model overexpressing the human SOD1 gene was 
produced in the 1980s and was used to examine the effects of increased dosage of the protein 
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in Down syndrome (Epstein et al 1987).  In 1994 the first transgenic mouse model 
overexpressing a mutant form of SOD1 associated with ALS, the G93A mutation, was found to  
exhibit motor neuron degeneration similar to that seen in ALS patients (Gurney et al 1994).  
Since this time, a variety of SOD1 mutations, both artificial and those found in ALS patients, 
have been expressed in mice to discern how alterations in the protein’s structure contribute to 
disease onset and progression (Joyce et al 2011).  Table 1.3.1 lists the SOD1 mutations that 
have been expressed in mouse models, as well as the age of disease onset and survival time 
for these animals.  Interestingly, the SOD1-A4V mutation, which is the most commonly 
occurring SOD1 mutation in human ALS (Deng et al 1993; Siddique & Deng 1996), does not 
cause motor neuron degeneration when expressed alone in transgenic mice, but must be co-
expressed with human wild-type SOD1 in order to produce a disease phenotype (Deng et al 
2006).  The G93A mutation, which is much less common in human ALS, is probably the most 
commonly studied mutation thanks to its use in transgenic mouse models of the disease. 
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Table 1.3.1 SOD1 mutations expressed in transgenic mouse models of ALS. 
 
Table was modified from Joyce, et al. (2011) 
ND indicates the survival time was not described. 
a  The SOD1-A4V mutation only produces motor neuron disease when co-expressed with the 
human wild-type SOD1. 
b  Artificial mutations that prevent copper from binding the enzyme. 
c  Mouse transgene. 
d  Age of onset and survival vary depending upon the copy number of the gene, with increased 
copy number leading to earlier onset and shorter survival. 
e  Artificial mutation that truncates the protein. 
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Since the discovery of ALS-associated mutations in TDP43, several TDP43 mouse 
models of ALS have been developed.  Most of these models overexpress the human wild-type 
TDP43 gene, however the human A315T mutation has been successfully inserted into 
transgenic mice.  These models also make use of different promoters which allow the transgene 
to be expressed in specific cell types or brain regions, as well as throughout the body (Joyce et 
al 2011).  The phenotype expressed by these models varies depending upon the promoter and 
expression level of the protein.  It is important to note that TDP43 aggregation seen in human 
patients is not always exhibited by TDP43 transgenic mice.  Since this is a relatively new area of 
research, there is still work to be done to produce better TDP43 mouse models of the disease.   
Many of the same human gene mutations used in mouse models have been utilized in 
rat models of ALS.  Both the H46R and G93A human SOD1 mutations have been successfully 
inserted into rats.  These SOD1 transgenic rat models exhibit an ALS-like phenotype similar to 
their mouse counterparts, upon overexpression of these mutant forms of protein.  Rat models 
expressing both the wild type TDP43 and a mutatant form containing the M337V mutation have 
also been developed (Zhou et al 2010).  Expression of wild type TDP43 does not lead to a 
disease phenotype in rats however the expression of the M337V mutation produces an ALS-like 
phenotype exhibiting lower motor neuron loss and gliosis, but does not mimic the TDP43 
aggregation seen in human patients much like the TDP43 transgenic mouse model.   
The popularity of rodents as models of human disease stems from the fact that they are 
evolutionarily closely related and their overall development parallels that of humans.  
Genetically, mouse chromosomes are organized in a similar fashion to those of humans, with 
genes displayed in similar patterns across the genome.  In addition, mice and rats can be inbred 
to create a homogeneous genetic background which is beneficial when studying the expression 
of a transgene (Gama Sosa et al 2012).  The technology used to insert genes into mice has 
been translated for use in rats, but is much less available for use in rats, which is probably the 
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reason for the greater variety in mouse models of disease.  These genetic manipulations have 
been expanded to include knocking down genes, and transgenic animals can be crossed with 
other strains of animals that are missing certain genes to study the effects of the removal of a 
protein on disease.  Mice and rats are small, easy to care for and breed, live in an environment 
similar to humans that can be tightly controlled in a lab setting, and can be easily used to study 
the effects of drugs.  Unlike invertebrate and fish models of disease, rodents can be 
administered drugs in the same manner as humans (i.e., orally, subcutaneously, intravenously, 
etc.) which is beneficial when conducting pharmacological studies that examine the route of 
administration, absorption, excretion, and things of that nature.  Rats are much larger than mice 
and have a greater capacity for learning in behavioral tasks, which is beneficial when drugs 
need to be inserted directly into the brain or when examining the effects of a disease or 
treatment on behavior.  With respect to neurodegenerative disorders, the organization of the 
rodent CNS is similar to that of humans, with the expression astrocytes and other cell types 
involved in creating the blood-brain barrier and the blood-spinal cord barrier, which is vital when 
studying treatments that need to cross these barriers in order to effectively treat diseases.  Mice 
and rats also exhibit immune function similar to that of humans and these disease models often 
display some of the same neuroinflammatory processes that are commonly observed in 
patients.    
Although transgenic rodents make good models of human diseases due to their 
similarities with humans, they are probably not the best models for ALS.  In mouse models of 
ALS that develop severe paralysis, such as the SOD1 G93A mouse, the paralysis only occurs in 
the rear limbs and is primarily a lower motor neuron disease.  Although humans develop lower 
motor neuron symptoms, they also show significant upper motor neuron degeneration, and 
mouse models do not which is a major disadvantage to studying these animals.  ALS rat models 
that overexpress mutant forms of SOD1 may be better models than their mouse counterparts as 
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they develop symptoms that are closer to those observed in human patients.  Rats 
overexpressing the G93A mutation have an aggressive disease and can exhibit symptoms in 
hind limbs or forelimbs (Joyce et al 2011; Nagai et al 2001), whereas mice expressing this 
mutation show only hind limb paralysis.  Both mouse and rat models of ALS show some of the 
pathological hallmarks that human patients exhibit, such as protein aggregation and activation 
of microglia and astrocytes, but they may also show artifacts resulting from the expression of 
the transgene itself which may not translate to human studies. 
1.4 Purpose of the Study 
ALS is a devastating neurodegenerative disease in which motor neurons are selectively 
killed.  The prognosis of the disease is typically poor and once a positive diagnosis is made, 
patients typically only have a few years of life left.  Due to the lack of treatment options for the 
disease patient quality of life tends to be poor, as patients not only become paralyzed, but they 
may lose the ability to speak and even breathe on their own.  Since motor neurons cannot 
divide to replace cells that have died, the best treatment options would be those that can 
prevent motor neuron death.  In order to achieve this, the disease would have to be detected 
early on, prior to significant cell death.  This would require patients seeking treatment at the 
earliest signs of symptoms, as well as reliable biological markers of the disease and better 
methods of detection.   
ALS research has advanced significantly in the past few decades, with the discovery of a 
wide range of molecular mechanisms providing several potential therapeutic targets of the 
disease.  A constantly expanding variety of animal models of the disease has aided in the 
discovery of drugs that may slow ALS progression, however many drugs that have shown to be 
beneficial in animal models of ALS have failed to show the same level of efficacy in human trials 
(Beghi et al 2007).  This may, in part, be due to the fact that there has been incomplete 
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metabolic profiling of animal models of the disease and overexpression of mutant ALS-
associated proteins may actually lead to systematic metabolic defects in these models.  In 
addition, many studies using animal models, as well as human patients, fail to separate male 
and female data and may miss potential gender differences in the disease itself, as well as 
gender differences related to treatments.  Several studies have implicated a neuroprotective 
effect of estrogen in spinal cord injury (Chaovipoch et al 2006; Kachadroka et al 2010) and ALS 
(Choi et al 2008; Groeneveld et al 2004) and hormones have been shown to effect  
inflammatory processes (Karpuzoglu & Ahmed 2006; Lang 2004; Salem 2004; Straub 2007), 
which can impact disease progression.  Metabolic differences have also been observed 
between men and women.  Women have been shown to have lower resting metabolic rates 
than men (Arciero et al 1993) and a variety of studies have suggested that there are gender 
differences in energy utilization that may be modulated by hormones (Wismann & Willoughby 
2006).  These basic gender differences in metabolism have implications for gender differences 
in xenobiotic metabolism.  In rats gender-specific differences have been observed in certain 
cytochrome P450s, enzymes important in drug metabolism (Kato & Yamazoe 1992), and human 
studies have shown that women recover from general anesthesia faster than men (Bajaj et al 
2007).  These observations suggest that gender should be considered when studying the 
general progression of a disease, as well as the response to drug treatments for a disease, in 
both animal and human studies in order to determine differences in underlying mechanisms and 
the best therapeutic intervention for the patient.    
The purpose of this study was to understand the gender-specific effects of treating 
transgenic mice overexpressing the human SOD1 protein containing the G93A mutation with L-
methionine sulfoximine (MSO), an irreversible inhibitor of glutamine synthetase (GS).  Initial 
studies using this drug in ALS mice showed that it extends the lifespan of these animals and 
targets glutamate excitotoxicity, lowering levels of glutamine and glutamate in specific brain 
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regions (Ghoddoussi et al 2010).  My studies have expanded on these experiments by looking 
at gender differences in survival of ALS mice treated with MSO and the impact of sex hormones 
on the disease progression and treatment efficacy.  These experiments, discussed in Chapter 2, 
show that MSO extends the lifespan of these animals in a gender-specific fashion, having a 
greater effect on females than males.  In addition, sex hormones play a role in MSO’s ability to 
extend lifespan, as gonadectomy removes the response to MSO in both males and females. 
The second portion of this study examines MSO’s effect on amino acid and nitrogen 
metabolism in SOD1 G93A mice.  The goal of these experiments was to characterize basic 
metabolism in untreated wild-type and ALS mice, as well as in mice treated with MSO, and to 
understand the effects of mutant transgene expression and MSO treatment on amino acid and 
nitrogen metabolism accounting for gender.  Enzymatic assays and analysis of plasma 
metabolite levels were performed to monitor metabolic changes between genders, as well as 
genotypes.  These experiments, discussed in Chapter 3, show that there are a variety of 
metabolic differences between males and females, some of which are specific to transgenic 
animals.  MSO treatment significantly lowers brain and spinal cord glutamine synthetase activity 
and shows no differences in activity levels between genders or genotypes, suggesting that its 
gender-specific effects on survival are probably not due to its effect on GS.  MSO treatment and 
SOD1 expression, however, do not have an effect on other enzymes involved in nitrogen 
metabolism, specifically glutaminase and carbamoyl phosphate synthetase one (CPSI).  
Interestingly, CPSI activity is higher in females than males providing evidence supporting 
underlying gender differences in nitrogen metabolism.  SOD1 mice show some oddities in their 
metabolic profiles, such as a cysteine deficiency, suggesting that overexpression of the 
transgene itself may have an impact on overall metabolic processes. 
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CHAPTER 2 
THE GENDER-SPECIFIC EFFECT OF MSO ON SURVIVAL 
2.1 Introduction 
2.1.1 Glutamine Synthetase 
Glutamine synthetase (GS) is an extremely important enzyme that is expressed in a 
variety of organisms, from bacteria to mammals.  It is a major enzyme involved in the 
metabolism of nitrogen found in all extant organisms and the genes encoding GS have been 
suggested to be some of the oldest functioning genes in existence (Kumada et al 1993). There 
are three different classes of glutamine synthetases:  (1) Class I glutamine synthetases (GSI) 
which are expressed by prokaryotes, (2) Class II glutamine synthetases (GSII) which are 
expressed by eukaryotes, plants, and certain bacteria (particularly bacteria belonging to the 
Rhizobiaceae, Frakiaceae, and the Streptomycetaceae families), and (3) Class III glutamine 
synthetases (GSIII) which have only been found in bacteria colonizing the gastrointestinal tracts 
of animals, specifically Bacteroides fragilis and Butyrivibrio fibrisolvens (Brown et al 1994).  The 
structure of glutamine synthetase varies and can be an octamer, decamer, or a dodecamer, 
depending upon the organism in which it is expressed (Eisenberg et al 2000; Krajewski et al 
2008; Liaw & Eisenberg 1994).      
 Class II glutamine synthetases are the only class expressed by eukaryotes.  The 
structures of Class II glutamine synthetases varies, but have been found to be octomeric in at 
least one species of plant (Phaseolus vulgaris) (Llorca et al 2006) and decameric in maize 
(Unno et al 2006) and some mammals (canines and humans) (Krajewski et al 2008).  The 
decameric form of GS is made up of two rings, each of which is composed of five monomers, 
which lie back-to-back forming the barrel-shaped enzyme.  At the interface of each monomer 
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there is an active site and the active sites of the pentameric rings are slightly offset, producing a 
decamer that contains a total of 10 active sites (Krajewski et al 2008).   
GS is responsible for converting glutamate into glutamine, catalyzing the reaction 
Glutamate + NH4
+
 + ATP     Glutamine + ADP + Pi in the presence of magnesium or 
manganese.  The crystal structure of human GS was determined with the enzyme bound to 
magnesium, ADP, and phosphate, and with the enzyme bound to magnesium, ADP, and an 
irreversible inhibitor of GS, methionine sulfoximine.  The structures show that there are three 
magnesium ions present in each active site and suggest that a single molecule of each reactant 
– glutamate, ATP, and ammonia – can enter an active site to produce glutamine (Krajewski et al 
2008).   As a result, the decamer has the potential to produce 10 molecules of glutamine, one 
from each active site.  The conversion of glutamate to glutamine is believed to take place in two 
steps, the first of which involves the enzyme binding to glutamate and ATP, forming the 
enzyme-bound intermediate, γ-glutamyl phosphate.  During the second step, which requires the 
presence of ADP in the active site, ammonium is covalently bound to the activated glutamate 
intermediate to form glutamine and phosphate and ADP are released (Krishnaswamy et al 
1962; Liaw & Eisenberg 1994; Meister 1985).   
 GS can be found in the cytosol or the mitochondria, depending upon the organism and 
the tissue in which it is expressed.  In vertebrate neural tissue GS is expressed primarily in 
astrocytes where it is found in the cytosol (Kennedy et al 1974; Linser & Moscona 1983; Smith 
& Campbell 1983; Smith et al 1987).  However, liver GS can be found in the cytosol or the 
mitochondria, depending upon the method of ammonia detoxification utilized by the organism.  
In organisms such as birds, reptiles and sharks, that utilize uricotelic or ureosmotic methods to 
remove excess nitrogen, liver GS is found in the mitochondria (Campbell et al 1987; Smith & 
Campbell 1983; 1987; Smith et al 1987).  In higher vertebrates that utilize ureotelic methods to 
remove excess nitrogen, like mammals, GS is cytosolic in liver (Smith & Campbell 1988; Wu 
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1963).  In mammalian liver GS is primarily found in pericentral hepatocytes, a small population 
of cells that surround the venules of the liver (Haussinger 1987).   
 Glutamine synthetase is expressed throughout the body and the concentration of GS in 
a cell, as well as enzyme activity, vary depending upon the cell type (van Straaten et al 2006).  
Glutamine is found in high concentrations in the body and is considered a non-essential amino 
acid, as it can be produced by GS and taken up from the diet (Nelson & Cox 2008).  As a result, 
cells can utilize GS either to produce glutamine or to remove the potentially toxic substances, 
glutamate and ammonia.  Lower levels of GS are expressed in cells utilizing the enzyme for 
glutamine production, while high levels of GS are found in cells that function primarily to remove 
ammonia and glutamate (Lie-Venema et al 1998; van Straaten et al 2006).  Organs expressing 
high levels of GS, typically express it in a subset of cells (Lie-Venema et al 1998; van Straaten 
et al 2006).  This is seen in the brain and liver where GS is restricted to certain cell types – 
astrocytes in the brain and pericentral hepatocytes in the liver.  In organs that express low levels 
of GS, such as adipocytes and myocytes, the enzyme appears to be expressed throughout the 
organ (Lie-Venema et al 1998; van Straaten et al 2006).  Mammalian GS has not been as well 
characterized as bacterial forms of the enzyme, which can be regulated by a variety of post-
translational modifications.   As a result, the regulation of mammalian GS is not fully understood, 
but it appears to occur at the level of translation, with protein stability playing a role in regulation 
(van Straaten et al 2006).    GS is susceptible to both reactive oxygen and nitrogen species and 
has been found to be reversibly inhibited by nitration of tyrosine residues, however this 
modification may be more important under conditions where cells are exposed to high levels of 
oxidative stress (Gorg et al 2007). 
GS is a central enzyme in nitrogen metabolism in a wide variety of organisms.  It is the 
only enzyme capable of producing glutamine, the most abundant amino acid in the body, which 
acts as a carrier of ammonia in the bloodstream and as a non-toxic form of glutamate in the 
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nervous system.  As mentioned in Chapter 1, GS is an important enzyme in the central nervous 
system, where it acts as the primary player in the recycling of the neurotransmitter glutamate.  
In the liver, GS produces glutamine that donates ammonia to CPSI for the production of urea 
and the excretion of excess nitrogen.  Glutamine is also important for protein production and 
can act as a fuel for a variety of cell types.        
2.1.2 L-Methionine Sulfoximine 
In the early twentieth century nitrogen trichloride (also called agene) was used to age 
and bleach flour that was used for animal and human consumption.  During this time it was 
noticed that there was a problem with dogs developing a nervous disorder (referred to as 
running fits), which was later determined to be caused by the consumption of foods containing 
flour that had been treated with nitrogen trichloride (Mellanby 1946).  Despite this finding, 
studies conducted on a variety of animals showed that there appeared to be species-specific 
sensitivity to foods that had been treated with agene, and humans, along with monkeys and 
rats, did not show any sensitivity to consumption of these substances (Newell et al 1949a; 
Newell et al 1949b).  Shortly after this discovery, it was determined that treating flour with agene 
lead to the production of a toxic factor which could be isolated (Bentley et al 1949; Campbell et 
al 1951; Reiner et al 1950).  Around this same time, this toxic factor was also synthesized and 
identified as methionine sulfoximine (Bentley et al 1950; Misani & Reiner 1950).   
Methionine sulfoximine (MSO) is a modified form of methionine where the sulfur atom is 
bound to an oxygen atom and an imine group, in addition to the methyl group.  Figure 2.1.1 (A 
and B) shows the structural similarities between methionine and methionine sulfoximine.  
Several studies conducted in the 1950s attempted to identify targets of MSO and in 1952, 
glutamine synthetase was identified as its primary target (Pace & McDermott 1952).  It has also 
been shown to inhibit alanine aminotransferase (De Robertis et al 1967) and stimulate ornithine 
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decarboxylase activity (Di Giacomo et al 1997).  MSO is also structurally similar to buthionine 
sulfoximine (BSO) (Figure 2.1.1C), which acts as an inhibitor of γ-glutamylcysteine synthetase, 
the first and rate-limiting step in the production of glutathione.  While BSO does not inhibit GS, 
MSO has been shown to inhibit γ-glutamylcysteine synthetase (Richman et al 1973).   
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Figure 2.1.2.1 Chemical structure of MSO and analogous compounds.   
MSO (A) is a modified form of the amino acid methionine (B) with an oxygen atom and an imine 
group attached to the sulfur atom.  BSO (C), an inhibitor of γ-glutamylcysteine synthetase, is 
structurally similar to MSO with the sulfur atom attached to a butyl group in place of the methyl 
group. 
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Despite the identification of other enzymatic targets of MSO, the vast majority of 
research conducted on this compound has focused on its ability to inhibit glutamine synthetase.  
Initial studies conducted to determine the mechanism by which MSO inhibits GS suggested that 
the compound competitively inhibited the enzyme, as the addition of glutamate seemed to 
prevent inhibition by MSO (Sellinger & Weiler 1963).  These studies lead to the idea that MSO 
behaved as a glutamate analog, binding the enzyme in the portion of the active site normally 
occupied by glutamate.  Further studies showed that inhibition of GS by MSO was more 
complex, as it required ATP and once the enzyme was inhibited, glutamate was no longer 
capable of reversing inhibition suggesting that MSO irreversibly inhibited GS.  These studies 
also showed that MSO was phosphorylated by the enzyme, producing a new compound 
(methionine sulfoximine phosphate) that interacted tightly with GS but could be removed by 
denaturing the enzyme (Rao & Meister 1972; Ronzio & Meister 1968; Rowe et al 1969).  
Methionine sulfoximine phosphate is produced when MSO and ATP bind the enzyme and GS 
phosphorylates MSO.   The phosoporylated product and ADP are left behind, stuck in the active 
site rendering the enzyme inactive (Krajewski et al 2008; Rao & Meister 1972; Ronzio & Meister 
1968; Rowe et al 1969).  It is important to note that MSO contains two chiral centers, one at the 
α-carbon and a second at the sulfur atom, and therefore has four potential isomers.  Only one of 
these isomers, L-methionine-S-sulfoximine, has been shown to bind to GS and become 
phosphorylated leading to enzymatic inhibition (Manning et al 1969) and has also been linked to 
the convulsant properties of MSO (Rowe & Meister 1970).   
The only way that GS can overcome inhibition by MSO is through degradation and 
production of new protein.  In studies where rats were given a single i.p. injection of a 
subconvulsive dose of MSO, it was shown that different tissues respond differently to the drug.  
Liver GS shows maximal inhibition four hours after MSO administration, while brain GS shows 
maximal inhibition 24 hours after administration.  In addition, the return to normal enzymatic 
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activity levels varies between tissues (Lamar 1968).  Similar studies conducted on mice agree 
with the results obtained from rats and show that liver GS has a higher turnover rate, as activity 
levels return to normal within 30-60 days of MSO administration, while brain GS levels are only 
75% of normal at 90 days after MSO administration (Rao & Meister 1972).  Maximal formation 
of methionine sulfoximine phosphate, the product that inhibits GS, occurs about 5 hours after 
MSO injection in both the brain and the liver.  However, it is more rapidly removed from the liver 
than the brain and complete removal corresponds to the return to normal enzymatic activity 
level (Rao & Meister 1972).   
Despite its ability to cause convulsions in certain species, MSO has shown to have some 
beneficial effects in certain disease models and has been a useful tool in understanding the 
importance of glutamine metabolism.  In diseases which elevate ammonia levels in the body, 
such as acute liver failure, brain GS attempts to lower ammonia levels by incorporating it into 
glutamine which builds up in astrocytes and disrupts the osmotic balance leading to astrocyte 
swelling.  MSO treatment of cell culture and rat models of this disease, decreases glutamine 
production by inhibiting GS and reduces astrocyte swelling (Norenberg & Bender 1994; Willard-
Mack et al 1996).  In a mouse model of acute liver failure, pretreatment with MSO has been 
shown to significantly increase survival and lower levels of several cytokines, including the pro-
inflammatory cytokine TNF-α (Jambekar et al 2011).  Treatment of ALS mice with MSO has also 
been shown to extend lifespan and target excitotoxicity by lowering levels of glutamine and 
glutamate in certain brain regions (Ghoddoussi et al 2010).  It is not entirely clear if all of the 
beneficial effects of MSO are due to glutamine synthetase inhibition, as there are other potential 
targets of the drug that have not been well characterized.  Human studies examining the effects 
of consuming agenized flour, did not show that consumption of foods containing MSO had any 
negative effects on people (Newell et al 1949a; Newell et al 1949b).  As a result, more work 
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needs to be done to fully understand how MSO exerts its beneficial effects and if it has any 
therapeutic potential.          
2.1.3 Effect of Gender on Lifespan, Disease Progression, and the Response to 
Methionine Sulfoximine 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder 
characterized by the death of motor neurons running through ventral roots and corticospinal 
tracts of the spinal cord through the brainstem and primary motor cortex.  The death of these 
motor neurons gives rise to symptoms such as involuntary muscle spasms, muscle weakness 
and atrophy, and eventually leads to paralysis.  Patients typically die within 2-5 years due to 
pulmonary complications and respiratory failure (Wijesekera & Leigh 2009). 
ALS has been subdivided into two categories: (1) Sporadic ALS, the most common type 
of the disease, which appears to have no genetic component, and (2) Familial ALS, which is 
hereditary and accounts for only 5-10% of all cases (Wijesekera & Leigh 2009).  The familial 
form of the disease tends to be autosomal dominant and has been linked to a variety of gene 
mutations, including the genes for TAR-DNA binding protein (TDP-43), and superoxide 
dismutase 1 (SOD1) (Wijesekera & Leigh 2009), the later mutation is commonly exploited in 
transgenic mouse models of the disease.  Despite the discovery of several inheritable mutations 
involved in ALS, the underlying cause of motor neuron death remains unclear. 
One mutation in particular, the SOD1 G93A mutation, has been transferred to a 
transgenic mouse (Gurney et al 1994) to create the primary animal model for characterizing this 
disease and for testing the effects of various drugs.  This mouse lives approximately 120-130 
days before the disease progresses to the point where the mouse must be euthanized.  In a 
previous study we showed that methionine sulfoximine (MSO), a well-characterized inhibitor of 
glutamine synthetase, can extend the lifespan of the SOD1 G93A mouse by 8% when given i.p. 
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injections of 20 mg/kg three times a week (Ghoddoussi et al 2010).  This lifespan extension, 
comparable to that seen with many other drugs tested on this mouse, was accompanied by 
changes in brain metabolites which support the conclusion that there is an interruption in the 
glutamine-glutamate cycle in the CNS, resulting in a decrease in both glutamine and glutamate 
and supporting the idea that the therapeutic effects are a consequence of a reduction in 
excitotoxicity. 
We have continued these studies to test both the effect of dosage (since this 
mechanism-based inhibitor has very long-lasting effects on glutamine synthetase) and the 
gender-specificity of this drug, since ALS and other neurodegenerative diseases display gender 
specificity – affecting one gender more than the other.  We also tested the role of sex hormones 
in both disease progression and the response to MSO treatment by measuring survival, disease 
progression, and response to MSO of ovariectomized female mice and castrated male mice.  
The results of those experiments demonstrate the involvement of sex hormones in both disease 
progression and the response of these mice to MSO treatment.   
2.2 Materials and Methods 
Animal Handling.  Breeding pairs of the SOD1 mouse – B6JL (G93A) – were purchased 
from Jackson Laboratories and offspring containing the human SOD1 G93A mutation were 
identified by PCR of tail DNA, using primers described for this strain by Jackson Laboratories 
(jax.org).  All animal experiments were approved by the Animal Investigation Committee of 
Wayne State University. 
Methionine sulfoximine (MSO), obtained from Sigma Chemical Company (catalogue no. 
5379) was dissolved in 0.9% saline and administered intraperitoneally (i.p.) at a dose of 20 
mg/kg. 
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 Mice were injected with MSO or saline once per week starting at 50 (+/- 2) days of age 
until they were euthanized.  Mice were observed daily by the supervising veterinarians and 
laboratory-animal staff and were euthanized when either 1) they lost 20% of their maximum 
body weight, 2) they were unable to right themselves when put on their back or side, or 3) if, in 
the opinion of the supervising veterinarians, the mice were in distress or unable to obtain 
adequate food and water. 
 Hang-time Analysis.  Mice were placed on a steel wire grid which was then inverted and 
placed over a plastic bin approximately 13 inches deep, with paper towels at the bottom to 
cushion the fall.  The hang-time for each mouse was recorded as the time before the mouse 
released the grid and fell or at 120 seconds if the mouse did not fall before then.  Mice were 
tested twice/week, starting at 50 days of age. 
 Animal Surgeries.  All surgeries were performed between 30 and 40 days of age, before 
the animals had reached sexual maturity.  Mice were anesthetized with i.p. injections of 0.4-0.75 
mg/g body weight Avertin.  A stock solution of Avertin was prepared by dissolving 25g of 2-2-2-
tribromoethanol (Sigma) in 15.5 mL of tert-amyl alcohol (Sigma).  This was then diluted to a 20 
mg/mL working solution by adding 0.5 mL of the stock Avertin to 39.5 mL of PBS and filtering 
through a sterile 45 µm filter.  Both the stock solution and the working solution were kept in foil-
wrapped containers and the working solution was stored at 4°C when not in use. 
 Ovariectomies were performed by first shaving the lower backs of female mice and then 
sterilizing the area with Betadine and isopropanol.  An incision was made in the middle of the 
lower back running parallel to the spinal cord.  The skin was gently pulled away from the muscle 
and the first ovary was located.  A very small incision was then made just below the kidney and 
the periovarian fat pad was gently pulled out of the body, bringing the ovary with it.  Being 
careful not to crush the ovary, mosquito forceps were used to crush the fallopian tube and 
cranial-most portion of the uterine horn.  The ovary was then removed by cutting above the 
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crushed area and the uterine horn was returned to the abdominal cavity.  This was then 
repeated on the other side.  Once both ovaries were removed, the skin incision was closed with 
wound clips. 
 Castrations were performed by first forcing the testicles to descend by applying light 
pressure to the abdominal region and pushing towards the tail.  The testicles were then shaved 
and the area was sterilized with Betadine and isopropanol.  An incision was made in the 
scrotum between the testicles.  A second incision was then made in the tunica of the first 
testicle and the testis, vas deferens, and the fat pad were gently pulled out of the body.  The 
blood vessels supporting the testis were cauterized and the testis was removed by cutting just 
below the site of cauterization.  This was repeated on the other side and the skin incision was 
closed with wound clips. 
 Statistics and Data Analysis.  The survival studies were analyzed by both parametric 
(Student’s t test) and nonparametric (Kaplan-Meier) methods.  Student’s t test significance 
values, p, are always two-tailed. Means are notated as x(y), where x is the mean and y is its 
standard error.  Unless noted, p values are from the t test.  Kaplan-Meier analysis 
supplemented the t test by allowing the comparison of the survival curves (e.g., log rank 
statistic).  The use of both types of analyses was possible because the certainty of death by the 
disease meant that no animals needed to be censored, although two mice died very early from 
causes unrelated to ALS and were removed from the study.  Effect size was determined by 
calculating Cohen’s d with the use of pooled standard deviations (Cohen 1988; Rosnow & 
Rosenthal 1996), and Cox regression was used to obtain the hazard ratio as an additional 
measure of effect size.  The interpretation of d given in the text is according to Cohen’s 
explanation.  The ‘hang-time’ analysis used the same statistical tools as the survival studies with 
the terminal event in the ‘time to event’ Kaplan-Meier procedure being the inability to hang onto 
the grid. 
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2.3 Results 
A weekly injection of MSO increases survival of the SOD1 G93A mouse.  We previously 
showed that mice injected with 20 mg/kg MSO had their survival extended by approximately 8% 
(Ghoddoussi et al 2010).  Since MSO is a mechanism-based inhibitor of glutamine synthetase, 
a single treatment lowers GS levels for an extended period of time, as animals have to 
synthesize more enzyme to overcome the inhibition – up to a week or more in rats and mice 
(Lamar 1968; Rao & Meister 1972).  A single weekly injection should therefore be just as 
effective as multiple injections.  Figure 2.3.1 shows the Kaplan-Meier survival curves for SOD1 
G93A mice treated with a weekly i.p. injection of either saline or MSO (20 mg/kg), starting at 50 
(+/- 2) days of age and illustrates that this dosing-schedule improves the survival of ALS mice 
(p=0.001, log rank test).  A single weekly injection extends the mean lifespan from 128 (1) to 
136 (2) days, where the value in parenthesis is the standard error of the mean. 
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Figure 2.3.1 Kaplan-Meier survival curves for MSO’s effect on the lifespan of SOD1 G93A mice. 
Animals were treated once a week with i.p. injections of either saline (diamonds) or 20 mg/kg 
MSO (squares).  Mice treated with MSO (136 (2) days, n=50) lived significantly longer than 
saline-treated mice (128 (1) days, n=50), p<0.001, two-tailed, d=0.7. 
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 The increase in survival in MSO-treated SOD1 G93A mice depends on gender.  A 
complete summary of the statistics for gender-dependent and treatment-dependent survival 
analyses is shown in Table 2.3.1. Cox regression analysis of the entire data set showed that 
gender and treatment (saline vs. MSO), were significantly affecting survival, with bootstrapped 
significance values of 0.008 and 0.001 respectively.  Castration or overiectomization were also 
significant at 0.006 and 0.04 respectively.  When we further analyzed the results by gender, 
MSO significantly extended the mean lifespan of both males and females, although females 
were more responsive.  The mean lifespan of females is extended from 130 (2) to 140 (2) days 
(p=0.001, d=1.0), while the mean lifespan of males is extended from 125(2) to 132(2) days 
(p=0.02, d=0.6) (Table 2.3.1 and Figure 2.3.2).  The effect sizes (d) indicate a greater effect on 
females.  The conclusion that the therapeutic effects of this drug on lifespan are greater on 
females than on males is also supported by further analysis of survival data of MSO-treated 
animals.  When comparing the mean lifespan of males and females treated with MSO, we see 
that females live significantly longer than males (140 (2) days and 132 (2) days respectively, 
p=0.004, d=0.8).  Kaplan-Meier survival analysis of saline-treated males compared to that of 
saline-treated females were not significantly different (p=0.09, log rank test), but the same 
analysis of the survival curves of MSO-treated males and females showed that MSO-treated 
females lived significantly longer than MSO-treated males (p=0.004, log rank test). 
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Table 2.3.1 Summary of survival comparisons and associated statistical values. 
 
Category Comparison n mean (SEM) p (t test) p (log rank) 
All Intact Saline 50 128 (1) 
  Mice MSO 50 136 (2) 0.001  0.0001  
Intact Saline 25 130 (2) 
  Females MSO 24 140 (2) 0.001  0.0004  
Intact Saline 25 125 (2) 
  Males MSO 26 132 (2)  0.02  0.02 
OVR Saline 9 129 (2) 
  Females MSO 9 130 (3) 0.8  0.4 
CSTR Saline 11 128 (3) 
  Males MSO 11 130 (4)  0.6  0.4 
Saline-treated Intact 25 130 (2) 
  females OVR 9 129 (2)  0.7  0.6 
Saline-treated Intact 25 125 (2) 
  males CSTR 11 128 (3)  0.4  0.4 
MSO-treated Intact 24 140 (2) 
  females OVR 9 130 (3)  0.01  0.004 
MSO-treated Intact 26 132 (2) 
  males CSTR 11 130 (4)  0.5  0.9 
Intact Females 25 130 (2) 
  Saline-treated Males 25 125 (2)  0.06 0.09  
Intact Females 24 140 (2) 
  MSO-treated Males 26 132 (2) 0.004  0.004  
Neutered Females 9 129 (2) 
  Saline-treated Males 11 128 (3) 0.8  0.9 
Neutered Females 9 130 (3) 
  MSO-treated Males 11 130 (4) 0.9  0.6  
 
Category = mice evaluated; Comparison = gender, treatment, or surgery group compared; n = 
the number of animals/group; Mean (SEM) = average age (standard error of the mean); p (t 
test) = p value determined by a bootstrapped t test with 1000 samples; p (log rank) = p value 
determined using Kaplan-Meier; OVR = ovariectomized; CSTR = castrated. 
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Figure 2.3.2 Kaplan-Meier survival curves of MSO’s effect on the longevity of each gender.   
The data shown in Figure 2.3.1 was separated by gender and replotted.  A.  The mean age of 
survival for females treated with MSO (140 (2) days, n=24) was significantly higher than that of 
saline-treated females (130 (2) days, n=25), p=0.001, two-tailed, d=1.0.  B.  The mean lifespan 
of male mice treated with MSO (132 (2) days, n=26) was also found to be significantly higher 
than that of saline-treated males (125 (2) days, n=25), p=0.02, two-tailed, d=0.6.  Diamonds 
represent saline-treated animals and squares represent animals treated with MSO. 
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 Tests of neuromuscular function.  We conducted an analysis of neuromuscular function, 
a hang-time analysis (see Materials and Methods), by measuring how long mice could hang on 
to an inverted wire grid before losing their grip and falling.  The results of this test were analyzed 
in two ways.  First, we plotted the average hang-time (in seconds, 120 maximum) for each 
population versus age, as shown in Figure 2.3.3 for female and male mice.  For female mice, 
MSO improves hang-time over the interval from 114 to 123 days of age (p<0.05 for the points 
indicated in Figure 2.3.3).  For male mice, treatment makes no significant difference in 
neuromuscular function.  We then carried out a Kaplan-Meier analysis of these same data, 
using a hang-time of zero as the terminal event.  This approach allows us to analyze the effects 
of gender and drug treatment on the disease progression.  Additionally, a hang-time of zero is a 
more objective measure of a disease endpoint than determining if a mouse has met our criteria 
for euthanasia.  The analysis, shown in Figure 2.3.4, demonstrates that MSO extends the time 
to the complete loss of hang-time competence for females (123 (2) to 132 (2) days, p=0.0008 
log rank test) and thus delays disease progression in the later stages of the disease.  It also 
confirms that this drug, a specific inhibitor of glutamine synthetase, exerts its effects in a 
gender-specific manner.  This analysis shows that the drug might benefit males – mostly in the 
later stages of the disease – in addition to females, but it clearly benefits females to a greater 
extent.  A complete summary of the gender-dependence and treatment-dependence of the 
Kaplan-Meier hang-time competence analyses are shown in Table 2.3.2. 
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Figure 2.3.3 Hang-time data for female mice and male mice treated with saline and 20 mg/kg 
MSO.   
Each of the four groups consisted of 17 mice except for the MSO-treated females, which 
consisted of 15 mice.  Each point represents the average hang-time of at least 15 mice 
measured at that age +/- 2 days.  In the curves for female mice (A) , we have calculated the 
significance for the points where the curves diverge using a t-test, and the resultant p values are 
listed above the three points on the graphs where MSO treatment produces a significant 
difference.  The curves for male mice (B) show no significant differences in hang-time.  Curves 
were truncated shortly after the mice started dying when how we treated dead mice in this 
analysis began to significantly affect the statistics. 
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Figure 2.3.4 Kaplan-Meier hang-time competence curves using zero hang-time (complete 
inability to hang on to a wire grid) as the terminal event.   
A.  The average age at which hang-time competence was lost in females was improved 
significantly with MSO treatment (132 (2) days, n=15) when compared to that of saline-treated 
females (123 (2) days, n=17), p=0.0004, two-tailed, d=1.4.  B.  In male mice, the average age at 
which hang-time competence was lost was not significantly improved by MSO treatment (122 
(2) days, n=17) when compared to saline treatment (118 (1) day, n=17), p=0.09, two-tailed, 
d=0.6.  Diamonds represent saline-treated animals and squares represent animals treated with 
MSO. 
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Table 2.3.2 Summary of hang-time competence comparisons and associated statistical values.   
 
Category Comparison n mean (SEM) p (t test) p (log rank) 
All Intact Saline 34 120 (1) 
  Mice MSO 32 127 (2) 0.002 0.0007 
Intact Saline 17 123 (2) 
  Females MSO 15 132 (2) 0.0004 0.0008 
Intact Saline 17 118 (1) 
  Males MSO 17 122 (2) 0.09 0.06 
OVR Saline 9 124 (2) 
  Females MSO 9 124 (3) 0.9 0.9 
CSTR Saline 11 123 (2) 
  Males MSO 11 126 (3) 0.4 0.3 
Saline-treated Intact 17 123 (2) 
  females OVR 9 124 (2) 0.7 0.6 
Saline-treated Intact 17 118 (1) 
  males CSTR 11 123 (2) 0.03 0.02 
MSO-treated Intact 15 132 (2) 
  females OVR 9 124 (3) 0.009 0.01 
MSO-treated Intact 17 122 (2) 
  males CSTR 11 126 (3) 0.2 0.07 
Intact Females 17 123 (2) 
  Saline-treated Males 17 118 (1) 0.02 0.02 
Intact Females 15 132 (2) 
  MSO-treated Males 17 122 (2) 0.0002 0.0004 
Neutered Females 9 124 (2) 
  Saline-treated Males 11 123 (2) 0.8 0.9 
Neutered Females 9 124 (3) 
  MSO-treated Males 11 126 (3) 0.6 0.2 
 
Category = mice evaluated; Comparison = gender, treatment, or surgery group compared; n = 
the number of animals/group; Mean (SEM) = average age (standard error of the mean); p (t 
test) = p value determined by the t test using bootstrapped samples of 1000; p (log rank) = p 
value determined using the log rank test for Kaplan-Meier, time to event; OVR = 
ovariectomized; CSTR = castrated. 
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Effects of castration and ovariectomization on survival and grip strength.  Given the 
strong gender effect of MSO treatment, we conducted the same analyses of survival and hang-
time on neutered mice – ovariectomized females and castrated males – to determine if female 
sex hormones were beneficial in the response to MSO, or if male sex hormones were 
detrimental to that response.  The Kaplan-Meier survival analysis shown in Figure 2.3.5A 
demonstrates that MSO does not extend the lifespan of ovariectomized females (p=0.4, log rank 
test), and the results of the Kaplan Meier hang-time competence analysis, shown in Figure 
2.3.6A, indicate that MSO does not slow neuromuscular deterioration (p=0.9, log rank test).  
Therefore, removing female sex hormones eliminates the beneficial effects of MSO on female 
mice. 
 Castrating the male mice tested the role of male sex hormones on disease progression 
in both the absence (saline) and presence of MSO.  Figure 2.3.5B shows the results of the 
Kaplan-Meier survival analysis and illustrates that MSO does not significantly affect castrated 
mouse survival (p=0.4, log rank test).  Nor does MSO treatment have a significant effect on the 
time to the complete loss of hang-time competence in castrated mice (p=0.3 log rank test, 
Figure 2.3.6B and Table 2.3.2).  So neutering mice eliminated the beneficial effects of MSO on 
survival of both male and female mice, and eliminated the beneficial effects of MSO on disease 
progression, as measured by grip in females. 
  
 
 
 
 
 
 
82 
 
 
Figure 2.3.5 Kaplan-Meier survival curves of MSO’s effect on longevity in the absence of sex 
hormones.   
Ovariectomized female and castrated male SOD1 G93A mice were treated once a week with 
i.p. injections of either saline (diamonds) or 20 mg/kg MSO (squares).  A.  The average lifespan 
of ovariectomized female mice treated with MSO (130 (3) days, n=9) was similar to that of 
saline-treated ovariectomized females (129 (2) days, n=9).  In the absence of estrogens, MSO 
no longer had an effect on the longevity of female mice, p=0.8.  B.  In castrated male mice, 
MSO does not have an effect on the average lifespan (130 (4) days, n=11) compared to saline 
treatment (128 (3) days, n=11), p=0.6. 
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Figure 2.3.6 Kaplan-Meier hang-time competence curves (using zero hang-time as the terminal 
event) for gonadectomized mice.   
A.  There is no difference in the average age at which hang-time competence was lost between 
ovariectomized females treated with MSO and saline (124 (3) days and 124 (2) days 
respectively, n=9 for each treatment group), p=0.8.  B.  MSO treatment did not increase the 
average age at which hang-time competence was lost in castrated males (126 (3) days and 123 
(2) days respectively, n=11 for each treatment group), p=0.4.  Diamonds represent saline-
treated animals and squares represent animals treated with MSO. 
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Interestingly, these studies showed that castration alone had a significant effect on the 
hang-time competence of the male mice.  Figure 2.3.7 shows a normal Kaplan-Meier analysis of 
the lifespan of saline-treated gonadectomized versus non-gonadectomized males and females.  
There was no significant difference in the survival curves due to gonadectomization for either 
gender (p=0.4 for females and p=0.4 for males as determined by the log rank test).  However, 
Figure 2.3.8 and Table 2.3.2 show the Kaplan-Meier analysis of hang-time, using zero grip time 
as the terminal event, and reveal that castration alone produces significant improvement in 
saline-treated male mice (p=0.02, log rank test), but ovariectomization has no effect on hang-
time competence of female mice (p=0.6, log rank test).  These results suggest that removal of 
male sex-hormones has a beneficial effect on neuromuscular function of male SOD1 G93A 
mice. 
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Figure 2.3.7 Kaplan-Meier survival plots comparing the longevity of saline-treated mice with 
intact gonads to those that have undergone gonadectomy.   
Diamonds represent saline-treated animals with intact gonads and squares represent 
gonadectomized saline-treated animals.  A. Saline-treated females with intact ovaries (130 (2) 
days, n=25) do not live significantly longer than ovariectomized females treated with saline (129 
(2) days, n=9), p=0.7, two-tailed, d=0.1.  B.  Saline-treated males with intact testes (125 (2) 
days, n=25) do not live significantly longer than castrated males treated with saline (128 (3) 
days, n=11), p=0.4, two-tailed, d=0.3. 
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Figure 2.3.8 Kaplan-Meier hang-time competence plots comparing saline-treated mice with 
intact gonads to those that have undergone gonadectomy.   
Diamonds represent animals with intact gonads and squares represent gonadectomized 
animals.  A.  For saline-treated female mice, there is no difference in the average age at which 
hang-time competence was lost between females with intact ovaries (123 (2) days, n=17) and 
ovariectomized females (124 (2) days, n=9), p=0.7, two-tailed, d=0.1.  B.  Castration of male 
mice significantly increases the average age at which hang-time competence was lost in saline-
treated males (123 (2) days, n=11 for castrated males, compared to 118 (1) day, n=17 for males 
with intact gonads), p=0.03, two-tailed, d=0.9.  
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2.4 Discussion 
We have previously shown that MSO, a potent inhibitor of glutamine synthetase, both 
extends the lifespan of SOD1 G93A mice and alters the levels of several neurochemicals - 
notably glutamine, glutamate, and GABA - in different brain regions (Ghoddoussi et al 2010).  
Those studies used the published dosage of 20 mg/kg MSO (Blin et al 2002), injected three 
times per week.  In this report we expanded those experiments in three ways: 1) by increasing 
the total number of mice tested, 2) by using a grip assay monitoring neuromuscular function to 
provide an alternative to death for measuring the effects of the drug, and 3) by examining 
gender-dependence of the response to MSO and, in particular, the involvement of male and 
female sex hormones in disease progression through ovariectomy and castration of SOD1 
G93A mice. 
 Our first survival study consisted of 30 mice – half treated with saline and half treated 
with MSO three times per week (Ghoddoussi et al 2010).  The current study consisted of 100 
mice – half treated with saline and half treated with MSO once a week.  Since MSO is a 
mechanism-based inhibitor of glutamine synthetase, inhibition can only be overcome by 
synthesizing more of the enzyme.  Hence, recovery of full brain GS activity takes a long time – 
up to several weeks (Lamar 1968; Rao & Meister 1972).  If the action of the drug on these mice 
involves inhibition of glutamine synthetase, the reduced dosage should have the same effects 
as the higher dosage.  We found that in fact the reduced dosing schedule produced essentially 
the same extension of lifespan in the SOD1 G93A mouse model for ALS, despite the reduction 
in frequency of administration, providing additional support for MSO having a significant effect 
on disease progression and again indicating that the therapeutic target is glutamine synthetase. 
 In order to reduce the uncertainties involved in applying criteria for euthanasia, we 
conducted grip (hang-time) assays to monitor neuromuscular function and then carried out a 
Kaplan-Meier analysis using the time the mice were unable to grip (hang-time of zero; i.e. total 
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failure of tested muscle strength) as the terminal event, instead of death.  This measurement is 
more objective and provides an additional check on disease progression.  While euthanasia 
criteria were applied in a blinded manner the decision was made by the veterinary staff, 
introducing a small measure of subjectivity to the survival analysis.   
 This Kaplan-Meier hang-time competence analysis also supported the conclusion that 
MSO is acting in a gender-specific fashion.  In the actual survival analysis, the drug appears to 
be working better on females than on males, although the extension of lifespan is signif icant for 
both.  While the log rank test for differences in survival due to MSO treatment resulted in a 
much smaller p value for females (0.0004) than for males (0.02), this does not mean that the 
MSO affected females more strongly.  Calculating effect sizes (d) according to Cohen (Cohen 
1988), the effect size for females (1.0) is larger than that for males (0.6).  This corresponds to 
36% of the females improving with MSO treatment, as compared to 26% of the males.  
Calculating hazard ratios by Cox regression, females reduced their risk of death on MSO by 
65%; while males reduced their risk of death by 46%, again indicating that MSO has a larger 
effect on female survival.  In the hang-time analysis, the effect of drug treatment did not reach 
significance for males (p=0.06, log rank test) while it did for females (p=0.0008).  More 
importantly, the 95% confidence intervals for the hazard ratio for males, in contrast to that for 
females, included a hazard ratio of 1.0, indicating that MSO does not necessarily improve 
neuromuscular function. 
 Both ovariectomizing females and castrating males eliminated the beneficial response of 
mice to MSO treatment, demonstrating that the therapeutic effects of this drug involve enzymes 
or pathways whose activities are influenced by estrogen or testosterone, or some other sex 
hormone.  Whether the hormone-dependent effects are on glutamine synthetase itself, or on 
some aspect of metabolism that is influenced by both glutamine synthetase and sex hormones, 
was not tested in these studies.  We have assayed brain glutamine synthetase activity in this 
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mouse model, as previously described (Ghoddoussi et al 2010) and found no significant gender 
differences in either treated or untreated mice.  Finally, the results from castrated male mice 
show that male sex hormones facilitate disease progression, since castration delayed 
progression in the hang-time analysis even though it did not ultimately affect lifespan.  
Testosterone or another hormone therefore acts on some process that accelerates 
neurodegeneration.  Ovariectomizing females, however, affected only the response to MSO but 
neither lifespan nor disease progression as measured by the hang-time assay.  The hormone-
responsive target affected by MSO treatment is therefore probably some pathway or protein that 
can ameliorate disease progression when MSO is present, but which is not otherwise a 
significant component of the disease process.  In fact, comparing our various measurements on 
ovariectomized females and castrated males revealed no significant differences between these 
groups (Tables 1 and 2).  The fact that the differences between males and females arise only in 
animals with intact gonads is another indication that sex hormones play a significant role in 
disease progression – male hormones exacerbate the disease, and both male and female 
hormones influence some aspect of metabolism or cell biology that can respond beneficially to 
treatment with MSO.   
In humans, the age of onset of ALS is between 50 and 60 years of age for both the 
sporadic and familial forms (Bruijn et al 2004), which are clinically indistinguishable from one 
another.  ALS has a slight male prevalence with a male to female ratio of 3:2 (Pasinelli & Brown 
2006; Wijesekera & Leigh 2009).  In large studies examining both sporadic and familial cases of 
ALS, the overall incidence and prevalence of the disease are greater in mean than women 
(McCombe & Henderson 2010).  Although gender does not seem to have an effect on survival, 
most of the ALS patients that fall within the younger age groups in these studies are men.  
Interestingly, the male to female ratio decreases with increasing age and approaches 1:1 after 
60 years of age (Haverkamp et al 1995), suggesting sex hormones may play a role in the 
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disease.  Gender differences in clinical features of the disease have also been noted, but are 
difficult to explain (McCombe & Henderson 2010).  Some potential explanations for these 
differences are biological differences between males and females - including gender differences 
in the overall immune response and the central nervous system and its ability to repair damage, 
possibly due to protective effects of certain hormones, and gender differences in exposure to 
certain toxins.   
 Mouse models of ALS also reflect several gender differences in the disease.  Survival 
data from SOD1 G93A transgenic mice shows that females have a slightly longer lifespan than 
males.  The average lifespan of female transgenic mice is between 130 and 135 days, whereas 
the average male lifespan is between 125 and 130 days (Choi et al 2008; Heiman-Patterson et 
al 2005).  Male mice typically show an earlier onset of the disease than females (Heiman-
Patterson et al 2005), which is consistent with data collected from ALS patients.  Studies looking 
at gender differences in the extension reflex and rotarod performance of these animals provide 
evidence suggesting the disease progresses more slowly in female mice (Choi et al 2008).  In 
contrast to our results, those studies showed that ovariectomizing these mice leads to 
accelerated disease progression (Choi et al 2008) and a decrease in the average lifespan.  This 
decrease in lifespan was shown to be reversed with 17β-estradiol treatment (Choi et al 2008; 
Groeneveld et al 2004), further supporting the idea that estrogen plays a protective role in 
female ALS mice.  Our studies, however, show no protection by female sex hormones in the 
absence of MSO, but suggest that male sex hormones facilitate the disease progression. 
 Data from both human and animal studies show that there are biological differences 
between males and females that can influence the progression of diseases like ALS.  If sex 
hormones can alter the progression of a disease, then they should be able to influence the 
effectiveness of treatment, as is seen in these studies.  Using the SOD1 G93A mouse model for 
ALS, Teng et al. showed that a β2-adrenoceptor agonist, clenbuterol, exhibited a gender-
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specific effect (Teng et al 2006).  Clenbuterol was able to help prevent weight loss, delay motor 
symptoms, and extend the median survival, and seemed to exert a protective effect on neurons 
in female, but not male, mice (Teng et al 2006).  It has also been shown that in the SOD1 
mouse, ROS production is increased in male spinal cords but not females, and that males and 
females had different responses to treatment with GCSF (Naumenko et al 2011).  Gender-
specific differences in both neurological parameters and electrophysiological changes have also 
been observed in the SOD1 mouse (Alves et al 2011). 
There has been little biochemical characterization of the overall metabolic profile of the 
SOD1 G93A mouse model for ALS, much less for information on the gender-specific differences 
in metabolites and metabolic enzymes.  The fact that an inhibitor directed at a central enzyme of 
nitrogen metabolism can delay disease progression and extend lifespan in a gender-specific 
manner suggests that this disease may involve a metabolic defect that responds to sex 
hormones, either directly or indirectly.  Such gender-specific differences must therefore be 
identified and accounted for in the development of therapies to treat ALS.  We are currently 
trying to identify metabolic differences between wild-type and SOD1 G93A mice in order to 
determine how treatment with MSO might influence those differences, in an effort to identify 
targets for other such “metabolic” therapies.  
 
     
 
 
 
 
 
 
 
 
 
92 
 
 
CHAPTER 3 
BIOCHEMICAL EFFECTS OF MSO TREATMENT ON ALS MICE 
3.1 Introduction 
3.1.1 Amino Acid Metabolism 
 Amino acids are the basic building blocks of proteins within the body and can be 
classified in a variety of ways – based on charge of the R-group, architecture, the body’s ability 
to synthesize them, or based on their degradative end products and the metabolic cycle they 
are then shuttled into.  There are 20 common amino acids and a variety of uncommon amino 
acids that are derived from them.  Of the 20 common amino acids, humans are capable of 
producing 11 of them, while the other 9 must be obtained through the diet (Nelson & Cox 2008).  
Histidine, isoleucine, leucine, lysine, methionine, phenylalanine, threonine, tryptophan, and 
valine must be provided in the diet and are therefore considered to be essential amino acids.  
The body has pathways that can produce alanine, asparagine, aspartate, glutamate, and serine 
and as a result, these amino acids are considered to be nonessential.  Arginine, cysteine, 
glutamine, glycine, proline, and tyrosine can also be produced by the body, but are required 
during development and some disease conditions and are therefore classified as conditionally 
essential amino acids (Nelson & Cox 2008).   
Amino acids are ultimately broken down into seven potential end products which 
converge at the citric acid cycle, where their carbon skeletons can be completely oxidized to 
carbon dioxide and water or go on to produce glucose or ketone bodies.   Those amino acids 
that are broken down to produce acetoacetyl-CoA (leucine, lysine, phenylalanine, tryptophan, 
and tyrosine) and acetyl-CoA (isoleucine, leucine, threonine, and tryptophan) are considered to 
be ketogenic because they can ultimately go on to produce ketone bodies.  Those amino acids 
that are converted to glutamate (glutamine, arginine, histidine, and proline) or broken down into 
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succinyl-CoA (isoleucine, methionine, threonine, and valine), fumarate (phenylalanine and 
tyrosine), oxaloacetate (asparagine and aspartate), or pyruvate (alanine, cysteine, glycine, 
serine, threonine, and tryptophan) are considered to be glucogenic amino acids because their 
carbon skeletons can be used for the production of glucose (Nelson & Cox 2008).  Tryptophan, 
tyrosine, isoleucine, phenylalanine, and threonine are both glucogenic and ketogenic.  Figure 
3.1.1.1 shows the structures of the common amino acids, organized by the charge of the R-
group.   
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Figure 3.1.1.1 The common amino acids.   
The 20 common amino acids contain a variety of R-groups that can be positively or negatively 
charged, polar (hydrophilic), nonpolar (hydrophobic), or aromatic.  Those amino acids in red are 
glucogenic, those in blue are ketogenic, and those in purple have the ability to be either 
ketogenic or glucogenic.  Essential amino acids are labeled with asterisks (*) and conditionally 
essential amino acids are labeled with a cross (†).  
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Protein obtained through the diet is denatured and broken down by the stomach and 
passed to the small intestine where it is further broken down and absorbed.  Absorption occurs 
through enterocytes, which line the small intestine and colon.  Microvilli on the surface of 
enterocytes increase the surface area available for the absorption of nutrients and the 
glycocalyx coating the inside of the gastrointestinal tract contains a variety of enzymes to aid in 
further protein breakdown (Purves et al 2001).  Individual amino acids and small peptide 
fragments can be taken up by enterocytes (Adibi et al 1967) through a variety of amino acid 
transport systems, some of which depend upon the sodium gradient within the gut for transport 
(Broer 2008).  The anatomy of the small intestine is such that it contains millions of projections 
(called villi) extending into the lumen, each of which contains venules and arterioles lining the 
center through which blood circulates (Tortora & Grabowski 1996).  One mechanism believed to 
be important in the uptake of amino acids by the intestine is the γ-glutamyl cycle, which utilizes 
intracellular glutathione to help bring amino acids into the cell (Cornell & Meister 1976; Meister 
et al 1979; Orlowski & Meister 1970).  Figure 3.1.1.2 shows the γ-glutamyl cycle, which brings 
amino acids into the cell by first attaching them to glutathione via γ-glytamyl transpeptidase and 
then releasing them inside the cell and replenishing glutathione.    Peptides taken up by 
enterocytes lining the villi in the lumen are broken down within the cell and transported into the 
blood stream through the basolateral membrane (Broer 2008).  Once in the bloodstream, amino 
acids are circulated to organs and taken up through transport systems similar to those utilized in 
the small intestine (Broer 2008).  The brain, which contains barriers preventing the entry of 
many substances, also expresses a variety of amino acid transport systems (Smith 2000) to 
bring in precursors of neurotransmitters and neuropeptides. 
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Figure 3.1.1.2 The γ-glutamyl cycle of amino acid uptake.   
1) γ-glutamyl transpeptidase (γ-GT) within the membrane transfers the γ-glutamyl moiety of 
glutathione to the amino acid, bringing it into the cell as γ-glutamyl amino acid (γ-Gaa).  2a) γ-
glytamyl cyclotransferase (γ-GCT) cleaves the amino acid, releasing it in the cytosol, and 
producing 5-oxoproline (5-OP).  2b) The cysteinyl-glycine (Cys-Gly) produced by γ-GT in the 
first step of the cycle is cleaved by peptidase into glycine and cysteine.  3) 5-oxoprolinase 
converts 5-OP into glutamate.  4) γ-glutamylcysteine ligase (γ-GCL) begins to replenish 
glutathione by attaching cysteine to the carboxylate group of glutamate to produce γ-glutamyl 
cysteine (γ-GC).  5) Glutathione synthetase replenishes glutathione (GSH) by attaching glycine 
to γ-GC.  
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3.1.2 L-Glutamine and Nitrogen Metabolism 
 L-Glutamine is the most abundant amino acid in the body, with plasma levels ranging 
from 500 to 700 µM in humans (Rennie et al 1981).  Glutamine obtained from the diet is 
absorbed by enterocytes in the intestine, which utilize glutamine as a source of energy and 
probably use most of what they absorb, resulting in very small amounts of dietary glutamine 
released into the bloodstream (Windmueller & Spaeth 1974).  Glutamine is in high demand in 
the body since most tissues utilize glutamine for a variety of cellular processes.  However, this is 
not a problem for most mammalian tissues, since they express glutamine synthetase (Krebs 
1935) and can therefore produce glutamine from glutamate.  In addition, skeletal muscle has the 
largest glutamine store in the body and has the ability to release it into circulation to maintain 
plasma glutamine levels (Newsholme 1994; Newsholme & Parry-Billings 1990), ensuring its 
availability for all tissues. 
Glutamine is probably the most important amino acid in the body due to the wide variety 
of roles it can play.  One of its most important roles is to detoxify ammonia and transport it 
through the bloodstream (Bulus et al 1989) to the liver for urea production.  Glutamine can act 
as an ammonia donor for carbamoyl phosphate synthetase I (CPSI) (Nelson & Cox 2008), the 
first enzyme in the urea cycle, and it can be converted to glutamate by mitochondrial 
glutaminase, which can also donate ammonia to CPSI.  Figure 3.1.2.1 shows the role of 
glutamine and glutamate in the urea cycle.  CPSI acts as the first and rate limiting enzyme in the 
urea cycle, catalyzing the reaction between bicarbonate, ammonia and two molecules of ATP to 
produce carbamoyl phosphate.  This carbamoyl phosphate is then used in the second step in 
the cycle, catalyzed by ornithine transcarbamoylase, where the phosphate group is released 
and it is combined with ornithine producing citrulline.  The citrulline is then transported to the 
cytosol where it undergoes a reaction with ATP, catalyzed by arginosuccinate synthetase, 
forming an intermediate that then reacts with aspartate (produced within the mitochondria) 
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yielding arginosuccinate.  Arginosuccinate lyase then removes fumarate from arginosuccinate to 
produce arginine, which is converted to urea and ornithine through the ureohydrolase arginase.  
The ornithine produced in this last step is then taken back up by the mitochondria for another 
round of the cycle (Berg et al 2007; Nelson & Cox 2008).   
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Figure 3.1.2.1 The urea cycle.   
The urea cycle starts in the mitochondrial matrix.  Amino acids enter the urea cycle as 
glutamate which can be taken up by mitochondria, or produced within the mitochondrial matrix 
from glutamine via glutaminase.  The carbon atom in urea comes from bicarbonate that is 
incorporated into carbamoyl phosphate, while one of the amino groups is donated by external 
amino acids and the other is donated by aspartate produced within the mitochondria via 
aspartate aminotransferase.   
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Glutamine has many other roles within the body, besides acting as a source of 
ammonia.  The kidneys utilize glutamine to maintain acid-base homeostasis (Newsholme et al 
2003) and in the brain glutamine acts as a nontoxic form of glutamate and ammonia (Nestler et 
al 2001).  Glutamine also acts as a source of metabolic intermediates for a variety of cells 
(Newsholme et al 2003).  Enterocytes consume glutamine as a source of energy, but other 
cells, such as colonocytes, fibroblasts, tumor cells, and proliferating immune cells, also utilize 
glutamine at high rates (Askanazi et al 1980; Kovacevic & McGivan 1983; Koyama et al 1998).  
Glutamine acts as a nitrogen donor for the production of nucleotides and can be incorporated 
into proteins (Nelson & Cox 2008), which makes it especially important for proliferating cells.  
Mononuclear cells lack the ability to synthesize glutamine (Ardawi & Newsholme 1983; Rohde 
et al 1996) and must rely on glutamine circulating in the bloodstream.  Lymphocyte proliferation 
upon stimulation is dependent upon the presence of glutamine in cell culture systems and the 
ability of stimulated lymphocytes to produce cytokines is dependent upon the extracellular 
concentration of glutamine (Ardawi & Newsholme 1982; 1983; Crawford & Cohen 1985; Rohde 
et al 1996; Wallace & Keast 1992).  In addition, the phagocytotic ability of peritoneal 
macrophages isolated from mice has been shown to be dependent upon glutamine (Parry-
Billings et al 1990; Wallace & Keast 1992).  
3.1.3 The Effects of Gender and MSO Treatment on Nitrogen Metabolism in SOD1 G93A 
Mice 
 The first disease-associated mutations in the gene encoding superoxide dismutase 1 
(SOD1) were discovered in 1993 and linked with the familial form of the ALS (Rosen et al 1993), 
which accounts for only 5-10% of all cases of the disease.  Mutations in SOD1 account for 
approximately 20% of familial cases, and a much smaller percentage of overall cases of ALS.  
Over 100 mutations in SOD1 have been characterized and associated with the disease, but the 
exact mechanism by which these mutations lead to disease is unknown.  Mutations in SOD1 
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have also been implicated in sporadic ALS and recent research suggests that the normal wild-
type form of SOD1 may play a role in the disease, through transcriptional and posttranslational 
modifications of the protein (Milani et al 2011).   
 Superoxide dismutases are a group of enzymes that scavenge superoxide free radical 
anions, converting them to hydrogen peroxide and molecular oxygen (McCord & Fridovich 
1969).  There are three isoforms of superoxide dismutase ubiquitously expressed by 
mammalian cells: 1) SOD1, a homodimeric copper/zinc-binding form of the enzyme found in the 
cytosol (Fridovich 1974); 2) SOD2, a tetromeric manganese-binding form of the enzyme found 
within the mitochondria (Abe & Okazaki 1987); and 3) SOD3, a tetromeric copper/zinc-binding 
form of the enzyme found outside of cells (Zelko et al 2002).  These three isoforms of the 
enzyme help to protect cells against oxidative damage that can occur as a result of oxidative 
phosphorylation (Zelko et al 2002).  All of the ALS-related SOD mutations have been isolated to 
the SOD1 isoform and most of these mutations allow the enzyme to retain its normal superoxide 
scavenging activity.  Disease associated mutations in SOD1 are believed to exert their 
deleterious effects through a toxic gain of function, however most of these mutations have not 
been well characterized and the exact functions gained through the various mutations are 
unknown. 
 These toxic functions gained by mutant SOD1 proteins can vary, depending upon the 
mutation, and can have a tremendous impact on metabolic processes within the cell.   Mutant 
SOD1 protein can undergo conformational changes which can result in new, potentially 
detrimental, protein-protein interactions.  Several studies have shown that mutant SOD1 
proteins have novel binding partners and can disrupt normal cellular functions.  Motor neuron 
cultures expressing mutant SOD1 protein have been used in immunoprecipitation studies that 
showed that SOD1 with the G93A mutation interacts with cytosolic malate dehydrogenase,  part 
of the malate-aspartate shuttle involved in maintaining the NADH/NAD+ balance in brain 
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mitochondria (Mali & Zisapels 2008).  Mutant SOD1 protein has also been shown to interact 
with the anti-apoptotic protein Bcl-2 (Pasinelli et al 2004).  When bound to Bcl-2, mutant SOD1 
induces a conformational change in the protein, resulting in the exposure of a toxic domain that 
has been found to be deleterious to cells in the spinal cords of mice and humans (Pedrini et al 
2010).  Mutant SOD1 protein with the G93A mutation has been shown to interact with TDP-43 in 
cell culture and animal models (Higashi et al 2010) and with cytosolic and mitochondrial lysyl-
tRNA synthetase, an enzyme required for the translation of protein, resulting in decreased 
mitochondrial protein synthesis and overall morphological changes in mitochondria (Kawamata 
et al 2008).  In addition, mutant SOD1 protein can form detergent insoluble aggregates with the 
heat shock proteins HSP70, HSP40, and αB-cyrstallin in cells isolated from transgenic mice 
(Shinder et al 2001). 
 Interactions between mutant SOD1 proteins and mitochondrial proteins, such as lysyl-
tRNA synthetase, indicate that the normally cytosolic protein ends up in the mitochondria where 
it can encounter different proteins.  Since mitochondria are vital to producing energy within the 
cell, mutant SOD1 entering the organelle where it could potentially come into contact with 
integral energy producing proteins might have a major impact on energy production.  In 
transgenic mouse models of ALS, expression of the mutant SOD1 protein has been shown to 
lead to morphological abnormalities, such as vacuolization occurring within the intermembrane 
space, in spinal cord mitochondria (Higgins et al 2003).  It has also been shown to be selectively 
recruited to mitochondria in cells of the spinal cord in areas affected by the disease (Liu et al 
2004).  Although most of these studies have focused on spinal cord tissue, studies of 
mitochondrial function have shown that mitochondrial respiration is decreased not only in 
mitochondria isolated from brain and spinal cord, but liver as well (Mattiazzi et al 2002).  Liver 
tissue from ALS patients shows morphological changes in mitochondria and rough ER, and 
records from these patients suggest that they also suffered from mild liver dysfunction (Nakano 
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et al 1987).  Transgenic mouse models of ALS also show global metabolic deficits and a high 
energy diet has been shown to extend the average lifespan (Dupuis et al 2004).  These data 
combined with data from human patients suggests that dysfunctional liver metabolism may play 
a role in ALS.  
 Since ALS is classified as a neurodegenerative disorder most research conducted on 
ALS patients and animal models focuses on the central nervous system.  Motor neurons are the 
primary target of degeneration and several cellular processes undergo alterations during the 
disease, all of which can lead to cell death.  However, in human and animal models where 
mutated genes are considered to be the cause of the disease, these mutated proteins are 
typically expressed throughout the body.  ALS is almost always age-related so the effects of 
expressing mutant proteins builds up over time and leads to cell death in motor neurons, but 
can affect other cell types which often go ignored because problems in these cells do not cause 
paralysis.  The following experiments were designed to test the hypothesis that transgenic mice 
overexpressing the human form of SOD1 containing the G93A mutation have defective nitrogen 
metabolism, specifically alterations in the urea cycle.  To test this hypothesis, we examined the 
activity of nitrogen-metabolizing enzymes in the brain (glutamine synthetase and glutaminase, 
which are also important to the glutamate-glutamine cycle) and examined the levels of several 
plasma metabolites, including ammonia.  Preliminary analysis of plasma metabolite levels 
suggested that nitrogen metabolism may be affected in these animals, so we followed up the 
plasma metabolite studies with assays of carbamoyl phosphate synthetase I and glutamine 
synthetase in the liver.  These assays were carried out in both wild-type and SOD1 G93A-
expressing mice. 
Since our previous studies showed that treating SOD1 G93A mice with an irreversible 
inhibitor of glutamine synthetase, MSO, significantly extends the lifespan and improves 
neuromuscular function in these mice in a gender-specific fashion (with females benefiting more 
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than males), we treated a group of mice with MSO and examined both the effects of MSO and 
gender on nitrogen metabolism.  The results of our experiments show that expression of the 
transgene does not affect glutamine synthetase activity, but MSO treatment significantly lowers 
GS activity in both genders and genotypes, suggesting that MSO’s gender-specific effects are 
not through its action on GS.  We found that there are gender-specific differences in plasma 
metabolite profiles in nontransgenice mice and metabolic profiles of these mice change with 
age, providing evidence for gender-specific and age-related changes in general metabolism.  
We also found that presymptomatic mice have several deficits in plasma metabolites indicative 
of underlying metabolic defects.  These plasma metabolite deficits are gender-specific, with 
males and females showing different metabolic profiles, and change with age suggesting that, at 
least early in the disease, compensatory mechanisms can “normalize” metabolism to some 
extent.  MSO treatment significantly alters the metabolic profile of SOD1 mice, while doing little 
to that of wild-type mice, and has the ability to alter metabolites in a gender-specific manner.  
Taken together, these data suggest that global metabolic defects play a role in the pathogenesis 
of ALS in this mouse model and that gender is also a significant factor in the disease.       
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3.2 Materials and Methods 
Animal Breeding and Care.  All animal experiments were approved by Wayne State 
University’s Animal Investigation Committee.  SOD1 breeding mice were obtained from Jackson 
Laboratories.  Female C57BL/6*SJL mice were crossed with B6SJL males overexpressing the 
human SOD1 transgene containing the G93A mutation (SOD1 G93A).  Offspring were 
genotyped by performing PCR on DNA isolated from tail clippings using primers recommended 
by Jackson Laboratories for this strain of transgenic mice (jax.org).  Animals were assigned to 
one of five groups – a 50, 70, or 110 day time point, or a surgery group which consisted of 
SOD1 females.   
Experimental Groups.  The 50 day group consisted of untreated wild-type and SOD1 
mice from which liver, central nervous system tissue and plasma were collected at 50 ± 2 days 
of age.  The 70 day group consisted of wild-type and SOD1 mice that were given weekly i.p. 
injections of saline or 20 mg/kg body weight MSO (prepared in 0.9% saline; Sigma Chemical 
Company, no. 5379) starting at 50 ± 2 days of age and were euthanized at 70 ± 2 days of age.  
The 110 day group consisted of wild-type and SOD1 mice that were given weekly i.p. injections 
of saline or 20 mg/kg body weight MSO starting at 50 ± 2 days of age and were euthanized at 
110 ± 2 days of age.  The 70 and 110 day mice were given their final injection within three days 
of euthanasia.   Central nervous system tissue, liver, and plasma were collected from 50 and 70 
day animals while only CNS tissue and plasma were collected from 110 day animals.   
Plasma and Tissue Collection.  A stock solution of Avertin was prepared by dissolving 25 
g of 2-2-2-tribromoethanol (Sigma Chemical Company) in 15.5 mL of tert-amyl alcohol (Sigma 
Chemical Company).  This solution was then used to prepare a working solution of 20 mg/mL by 
dissolving 0.5 mL of the stock solution in 39.5 mL of PBS.     
Mice were anesthetized with an i.p. injection of Avertin (0.4-0.75 mg/g body weight) and 
blood was collected via cardiac puncture.  Blood was placed in BD Microtainer tubes containing 
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lithium heparin and centrifuged at 13,000 rpm for 3 minutes in a Sorvall Biofuge pico desktop 
centrifuge to obtain plasma.  For the 50 and 70 day groups, 100 µL aliquots of plasma were 
taken for plasma ammonia analysis and the remaining plasma was immediately frozen on dry 
ice for later use.  For the 110 day group, plasma was frozen on dry ice immediately.  All tissue 
samples were placed in centrifuge tubes and immediately frozen on dry ice and thawed prior to 
homogenization. 
Plasma Ammonia Determination.  Plasma ammonia levels were determined using an 
ion-exchange resin and the Berthelot indophenol reaction as described by Brusilow (Brusilow 
1991).  A 100 µL aliquot was taken immediately after obtaining the plasma and added to a 
microfuge tube containing 200 µL of deionized water and 50 µL of prepared ion-exchange resin 
(BioRad AG 50W-X4 Resin, 100-200 Mesh hydrogen form).  The procedure was carried out 
according to Brusilow (1991) and absorbance values were read at 630 nm.  Ammonia levels 
were determined by comparing sample absorbances to those of an ammonium sulfate standard 
curve and values were expressed as µmoles of ammonia per liter of plasma. 
Plasma Metabolite Analysis.   Plasma samples that were not used for ammonia 
determination were immediately frozen on dry ice and transported to the Biochemical Genetics 
Laboratory in the Detroit Medical Center where Dr. Robert Grier processed and analyzed them 
for a variety of metabolites using HPLC.   
Glutamine Synthetase Activity Assays.  Brain and spinal cord preparation for GS activity 
were carried out according to Alton Meister’s Methods in Enzymology protocol (Meister 1985).  
Liver sample preparation was carried out using a modified version of Pierson’s protocol for 
preparation of samples for CPSI activity assays (Pierson 1980).  GS activity was determined 
using a modified version of Meister’s protocol. 
 Whole mouse brains and spinal cords were thawed and homogenized by hand using a 
glass and Teflon Dounce homogenizer in 1-2mL of homogenizing buffer (150 mM KCl, 5 mM 2-
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mercaptoethanol, 1 mM EDTA, 1 mM PMSF, and protease inhibitor cocktail (Sigma, P8340), pH 
7.2).  Brain and spinal cord homogenates were centrifuged for five minutes at 5000 rpm in a 
Sorvall RC 5B Plus centrifuge (SS-34 rotor) cooled to 4°C.  Liver samples were prepared by 
homogenizing 100 mg of liver in 2mL of buffer containing 50 mM triethanolamine, 10 mM ATP, 
15 mM magnesium acetate, and 1 mM dithiothreitol, pH 8, using 4-5 strokes in a motorized 
glass and Teflon Dounce homogenizer set to a speed of six.  Liver homogenates were 
centrifuged in a Sorvall Ultracentrifuge (OTD65B; Beckman TY 65 rotor) cooled to 4°C at 37,000 
x g for 15 minutes.  After centrifugation, 1 mL of the supernatant was added to 10 µL protease 
inhibitor cocktail (Sigma, P8340) and 10 µL of 100 mM PMSF.  Protein concentrations for brain, 
spinal cord, and liver samples were determined using the Coomassie Plus Protein Assay 
(Thermoscientific).   
 Enzyme activity was determined by following the reaction in which GS catalyzes the 
conversion of L-glutamine to L-γ-glutamyl hydroxamate in the presence of hydroxylamine, ADP, 
arsenate, and Mn2+: 
 
 
This reaction was carried out by adding 100 µg of protein from sample homogenates to 0.5 mL 
of GS reaction buffer (100 mM imidazole, 0.2 mM MnCl2, 62.5 mM hydroxylamine, 10 mM 
sodium arsenate, 0.4 mM ATP, and 100 mM L-glutamine, pH 7.4) and incubating in a 37°C 
water bath.  After 10 minutes the reaction was quenched with 0.5 mL stop solution consisting of 
370 mM FeCl3, 670 mM HCl, and 200 mM trichloroacetic acid.  Samples were centrifuged for 
three minutes at 15,000rpm in a Sorvall Microspin 24S desktop centrifuge and absorbances 
were read at 535 nm.   
GS activity assays were performed on 5-9 animals per treatment group for each gender 
at every time point.  Absorbance values were converted to micromoles of product formed by 
ADP, Mn
2+
, Asi 
L-γ-Glutamyl Hydroxamate + NH3. L-Glutamine + NH2OH 
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comparing them to an L-γ-glutamyl hydroxamate standard curve and specific activities were 
determined accordingly. 
Glutaminase Activity Assays.  Glutaminase activity assays were carried out on the same 
brain homogenates used for GS activity assays.  Brain glutaminase activity was determined by 
monitoring the production of ammonia using a modified version of Sigma’s protocol for the 
enzymatic assay of glutaminase from E. coli.  Test tubes containing 0.9 mL of glutaminase 
reaction buffer (100 mM sodium phosphate, and 20 mM L-glutamine, pH 8.0) were equilibrated 
to 37°C in a water bath and 100 µL of brain homogenate was added.  The reaction was allowed 
to proceed for 15 minutes at 37°C before being quenched with 9 mL of cold deionized water on 
ice.  A 100 µL aliquot from the quenched reaction mixture was added to a tube containing 200 
µL of deionized water and 50 µL of the prepared ion-exchange resin used for determining 
ammonia levels.  The ammonia assay was then carried out from this point to determine the 
amount of ammonia produced during the reaction.   
Several controls were run to eliminate any color development due to ammonia 
contamination of water, glutamine hydrolysis, and protein breakdown within samples.  Controls 
in which the reaction was immediately quenched on ice following the addition of homogenate 
were run for each sample to determine any background from protein breakdown within the 
sample itself.  A hot blank (containing reaction buffer and no protein) was assayed to determine 
any background due to glutamine hydrolysis.  A corresponding cold blank (containing reaction 
buffer and no protein), which was quenched immediately on ice, was also assayed to determine 
any background from ammonia contamination of the deionized water. 
Ammonia produced during the reaction was quantified by reading absorbances of 
samples at 630 nm and comparing them to absorbance values from an ammonium sulfate 
standard curve.  Glutaminase activity assays were performed on 5-8 brain samples per 
treatment group for each gender at every time point. 
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Carbamoyl Phosphate Synthase I Activity Assays.  Sample preparation and carbamoyl 
phosphate synthetase I enzymatic activity assays were carried out according to a modified 
version of a protocol by Pierson (Pierson 1980).  A 100 mg sample of mouse liver was 
homogenized in 2 mL of buffer containing 50 mM triethanolamine, 10 mM ATP, 15 mM 
magnesium acetate, and 1 mM dithiothreitol with a final pH of 8.0.  Four to five strokes of a 
motor-driven glass and Teflon Dounce homogenizer were used to homogenize samples, which 
were then centrifuged at 37,000 x g for 15 minutes in a 4°C Sorvall Ultracentrifuge (OTD65B, 
TY65 rotor).  A 0.5 mL aliquot of the resulting supernatant was desalted by running it over a 
Sephadex G-25 spin column (GE Healthcare PD MiniTrap G-25; 28-9180-07), according to the 
manufacturer’s specifications.  Protein concentrations were determined by using the Coomassie 
Plus Protein Assay (Thermoscientific).   
Enzyme activity was determined by adding 5 µL of desalted liver homogenate to 200 µL 
of CPSI reaction buffer (50 mM NH4HCO3, 50 mM triethanolamine, 10 mM magnesium acetate, 
5 mM ATP, 5 mM N-acetyl-L-glutamic acid, and 1 mM dithiothreitol, pH 8.0) and incubating at 
37°C for 10 minutes.  The carbamoyl phosphate produced during the reaction was then 
chemically converted to hydroxyurea by adding 10 µL of 2 M hydroxylamine, pH 7.0, and 
incubating for 10 minutes at 95°C.  To quantify the hydroxyurea, 800 µL of chromogenic reagent 
was added and samples were incubated for another 15 minutes at 95°C.  Samples were cooled 
to room temperature and absorbances were measured at 458 nm. 
The chromogenic reagent was prepared fresh just prior to use (during the last 5 minutes 
of the first 95°C incubation) and consisted of equal volumes of Solutions A and B.  Solution A 
was made by dissolving 0.85 g antipyrine in 40% (v/v) H2SO4.  Solution B was prepared by 
dissolving 0.625 g of 2, 3-butanedione monoxime in 100 mL of 5% (v/v) acetic acid in a brown 
bottle.   
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The concentration of hydroxyurea was determined by use of a carbamoyl phosphate 
standard curve.  The standard curve was prepared by adding known amounts of carbamoyl 
phosphate to 200 µL of CPSI reaction buffer (without ATP, N-acetyl-L-glutamic acid, and 
dithiothreitol), converting the carbamoyl phosphate to hydroxyurea by the addition of 10 µL of 2 
M hydroxylamine, and measuring the absorbance at 458 nm.  The carbamoyl phosphate 
standard curve was linear up to 100 nmoles and the equation of the line of regression was used 
to calculate the amount of carbamoyl phosphate produced.  Specific activities were calculated 
accordingly.  CPSI activity assays were performed on 10 animals per treatment group for each 
gender at the 70 day time point. 
Statistical Analysis of Data.  Data were organized by gender and genotype and each 
data set was subjected to a Grubb’s test using an online calculator 
(http://www.graphpad.com/quickcalcs/Grubbs1.cfm).  Data points which failed Grubb’s test with 
an α value of 0.01, extreme outliers, were dropped from the analysis.  Two male wild-type mice 
were dropped from the spinal cord GS analysis (one from the 50 day group and one from the 70 
day saline-treated group), two 110 day old saline-treated wild-type mice were dropped from both 
the brain and spinal cord GS analysis (one female and one male), one 110 day old MSO-treated 
female wild-type mouse was dropped from the brain glutaminase analysis, two male wild-type 
mice were dropped from the plasma ammonia analysis (one 50 day old and one saline-treated 
70 day old mouse), and one 70 day old MSO-treated female wild-type mouse was dropped from 
the liver GS analysis.  Animals that were suspected of having received the wrong treatment 
were also dropped from the analysis.  Once outliers were detected and removed, data files were 
analyzed using SPSS.  An analysis of variance (ANOVA) was used to analyze data from all 
enzyme activity assays and plasma ammonia data.  A multivariate analysis of variance 
(MANOVA) was used to analyze plasma metabolite data.  Plasma metabolites that were below 
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the detection limit were entered as zero and the MANOVA was carried out.  Student’s t test was 
used to double check ANOVA and MANOVA p values. 
3.3 Results 
3.3.1 Glutamine Synthetase Activity in the CNS 
  Glutamine synthetase is a cytosolic enzyme expressed primarily in astrocytes in the 
central nervous system.  MSO is an irreversible inhibitor of glutamine synthetase and a single 
subconvulsive dose has been shown to inhibit brain glutamine synthetase activity in mice for 
several weeks, with the enzyme regaining 75% of control activity after 90 days (Rao & Meister 
1972).  Survival studies in which SOD1 G93A mice were given a single i.p. injection of 20 mg/kg 
MSO once per week showed that this dosing schedule had a positive impact on survival, 
extending lifespan by about 10% (see Chapter 2).  As a result we measured the specific activity 
of the enzyme in central nervous system tissue (brain and spinal cord) to monitor changes that 
may occur with age as the disease progresses.  Brain and spinal cord samples were 
homogenized and assayed for glutamine synthetase activity (see Materials and Methods) at 
three time points.  Treatment was started at 50 ± 2 days of age and treated animals were 
euthanized at 70 ± 2 and 110 ± 2 days of age.  Animals in the 50 day group were not exposed to 
i.p. injections and were euthanized at 50 ± 2 days of age.  The 50 day time point provided a 
baseline level of glutamine synthetase activity at the time treatment was started, while the 70 
day time point provided presymptomatic GS activity after four i.p. injections of saline.  The 110 
day time-point provided end-stage GS activity levels after long-term treatment. 
 End-stage mice expressing the SOD1 G93A transgene have lower glutamine synthetase 
activity.  Figure 3.3.1.1 shows the specific activity of brain glutamine synthetase in untreated 50 
day old animals (A) and saline-treated 70 and 110 day old animals (B and C respectively).  
There is no difference in GS activity between wild-type and SOD1 untreated presymptomatic 
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mice (Figure 3.3.1.1A).  At 70 days of age, GS activity remains the same and continues to show 
no difference between wild-type and SOD1 saline-treated mice (Figure 3.3.1.1B).  However, at 
110 days of age, GS activity is significantly reduced in both wild-type and SOD1 mice treated 
with saline when compared to 70 day old saline-treated animals, with p<0.001 for both groups.  
Figure 3.3.1.1C shows that in the 110 day age group, saline-treated SOD1 mice have 
significantly lower GS activity (890 ± 70 nmoles/min/mg protein) than their wild-type 
counterparts (1130 ± 20 nmoles/min/mg protein), p<0.001.   
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Figure 3.3.1.1 Brain glutamine synthetase activity in wild-type and SOD1 mice.   
The specific activity of GS was measured in brain homogenates from 50, 70, and 110 day old 
wild-type (WT) and SOD1 mice.  Data are presented as the average specific activity with error 
bars representing the S.E.M.  Green bars indicate the enzyme activity of wild-type mice while 
purple bars indicate the activity of SOD1 mice.  A.  Average specific activity of brain GS in 50 
day old untreated wild-type and SOD1 mice (n=16 mice/group).  B.  Average specific activity of 
brain GS in 70 day old saline-treated wild-type and SOD1 mice (n=18 wild-type and n=16 SOD1 
mice).  (C)  Average specific activity of brain GS in 110 day old saline-treated wild-type and 
SOD1 mice (n=15 wild-type and n=13 SOD1 mice; ** indicates p<0.01).   
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Since the majority of neurodegeneration occurs within the spinal cord of SOD1 G93A 
mice, we also looked at GS activity in whole spinal cord homogenates to examine changes with 
age and disease progression.  Spinal cord samples were extracted from the same animals that 
brain samples were taken from; however one wild-type spinal cord sample from the 50 day 
group was determined to be an outlier and subsequently dropped from the analysis.  The 
specific activity of spinal cord GS is significantly lower (approximately 40-50% lower) than that 
of brain GS in both wild-type and SOD1 mice, with p<0.001.  Figure 3.3.1.2 shows the specific 
activity of GS from spinal cord homogenates of 50 day old untreated mice, as well as 70 and 
110 day old saline-treated mice.  At 50 days of age, the specific activity of spinal cord GS is 
similar in wild-type and SOD1 mice (Figure 3.3.1.2A).  There is no change in GS activity in 70 
day old saline-treated mice and the specific activity of GS of SOD1 mice remains the same as 
that of wild-type mice (Figure 3.3.1.2B).  Overall, the spinal cord GS activity follows the same 
trend as that of brain GS activity and by 110 days of age, the average specific activity 
significantly decreases in both SOD1 and wild-type mice when compared to their 70 day old 
counterparts, with p<0.001 for SOD1 mice and p<0.01 for wild-type mice.  As with brain GS 
activity, saline-treated SOD1 mice show significantly lower spinal cord GS activity (450 ± 50 
nmoles/min/mg protein) than wild-type mice (630 ± 30 nmoles/min/mg protein) at 110 days of 
age, p<0.01 (Figure 3.3.1.2C).   
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Figure 3.3.1.2 Spinal cord glutamine synthetase activity in wild-type and SOD1 mice.   
The specific activity of GS was measured in spinal cord homogenates from 50, 70, and 110 day 
old wild-type (WT) and SOD1 mice.  Data are presented as the average specific activity with 
error bars representing the S.E.M.  Green bars indicate the enzyme activity of wild-type mice 
while purple bars indicate the activity of SOD1 mice.  A.  Average specific activity of spinal cord 
GS in 50 day old untreated wild-type and SOD1 mice (n=15 WT and n=16 SOD1 mice).  B.  
Average specific activity of spinal cord GS in 70 day old saline-treated wild-type and SOD1 mice 
(n=18 wild-type and n=16 SOD1 mice).  C.  Average specific activity of spinal cord GS in 110 
day old saline-treated wild-type and SOD1 mice (n=15 wild-type and n=13 SOD1 mice; ** 
indicates p<0.01).   
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End-stage male and female SOD1 mice show lower levels of brain and spinal cord GS 
activity.  Glutamine synthetase activity data were further broken down by gender and genotype 
to examine the effects of gender on enzyme activity.  Figure 3.3.1.3 shows the average specific 
activity of brain glutamine synthetase broken down by gender and genotype.  Untreated male 
and female wild-type and SOD1 mice all have similar levels of brain GS activity (Figure 
3.3.1.3A).  Saline-treated animals in the 70 day age group show levels of brain GS activity 
similar to that of untreated 50 day mice, with no gender or genotype differences (Figure 
3.3.1.3B).  In saline-treated male and female mice of both genders, the specific activity of brain 
GS significantly decreases between 70 and 110 days of age, p<0.01.  Male and female SOD1 
mice experience a greater decrease in GS activity than their wild-type counterparts.  This age 
group shows that saline-treated wild-type males and females have similar levels of brain GS 
activity (Figure 3.3.1.3C).  Both 110 day old male and female SOD1 mice, have lower levels of 
GS activity than their wild-type counterparts, with SOD1 males showing significantly lower brain 
GS (760 ± 80 nmoles/min/mg protein) activity than wild-type males (1110 ± 30 nmoles/min/mg 
protein), p<0.001.  
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Figure 3.3.1.3 Brain glutamine synthetase activity broken down by gender and genotype.   
Data are presented as the average specific activity with error bars representing the S.E.M.  
Green bars indicate the enzyme activity of wild-type mice while purple bars indicate the activity 
of SOD1 mice.  A.  Average specific activity of brain GS in 50 day old untreated male and 
female wild-type and SOD1 mice (n=8 mice/group).  B.  Average specific activity of brain GS in 
70 day old saline-treated male and female wild-type and SOD1 mice (n=9 wild-type mice/group 
and n=8 SOD1 mice/group).  C.  Average specific activity of brain GS in 110 day old saline-
treated male and female wild-type and SOD1 mice (n(F,WT)=7, n(M, WT)=8, n(F, SOD1)=8, 
n(M, SOD1)=5; ** indicates p<0.01).   
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When spinal cord GS activity data are broken down by gender and genotype, enzyme 
activity in spinal cord homogenates is significantly lower than that of brain homogenates.  Figure 
3.3.1.4 shows the specific activity of spinal cord GS broken down by gender and genotype.  In 
50 day old untreated mice, enzyme activity is approximately the same across all groups (Figure 
3.3.1.4A).  Saline-treated male and female wild-type and SOD1 mice in the 70 day group, have 
spinal cord GS activity similar to that of untreated 50 day old animals, with no gender or 
genotype differences in enzyme activity (Figure 3.3.1.4B).  Between 70 and 110 days of age, 
the specific activity of GS in spinal cord significantly decreases, with female SOD1 mice 
showing the greatest decrease in activity.  Like with brain GS activity, spinal cord GS activity is 
lower in both male and female saline-treated SOD1 mice than wild-type mice (Figure 3.3.1.4C).  
Saline-treated female SOD1 mice show significantly lower GS activity (410 ± 50 nmoles/min/mg 
protein) than their wild-type counterparts (650 ± 60 nmoles/min/mg protein), p<0.01. 
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Figure 3.3.1.4 Spinal cord glutamine synthetase activity broken down by gender and genotype.  
Data are presented as the average specific activity with error bars representing the S.E.M.  
Green bars indicate the enzyme activity of wild-type mice while purple bars indicate the activity 
of SOD1 mice.  A.  Average specific activity of spinal cord GS in 50 day old untreated male and 
female wild-type and SOD1 mice (n=8 mice/group, except for male, wild-type where n=7).  B.  
Average specific activity of spinal cord GS in 70 day old saline-treated male and female wild-
type and SOD1 mice (n=9 wild-type mice/group and n=8 SOD1 mice/group).  C.  Average 
specific activity of spinal cord GS in 110 day old saline-treated male and female wild-type and 
SOD1 mice (n(F,WT)=7, n(M, WT)=8, n(F, SOD1)=8, n(M, SOD1)=5; ** indicates p<0.01).   
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A weekly i.p. injection of 20 mg/kg MSO lowers brain and spinal cord glutamine 
synthetase activity.  To examine the effects of MSO treatment on brain and spinal cord 
glutamine synthetase activity, we first grouped the data by genotype to determine if MSO 
treatment affected SOD1 animals differently than wild-type animals.  Figure 3.3.1.5 shows the 
effects of MSO treatment on brain GS activity in 70 and 110 day old mice.  In 70 day old wild-
type and SOD1 mice, a single weekly injection significantly inhibits brain GS activity by 
approximately 90% (Figure 3.3.1.5A).  Glutamine synthetase activity in wild-type mice is 
significantly reduced from 1380 ± 30 nmoles/min/mg protein (saline-treated mice) to 170 ± 20 
nmoles/min/mg protein with MSO treatment (p<0.001), while brain GS activity of SOD1 mice is 
reduced from 1340 ± 60 nmoles/min/mg protein (saline-treated mice) to 150 ± 10 
nmoles/min/mg protein with MSO treatment (p<0.001).  As previously mentioned, brain 
glutamine synthetase activity in saline-treated mice is significantly lower in 110 day old mice 
than in 70 day old mice in both genotypes.  This trend, however, is not reflected in MSO-treated 
mice.  MSO treatment inhibits brain GS to the same extent in 110 day old mice, by 
approximately 90% (Figure 3.3.1.5B).  Glutamine synthetase activity in 110 day old wild-type 
mice is significantly reduced from 1130 ± 20 nmoles/min/mg protein (saline treatment) to 140 ± 
10 nmoles/min/mg protein with MSO treatment (p<0.001), while enzyme activity of SOD1 mice 
is reduced from 890 ± 70 nmoles/min/mg protein (saline treatment) to 120 ± 10 nmoles/min/mg 
protein with MSO treatment (p<0.001). 
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Figure 3.3.1.5 Brain glutamine synthetase activity in saline and MSO-treated mice.   
Wild-type and SOD1 mice were treated with a single weekly i.p. injection of MSO and brain GS 
activity was measured at different time points.  Data are presented as the average specific 
activity with error bars representing the S.E.M.  Blue bars indicate the enzyme activity of wild-
type and SOD1 mice treated with saline, while red bars indicate the activity of wild-type and 
SOD1 mice treated with MSO. A.  MSO treatment significantly lowers the specific activity of 
brain GS in both wild-type and SOD1 mice at 70 days of age (n=18 wild-type mice/treatment, n 
(SOD, Saline) =16, and n (SOD, MSO) =17).  B. MSO treatment lowers the specific activity of 
brain GS in 110 day old mice (n (WT, Saline) =15, n (WT, MSO) =18, n (SOD, Saline) =13, and 
n (SOD, MSO) =15).  *** indicates that values are significant with p<0.001. 
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Figure 3.3.1.6 compares the specific activity of spinal cord glutamine synthetase of mice 
treated with saline to that of MSO-treated mice.  Like brain GS activity, spinal cord GS activity is 
inhibited by 90% with a single weekly injection of MSO in wild-type and SOD1 70 day old mice 
(Figure 3.3.1.6A).  Enzyme activity in the spinal cord of 70 day old saline-treated SOD1 mice 
(770 ± 30 nmoles/min/mg of protein) is significantly lower than that of brain GS (1340 ± 60 
nmoles/min/mg protein), and MSO further decreases spinal cord GS activity (50 ± 5 
nmoles/min/mg protein).  Saline-treated wild-type mice from this age group show a similar 
pattern of enzyme activity, with significantly higher GS activity in brain than spinal cord and a 
corresponding decrease in activity with MSO treatment, which does not differ significantly from 
SOD1 mice.  There is no difference in the enzyme activity of MSO-treated mice between 70 and 
110 days of age, unlike what was seen in saline-treated animals.  Like with 70 day wild-type and 
SOD1 mice, we see a 90% reduction in the average specific activity of GS isolated from spinal 
cord with MSO treatment (Figure 3.3.1.6B).  MSO treatment reduces spinal cord GS activity in 
110 day old SOD1 mice from 450 ± 50 nmoles/min/mg protein (saline treatment) to 40 ± 5 
nmoles/min/mg protein (p<0.001), while spinal cord GS activity in wild-type mice is reduced from 
630 ± 30 nmoles/min/mg protein to 50 ± 5 nmoles/min/mg protein (p<0.001).   As seen with 
saline-treated mice, brain GS activity is significantly higher than spinal cord GS activity with 
MSO treatment for both age groups, with p<0.001.           
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Figure 3.3.1.6 Spinal cord glutamine synthetase activity in saline and MSO-treated mice.   
Wild-type and SOD1 mice were treated with a single weekly i.p. injection of MSO and brain GS 
activity was measured at different time points.  Data are presented as the average specific 
activity with error bars representing the S.E.M.  Blue bars indicate the enzyme activity of wild-
type and SOD1 mice treated with saline, while red bars indicate the activity of wild-type and 
SOD1 mice treated with MSO. A.  MSO treatment significantly lowers the specific activity of 
spinal cord GS in both wild-type and SOD1 mice at 70 days of age (n (WT, Saline) =18, n (WT, 
MSO) =17, n (SOD, Saline) =16, and n (SOD, MSO) =17).  B. MSO treatment lowers the 
specific activity of spinal cord GS in 110 day old mice (n (WT, Saline) =15, n (WT, MSO) =18, n 
(SOD, Saline) =13, and n (SOD, MSO) =15).  *** indicates that values are significant with 
p<0.001. 
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MSO treatment does not inhibit brain and spinal cord glutamine synthetase activity in a 
gender-specific fashion.  To examine whether or not MSO inhibits the activity of GS in the 
central nervous system in a gender-specific manner, both brain and spinal cord GS activity data 
were broken down by gender and genotype.  Figure 3.3.1.7 shows brain GS activity broken 
down by gender and genotype and compares the activity of saline and MSO-treated mice.  The 
specific activity of brain glutamine synthetase is inhibited by approximately 90% in male and 
female wild-type and SOD1 mice at 70 days of age, with no significant gender or genotype 
differences in enzyme activity (Figure 3.3.1.7A).  Although we see a slight decrease in the 
specific activity of brain GS in MSO-treated male and female wild-type and SOD1 mice between 
70 and 110 days, this difference is not considered significant like that of saline-treated animals.  
Overall, MSO significantly reduces brain GS activity in 110 day old male and female wild-type 
and SOD1 mice to the same extent as 70 day old mice with no significant gender or genotype 
differences (Figure 3.3.1.7B). 
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Figure 3.3.1.7 Brain glutamine synthetase specific activity broken down by gender and 
genotype.   
Data are presented as the average specific activity with error bars representing the S.E.M.  Blue 
bars indicate the enzyme activity of male and female wild-type and SOD1 mice treated with 
saline, while red bars indicate the activity of male and female wild-type and SOD1 mice treated 
with MSO.  A.  The specific activity of brain glutamine synthetase is significantly decreased by 
MSO treatment in 70 day old male and female wild-type and SOD1 mice (n=8 male and 8 
female WT mice/group, n=8 female SOD1 mice/group, n(M, SOD1, Saline)=8, and n(M, SOD1, 
MSO)=9).  B.  The specific activity of brain glutamine synthetase is significantly decreased by 
MSO treatment in 110-day old male and female wild-type and SOD1 mice (n=5-9 mice/group).  
*** indicates that values are significant with p<0.001. 
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Figure 3.3.1.8 shows spinal cord glutamine synthetase activity broken down by gender 
and genotype and compares that of saline to MSO-treated mice.  In MSO-treated animals the 
specific activity of brain GS is significantly higher than that of spinal cord GS in male and female 
wild-type and SOD1 mice, with p<0.001 for all groups. Like with brain GS activity, spinal cord 
enzyme activity is significantly reduced by approximately 90% in male and female wild-type and 
SOD1 mice at 70 (Figure 3.3.1.8A) and 110 (Figure 3.3.1.8B) days of age.  While there are no 
gender or genotype differences in enzyme activity of 70 day old mice, there is a decrease in GS 
activity in saline-treated male and female SOD1 mice compared to their wild-type counterparts 
at 110 days of age, but this difference is not reflected in MSO-treated animals in this age group.      
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Figure 3.3.1.8 Spinal cord glutamine synthetase activity broken down by gender and genotype. 
Data are presented as the average specific activity with error bars representing the S.E.M.  Blue 
bars indicate the enzyme activity of male and female wild-type and SOD1 mice treated with 
saline, while red bars indicate the activity of male and female wild-type and SOD1 mice treated 
with MSO.  A.  The specific activity of spinal cord glutamine synthetase is significantly 
decreased by MSO treatment in 70 day old male and female wild-type and SOD1 mice (n=8-9 
mice/group).  B.  The specific activity of spinal cord glutamine synthetase is significantly 
decreased by MSO treatment in 110-day old male and female wild-type and SOD1 mice (n=5-9 
mice/group).  *** indicates that values are significant with p<0.001. 
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In general, we see that brain and spinal cord glutamine synthetase activity is about the 
same in presymptomatic wild-type and SOD1 mice - 50 day old untreated and 70 day old saline-
treated mice.  Changes in GS activity occur between 70 and 110 days of age, when both brain 
and spinal cord GS activity of saline-treated wild-type and SOD1 mice decrease significantly.  
This decrease in activity is greater in SOD1 mice and probably begins around the time of 
symptom onset, approximately 90 days of age. The specific activity of brain glutamine 
synthetase in untreated and saline-treated control mice is approximately 40-50% higher than 
that of spinal cord GS for all age groups.  When the data are broken down by gender and 
genotype, there are no significant differences in either brain or spinal cord GS activity observed 
in presymptomatic mice.  We continue to see a decrease in activity between 70 and 110 day old 
saline-treated mice, but it is independent of gender and genotype.  In the 110 day age group, 
both male and female saline-treated SOD1 mice show lower levels of brain and spinal cord GS 
activity.  Male SOD1 mice show significantly lower brain GS activity when compared to wild-type 
male mice, while female SOD1 mice show significantly lower spinal cord GS activity when 
compared to their wild-type counterparts.  A single weekly injection of MSO (20 mg/kg body 
weight) significantly reduces both brain and spinal cord activity by about 90%.  Prolonged 
treatment (110 days – about 10 injections) inhibits enzyme activity to the same extent as short-
term treatment (70 days – about 4 injections), and results in no gender or genotype differences 
in brain or spinal cord GS activity.  
3.3.2 Glutaminase Activity in the Brain 
 We have shown that treating ALS mice with MSO at a dose of 20 mg/kg three times a 
week, not only increases the lifespan of these animals, but also lowers levels of some 
neurochemicals (glutamine, glutamate, and GABA) and increases levels of the antioxidant 
tripeptide glutathione in specific regions of the brain (Ghoddoussi et al 2010).  Survival studies, 
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explained in Chapter 2, show that reducing the dosing schedule of MSO to 20 mg/kg 
administered once a week has the same effect on the survival of SOD1 G93A mice.  The results 
of the brain and spinal cord glutamine synthetase assays show that MSO treatment reduces 
enzyme activity by 90% in all animals.  One would expect that this inhibition of glutamine 
synthetase would lower levels glutamine while simultaneously increasing levels of glutamate, 
because this excitotoxic amino acid would no longer be able to be converted to glutamine.  The 
aforementioned results indicate that this is not the case and that MSO somehow lowers levels of 
glutamate, along with glutamine.  In an effort to better understand how MSO lowers glutamate 
levels in the brain, we examined the activity of brain glutaminase, the neuronal enzyme 
responsible for converting glutamine back into glutamate.  Using a modified version of Sigma’s 
protocol for assaying the enzymatic activity of glutaminase purified from E. coli, we were able to 
monitor the specific activity of glutaminase from mouse brain homogenates by measuring the 
production of ammonia. 
 The specific activity of brain glutaminase is not affected by the overexpression of mutant 
SOD1 protein.   The specific activity of brain glutaminase was measured using the same mouse 
brain homogenates that were assayed for glutamine synthetase activity.  Enzyme activity was 
measured in untreated 50 day old animals, as well as saline and MSO-treated 70 and 110 day 
old animals.  Figure 3.3.2.1 shows the average specific activity of brain glutaminase from wild-
type and SOD1 mice.  At 50 days of age, untreated wild-type and SOD1 mice have similar 
levels of glutaminase activity in the brain (Figure 3.3.2.1A).  At 70 days of age, saline-treated 
wild-type mice show a slight decrease in glutaminase activity while SOD1 mice show no change 
(Figure 3.3.2.1B).  Glutaminase activity increases slightly by 110 days of age in both wild-type 
and SOD1 saline-treated mice, but this change is not significant (Figure 3.3.2.1C).   
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Figure 3.3.2.1 Specific activity of brain glutaminase in wild-type and SOD1 mice. 
Data are presented as the average specific activity bars with error bars representing the S.E.M.  
Green bars represent data from wild-type mice while purple bars represent data from SOD1 
mice.  A. In untreated 50 day old mice there is no difference in specific activity of brain 
glutaminase in wild-type and SOD1 mice (n=15 SOD1 and n=16 WT mice).  B.  The activity of 
brain glutaminase does not change in 70 day old wild-type and SOD1 mice (n=16 mice/group).  
C.  By 110 days of age, the average specific activity of glutaminase seems to increase in both 
wild-type and SOD1 mice, however this change is not significant (n=13 SOD1 and n=15 WT 
mice). 
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There are no gender differences in the specific activity of brain glutaminase.  To 
examine gender differences in brain glutaminase activity, the data were broken down by gender 
and genotype.  Figure 3.3.2.2 shows the average specific activity of brain glutaminase of 
untreated 50 day old animals and saline-treated 70 and 110 day old animals broken down by 
gender and genotype.  There are no significant gender differences in the enzyme activity of 
untreated 50 day old animals (Figure 3.3.2.2A).  In 70 day old saline-treated mice, it appears as 
though there may be a gender difference in brain glutaminase activity, with females showing 
lower activity than males (Figure 3.3.2.2B).  Saline-treated male SOD1 mice in this age group 
have significantly higher brain glutaminase activity (88 ± 12 nmoles/min/mg protein) than female 
SOD1 mice (56 ± 7 nmoles/min/mg protein), with p<0.05, however the difference between male 
and female wild-type mice is not considered significant.  Between 70 and 110 days of age, the 
average specific activity of glutaminase appears to increase in female mice and decrease in 
male mice of both genotypes. However, this difference is only significant for wild-type females 
where glutaminase activity increases from 52 ± 8 nmoles/min/mg protein at 70 days of age to 87 
± 11 nmoles/min/mg protein at 110 days of age (p<0.05).  In 110 day old saline-treated mice 
(Figure 3.3.2.2C), there again appears to be a gender difference in enzyme activity with females 
now having higher glutaminase activity than males, however this was not found to be significant. 
 
 
 
 
 
 
 
 
132 
 
 
Figure 3.3.2.2 Brain glutaminase activity broken down by gender and genotype. 
Data are presented as the average specific activity bars with error bars representing the S.E.M.  
Green bars represent data from wild-type mice while purple bars represent data from SOD1 
mice.  A.  When glutaminase activity data are broken down by gender and genotype, there are 
no clear gender differences in 50 day old untreated mice (n=8 mice/group except for the female 
SOD1 group which contains 7 mice).  B.  In 70 day old saline-treated mice, females appear to 
have lower brain glutaminase than males (n=8 mice/group; * indicates values are significant 
with p<0.05).  C.  Female saline-treated mice appear to have higher glutaminase activity than 
male saline-treated mice at 110 days of age (n=5-8 mice/group). 
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MSO treatment does not impact glutaminase activity in the brain.  Figure 3.3.2.3 
compares the average specific activity of brain glutaminase in saline-treated wild-type and 
SOD1 mice to that of MSO-treated wild-type and SOD1 mice.  MSO treatment does not have an 
effect on glutaminase activity in the brains of 70 day old mice (Figure 3.3.2.3A).  The average 
specific activities of glutaminase from MSO-treated wild-type and SOD1 mice are similar to that 
of saline-treated mice.  In 110 day old mice, brain glutaminase activity is elevated in saline and 
MSO-treated wild-type and SOD1 mice compared to 70 day old mice, but this increase in 
activity is not significant.  In the 110 day age group brain homogenates of both genotypes show 
higher glutaminase activity with MSO treatment (Figure 3.3.2.3B), however this increase is not 
significant.    
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Figure 3.3.2.3 The effects of MSO treatment on glutaminase activity. 
Data are presented as the average specific activity with error bars representing the S.E.M.  Blue 
bars represent data from saline-treated wild-type and SOD1 mice and red bars represent data 
from mice treated once a week with 20 mg/kg MSO.  A.  The average specific activity of 
glutaminase from 70 day old saline-treated wild-type and SOD1 mice compared to that of MSO-
treated mice (n=16 mice/group).  B.  The average specific activity of glutaminase from 110 day 
old saline-treated wild-type and SOD1 mice compared to that of MSO-treated mice (n=13-19 
animals/group). 
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There are no significant gender differences in glutaminase activity with MSO treatment.  
Glutaminase activity data were further broken down by gender and genotype to determine if 
MSO treatment affects glutaminase activity in a gender-specific fashion.  Figure 3.3.2.4 
compares saline and MSO-treated mice by gender and genotype.  Based on these data, the 
effects of MSO on glutaminase activity of male and female wild-type and SOD1 mice are 
unclear.  In Figure 3.3.2.4A, it appears as though MSO may be elevating enzyme activity in 
females while reducing it in males in 70 day old mice, however none of these changes were 
considered statistically significant.  The results of glutaminase activity assays performed on 110 
day old mice treated with saline and MSO are equally confusing.  In this age group, it appears 
as though MSO may be elevating glutaminase activity in male SOD1 and female wild-type mice, 
lowering activity in male wild-type mice, and having no effect on female SOD1 mice (Figure 
3.3.2.4B).  Like with the 70 day age group, these changes in enzyme activity with MSO 
treatment were not found to be significant.   
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Figure 3.3.2.4 Brain glutaminase activity of saline and MSO-treated mice broken down by 
gender and genotype. 
Data are presented as the average specific activity with error bars representing the S.E.M.  Blue 
bars represent data from saline-treated wild-type and SOD1 mice and red bars represent data 
from mice treated once a week with 20 mg/kg MSO.  A.  The average specific activity of 
glutaminase from 70 day old saline-treated wild-type and SOD1 mice compared to that of MSO-
treated mice broken down by gender and genotype (n=8 mice/group).  B.  The average specific 
activity of glutaminase from 110 day old saline-treated wild-type and SOD1 mice compared to 
that of MSO-treated mice broken down by gender and genotype (n=5-9 animals/group). 
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Overall, the results of the glutaminase activity assays show no differences in enzyme 
activity.  We see no differences in activity levels of wild-type and SOD1 mice at all time points, 
and enzyme activity doesn’t appear to change with age.  When the data are broken down by 
gender and genotype, there are no significant gender differences in glutaminase activity in 
untreated 50 day old mice.  It appears as though gender differences in activity begin to emerge 
at 70 days of age, with females exhibiting lower levels of brain glutaminase activity than males, 
but only SOD1 mice show a significant gender difference in enzyme activity.  By 110 days of 
age, there seems to be a reversal in activity levels, with males now exhibiting lower glutaminase 
activity than females, but these differences were not significant.  MSO treatment does not have 
a clear effect on glutaminase activity and it has not been determined to interact directly with the 
enzyme.  If MSO has an effect on glutaminase it may be region-specific or indirect, possibly 
through altering levels of reactants, such as glutamate.        
3.3.3 Plasma Metabolite Analysis 
 Glutamine synthetase is the only enzyme capable of producing glutamine and is 
expressed in varying concentrations throughout the body (van Straaten et al 2006).  Glutamine 
is the most abundant free amino acid in the body (Brosnan 2003) and acts as an ammonia 
carrier in the bloodstream.  It is considered to be a nonessential amino acid and can be taken 
up from the diet, and as a result the primary role of GS in certain organs is not to produce 
glutamine but to detoxify glutamate and ammonia.    We have previously shown that MSO 
lowers levels of glutamate, glutamine, and GABA in certain brain regions (Ghoddoussi et al 
2010), but GS is expressed throughout the body and widespread inhibition of the enzyme by 
MSO could potentially alter these chemicals in other areas.   
Glutamine plays several roles in the body.  It donates nitrogen for the production of 
purines and ammonia to CPSI for the production of carbamoyl phosphate, leading to the 
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production of arginine which then continues on to form urea (in the liver) and nitric oxide 
(through nitric oxide synthases in a variety of tissues) (Newsholme et al 2003). Glutamine is 
also involved in protein synthesis and acts as a precursor in the production of glutamate (Nelson 
& Cox 2008; Newsholme et al 2003).  Glutamate, which in most cells is the immediate product 
of glutamine metabolism, can act as a precursor for GABA and n-acetyl glutamate (an allosteric 
activator of CPSI),  and indirectly acts as a precursor for glucose through α-ketoglutarate and its 
flow into the Citric Acid Cycle (Newsholme et al 2003).  Glutamate is also involved in protein 
synthesis and is one of three amino acids that make up the antioxidant glutathione.  Altering 
glutamine levels through the use of MSO has the potential to affect several aspects of 
metabolism throughout the body.  We decided to examine a variety of amino acids, and other 
metabolites including ammonia, in the plasma of presymptomatic mice to 1) understand the 
effects that the overexpression of the mutant SOD1 protein has on nitrogen metabolism and 2) 
monitor the effects of MSO treatment on nitrogen metabolism.    
Young untreated SOD1 mice have elevated levels of plasma ammonia.  Plasma 
ammonia levels were examined in 50 day old untreated wild-type and SOD1 mice, as well as 
saline-treated 70 day old animals.  Figure 3.3.3.1 shows the results of the plasma ammonia 
analysis.  In 50 day old untreated mice, plasma ammonia levels are significantly higher in SOD1 
animals (78 ± 7 µmoles/L plasma) when compared to wild-type mice of the same age (52 ± 5 
µmoles/L plasma), with p<0.01 (Figure 3.3.3.1A).  Between 50 and 70 days of age, plasma 
ammonia levels drop and both 70 day old wild-type and SOD1 mice treated with saline have 
significantly lower levels of ammonia detected in their plasma when compared to untreated 50 
day old animals (p<0.001).  By 70 days of age, plasma ammonia levels have evened out and no 
longer differ between wild-type and SOD1 mice (Figure 3.3.3.1B).  
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Figure 3.3.3.1 Plasma ammonia concentrations in wild-type and SOD1 mice. 
Plasma ammonia levels are expressed as the average concentration of ammonia in µmoles/L of 
plasma with error bars representing the S.E.M.  Green bars indicate plasma ammonia levels in 
wild-type mice, while purple bars indicate that of SOD1 mice.  A.  The average concentration of 
ammonia in 50 day old, untreated wild-type and SOD1 mice (n=31 mice/group; ** indicates that 
values differ significantly with p<0.01).  B.  The average concentration of ammonia in 70 day old 
wild-type and SOD1 mice treated with saline (n=24 mice/group). 
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Plasma ammonia levels in SOD1 mice show no gender-specific differences.  Figure 
3.3.3.2 shows the plasma ammonia data broken down by gender and genotype.  In 50 day old 
untreated mice, both female and male SOD1 mice have higher levels of ammonia in their 
plasma.  Female SOD1 mice were found to have significantly higher levels of ammonia (83 ± 11 
µmoles/L plasma) than wild-type females (56 ± 5 µmoles/L plasma), with p<0.05, while males 
were not found to differ significantly (Figure 3.3.3.2A).  There are no significant differences in 
the levels of plasma ammonia between males and females of the same genotype.  Between 50 
and 70 days of age, plasma ammonia levels drop in all groups analyzed.  There is a much 
larger decrease in plasma ammonia levels of SOD1 males and females  than in wild-type males 
and females, but the overall decrease is significant for all groups (p<0.01).   Interestingly, by 70 
days of age, plasma ammonia in saline-treated SOD1 male and female mice resemble that of 
male and female wild-type mice, with no significant differences between genders (Figure 
3.3.3.2B).    
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Figure 3.3.3.2 Plasma ammonia concentrations broken down by gender and genotype. 
Plasma ammonia levels are expressed as the average concentration of ammonia in µmoles/L of 
plasma with error bars representing the S.E.M.  Green bars indicate plasma ammonia levels in 
wild-type male and female mice, while purple bars indicate that of SOD1 male and female mice.  
A. Plasma ammonia levels are higher in both male and female SOD1 mice in 50 day old 
untreated mice (n=16 female mice/group and n=15 male mice/group; * indicates that values 
differ significantly with p<0.05).  B.  Plasma ammonia levels in 70 day old saline-treated mice 
broken down by gender and genotype (n=12 mice/group). 
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A single weekly injection of MSO elevates plasma ammonia levels in wild-type and 
SOD1 mice.  Animals were given an i.p. injection of saline or 20 mg/kg MSO starting at 50 ± 2 
days of age and continued to receive a weekly injection until euthanized at 70 ± 2 days of age.  
Plasma was taken and immediately assayed for ammonia content and the results are presented 
in Figure 3.3.3.3.  In both wild-type and SOD1 mice, treatment with MSO significantly increases 
plasma ammonia levels with p<0.01 (Figure 3.3.3.3A).  These data were further broken down by 
gender and genotype to determine if MSO has a gender-specific effect on plasma ammonia 
levels.  MSO treatment significantly increases plasma ammonia levels in all groups with p<0.05, 
except male SOD1 mice where the elevation in plasma ammonia was not found to be significant 
(Figure 3.3.3.3B).  Male wild-type mice have the lowest levels of plasma ammonia of all groups 
examined, when treated with both saline and MSO.  Male wild-type mice treated with MSO have 
significantly lower levels of plasma ammonia (34 ± 2 µmoles/L plasma) when compared with 
both female wild-type mice treated with MSO (48 ± 4 µmoles/L plasma; p<0.01) and male SOD1 
mice treated with MSO (50 ± 7 µmoles/L plasma; p<0.05). 
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Figure 3.3.3.3 The effects of MSO treatment on plasma ammonia levels. 
Plasma ammonia levels are expressed as the average concentration of ammonia in µmoles/L of 
plasma with error bars representing the S.E.M.  Blue bars indicate plasma ammonia levels in 
wild-type and SOD1 mice treated with saline, while red bars indicate that of wild-type and SOD1 
mice treated with MSO.  A.  The effects of MSO treatment on plasma ammonia levels in 70 day 
old wild-type and SOD1 mice (n=24 mice/group; ** indicates that values differ significantly with 
p<0.01).  B.  The effects of MSO treatment on plasma ammonia levels in 70 day old male and 
female wild-type and SOD1 mice (n=12 mice/group; * indicates that values differ significantly 
with p<0.05). 
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Several glucogenic amino acids are significantly lower in presymptomatic SOD1 mice 
when compared to wild-type mice.  Mouse plasma samples were obtained by anesthetizing 
mice and drawing blood directly from the heart, which was immediately centrifuged in plasma 
separator tubes.  If needed, a portion of the plasma was used for ammonia determination and 
the rest was immediately frozen on dry ice and then placed at -80°C until analyzed for 
metabolite content.  Plasma samples were taken from 50 day old untreated mice as well as 70 
day old saline and MSO-treated mice of both genotypes.  In 50 day old, untreated animals 
several plasma metabolites were found to differ significantly between wild-type and SOD1 G93A 
mice.   The top of Table 3.3.3.1 compares the concentrations (expressed in µmoles/L with the 
standard error of the mean in parentheses) of several plasma metabolites analyzed in SOD1 
mice (n=13) and compares them to those of wild-type control animals (n=19) of the same age.  
A multivariate analysis of variance (MANOVA) was used to compare plasma metabolite 
concentrations and the p values obtained are listed in the right-most column of the table.  
Phosphoserine, phosphoethanolamine, urea, and citrulline are all significantly lower in SOD1 
plasma compared to wild-type plasma.  Lysine, a ketogenic amino acid that can be converted 
into acetoacetyl-CoA and eventually ketone bodies, is significantly lower in SOD1 plasma.  In 
addition, aspartate, cystine, methionine, and arginine, all of which are glucogenic amino acids 
and can be converted to glucose and glycogen, are also significantly lower in the plasma of 
SOD1 animals at 50 days of age.  Asparagine and glutamine, which are also glucogenic amino 
acids, are elevated in SOD1 plasma when compared to that of wild-type animals.  Of the 
metabolites that differ between SOD1 and wild-type mice, glutamine, methionine and lysine are 
essential, while cystine and arginine are considered to be conditionally essential amino acids.  
Interestingly, cystine was detectable in all wild-type plasma samples but could only be detected 
in one SOD1 sample. 
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Table 3.3.3.1 Plasma metabolite differences between 50 day old untreated and 70 day old 
saline-treated SOD1 and wild-type mice. 
 
Age Metabolite WT SOD1 p (MANOVA) 
50 Days 
Phser 14.43 (0.84) 6.76 (1.24) 0.000009 
Pea 11.55 (1.27) 5.57 (2.00) 0.01 
Urea 9866.08 (358.87) 8088.85 (696.89) 0.02 
Asp 18.03 (1.51) 11.32 (0.87) 0.002 
Asn 38.98 (2.09) 47.83 (4.03) 0.04 
Gln
†
 560.08 (13.21) 676.66 (37.19) 0.002 
Citr 109.36 (4.91) 87.14 (5.46) 0.006 
Cys
†
 27.91 (2.40) 0.36 (0.36) 0.000000 
Met* 87.38 (5.84) 65.47 (7.01) 0.02 
Lys* 319.96 (12.69) 273.63 (16.00) 0.03 
Arg
†
 122.45 (8.41) 86.84 (7.51) 0.006 
70 Days 
(Saline) 
Pea 6.11 (1.74) 1.12 (0.61) 0.008 
Asp 13.06 (1.38) 9.15 (0.35) 0.007 
Sarc 9.33 (5.38) 32.38 (5.12) 0.005 
Ala 720.05 (52.53) 593.61 (32.61) 0.045 
Cys
†
 13.34 (5.45) 0.00 (0.00) 0.02 
Pro
†
 116.87 (10.32) 75.54 (11.55) 0.01 
 
Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L. 
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen. 
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or 
acetyl-CoA. 
* indicates essential amino acids. 
† indicates conditionally essential amino acids. 
n (WT, 50 days) = 19 
n (SOD1, 50 days) = 13 
n (WT, 70 days) = 12 
n (SOD1, 70 days) = 14 
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When we examine plasma metabolite changes in 70 day old SOD1 and wild-type mice 
treated with saline we see a strikingly different profile.  There are fewer metabolite differences 
between saline-treated SOD1 and wild-type mice at 70 days of age and the metabolites that 
differ significantly between the two groups are different from what we see in 50 day old 
untreated mice.  The bottom of Table 3.3.3.1 shows the amino acids that differ significantly 
between 70 day old saline-treated SOD1 and wild-type mice, as well as the p values obtained 
from the MANOVA.  As with 50 day old untreated mice, phosphoethanolamine, aspartate, and 
cystine levels were all found to be significantly lower in saline-treated SOD1 mice when 
compared to saline-treated wild-type mice.  Cystine levels were found to follow a similar pattern 
in 70 day old animals, with levels being undetectable in all SOD1 plasma analyzed.  Alanine and 
proline levels were also found to be significantly lower in saline-treated SOD1 animals, while 
sarcosine (N-methylglycine) levels were found to be elevated in SOD1 plasma.  Of these 
metabolites, aspartate, alanine, cystine, and proline are all glucogenic and both cystine and 
proline are considered to be conditionally essential amino acids.  We also no longer see 
significant differences in plasma urea or glutamine levels in SOD1 mice at 70 days of age. 
Many metabolites vary between genotypes within the same gender.  When we break the 
data from Table 3.3.3.1 down and look at genotype differences in plasma metabolites within 
each gender, we see that male and female SOD1 mice, when compared to their wild-type 
counterparts, have different plasma metabolite profiles.  Table 3.3.3.2 shows the data broken 
down by gender, comparing wild-type mice to SOD1 mice.  Female SOD1 mice in the 50 day 
age group show a variety of differences in plasma metabolites, some of these differences are 
the same seen in Table 3.3.3.1, while other differences are specific to females and are not 
detected when gender is not accounted for.  For example, lower levels of plasma 
phosphoserine, citrulline, cystine, methionine, lysine, and arginine, and higher levels of 
glutamine, seen in female SOD1 mice agree with plasma metabolite differences seen between 
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wild-type and SOD1 mice when gender is not accounted for.   However, when we examine 
genotype differences in plasma metabolites of female mice, we now detect significant 
differences in threonine and ornithine, both of which are significantly lower in plasma from 
SOD1 females (Table 3.3.3.2).  When we look at 50 day old male mice a similar pattern is 
observed, where several of the plasma metabolite differences agree with those seen in Table 
3.3.3.1 and new male-specific differences become apparent.  Lower levels of plasma 
phosphoserine, phosphoethanolamine, urea, aspartate, and cystine, and higher levels of 
asparagine and glutamine, detected in male SOD1 mice when compared to male wild-type mice 
agree with differences seen when gender is not accounted for.  However, focusing on genotype 
differences in plasma metabolites from male mice shows that there are several metabolite 
differences that are specific to males.  Male SOD1 mice show significantly higher plasma levels 
of alanine, tyrosine, phenylalanine, and proline, which are not seen in females.   
Several of the plasma metabolite differences between 50 day old wild-type and SOD1 
mice are not considered to be gender-specific.  Decreased levels of phosphoserine and cystine, 
and elevated levels of glutamine are seen in both male and female SOD1 mice when the data 
are broken down by gender.  It is also interesting to point out that several of the differences 
seen in 50 day old SOD1 mice in Table 3.3.3.1 are accounted for by only one gender.  Lower 
levels of methionine, lysine, and arginine are specific to females, while male specific changes 
include alterations in levels of phosphoethanolamine, urea, aspartate, and asparagine.   
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Table 3.3.3.2 Plasma metabolite profiles of 50 and 70 day old mice broken down by gender. 
Age & Gender Metabolite WT SOD1 p (MANOVA) 
50 day 
Females 
Phser 14.45 (1.47) 8.66 (1.54) 0.02 
Thr* 203.07 (10.99) 131.50 (16.26) 0.002 
Gln
†
 568.60 (16.63) 709.78 (74.95) 0.04 
Citr 119.86 (8.34) 72.97 (7.40) 0.002 
Cys
†
 23.32 (3.73) 0.77 (0.77) 0.0003 
Met* 97.44 (10.56) 47.63 (6.17) 0.003 
Orn 99.00 (8.66) 53.06 (8.53) 0.003 
Lys* 356.96 (17.17) 255.59 (24.42) 0.004 
Arg
†
 138.40 (13.63) 76.58 (11.60) 0.007 
50 day 
Males 
Phser 14.40 (0.96) 5.13 (1.75) 0.0002 
Pea 11.02 (2.28) 2.37 (1.82) 0.01 
Urea 10907.49 (366.39) 8117.83 (1287.87) 0.03 
Asp 20.73 (1.76) 11.20 (1.15) 0.001 
Asn 35.65 (2.21) 53.62 (4.98) 0.002 
Gln
†
 552.41 (20.69) 648.27 (28.90) 0.01 
Ala 532.65 (19.38) 754.24 (26.03) 0.000004 
Cys
†
 32.04 (2.58) 0.00 (0.00) 0.000000 
Tyr
†
 65.22 (3.55) 81.65 (5.26) 0.02 
Phe* 58.07 (2.25) 68.15 (3.43) 0.02 
Pro
†
 84.78 (4.10) 129.72 (11.49) 0.0008 
70 day Females Pea 11.21 (1.40) 1.61 (1.06) 0.0002 
Sarc 8.90 (5.65) 37.80 (4.86) 0.002 
70 day Males Gly
†
 325.48 (13.66) 281.24 (5.40) 0.009 
Ala 673.60 (28.49) 521.33 (43.07) 0.02 
Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L. 
Amino acids highlighted in red are glucogenic, those in blue are ketogenic, and purple indicates 
amino acids that can be both ketogenic and glucogenic.  
* indicates essential amino acids and † indicates conditionally essential amino acids. 
n (WT, F, 50 days) = 9  n (WT, M, 50 days) = 10 
n (SOD1, F, 50 days) = 6   n (SOD1, M, 50 days) = 7 
n (WT, F, 70 days) = 6  n (WT, M, 70 days) = 6 
n (SOD1, F, 70 days) = 7  n (SOD1, M, 70 days) = 7 
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When we look at genotype differences between 70 day old female and male mice, we 
see that there are far fewer metabolite differences than with 50 day old mice.  The bottom of 
Table 3.3.3.2 shows the differences between 70 day old saline-treated wild-type and SOD1 
female and male mice.  Some of the genotype differences seen in Table 3.3.3.1, when the data 
were examined by genotype only, disappear when gender is accounted for, while the other 
differences appear to be gender-specific.  When we look at 70 day old females treated with 
saline, we see that SOD1 females have significantly lower levels of phosphoethanolamine, with 
elevated sarcosine, which agrees with the genotype differences seen in Table 3.3.3.1.  These 
alterations in phosphoethanolamine and sarcosine are specific to females, as males show no 
significant changes in levels of these metabolites.  When we look at 70 day old males treated 
with saline, we see that SOD1 males show decreased plasma levels of glycine and alanine, 
which are not shared with females but are seen when gender is not accounted for (Table 
3.3.3.1).  Significant differences in aspartate and proline, observed between wild-type and 
SOD1 mice (Table 3.3.3.1) are no longer seen when gender is accounted for.   Differences in 
cystine levels do not reach significance when gender is accounted for, but continue to be 
undetectable in 70 day old saline-treated SOD1 male and female mice.   
 Several plasma metabolites differ between males and females of the same genotype.  
When the plasma metabolite data are broken down by genotype and analyzed for gender 
differences, 50 day old wild-type mice show more gender differences than SOD1 mice.  Table 
3.3.3.3 shows the plasma metabolites that differ significantly between 50 day old female and 
male wild-type and SOD1 mice, as well as differences between saline-treated 70 day old 
females and males.  Nine plasma metabolites differ between 50 day old female and male mice – 
urea, threonine, serine, alanine, citrulline, tyrosine, lysine, histidine, and tryptophan.  Of these 
metabolites, only urea is significantly higher in male wild-type mice.  Male wild-type mice show 
significantly lower levels of the other eight plasma metabolites.  This is much different than what 
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is observed in SOD1 mice.  First, there are fewer plasma metabolites that differ between male 
and female SOD1 mice.  The overall plasma metabolite profile of these animals is different than 
that of wild-type mice.  Only two of the significantly different metabolites in SOD1 mice – 
threonine and citrulline – overlap with the metabolites that differ in wild-type mice.  All of the 
differences seen between SOD1 females and males occur because males have significantly 
higher levels than females, whereas the differences in wild-type animals are due to males 
having significantly lower levels than females.  SOD1 males have significantly higher levels of 
threonine than SOD1 females, but their levels of threonine are closer to those of wild-type 
females, which have higher threonine levels than wild-type males.  We also see that levels of 
citrulline in SOD1 male mice, which are significantly higher than those of SOD1 females, are 
similar to citrulline levels in wild-type male mice.   
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Table 3.3.3.3 Gender differences in plasma metabolites of wild-type and SOD1 mice. 
 
Age & Genotype Metabolite Female Male p (MANOVA) 
50 day 
WT 
Urea  8708.96 (354.88)  10907.49 (366.39)  0.0005  
Thr*  203.07 (11.00)  163.34 (9.19)  0.01  
Ser  163.93 (7.19)  138.98 (4.92)  0.01  
Ala  627.88 (40.72)  532.65 (19.39)  0.04  
Citr  119.86 (8.34)  99.90 (3.88)  0.04  
Tyr
†
  79.45 (5.61)  65.22 (3.55)  0.04  
Lys*  356.96 (17.17)  286.65 (10.76)  0.02  
His*  73.38 (2.87)  66.08 (2.76)  0.03  
Trp*  76.56 (3.39)  43.50 (7.64)  0.001  
50 day 
SOD1  
Thr*  131.50 (16.26)  187.67 (12.48)  0.02  
Citr  72.97 (7.40)  99.29 (4.30)  0.009  
Met*  47.63 (6.17)  80.77 (8.41)  0.01  
Orn  53.06 (8.53)  88.90 (11.71)  0.04  
Pro
†
  77.27 (10.86)  129.72 (11.49)  0.007  
70 day 
WT 
Taur  374.83 (20.66) 281.63 (21.25) 0.01  
Pea  11.21 (1.40) 1.02 (1.02) 0.0002  
Gln*  638.99 (34.74) 531.61 (29.86) 0.04  
1-Mhis  15.07 (1.41) 10.09 (1.22) 0.02  
His*  81.79 (3.31) 67.63 (2.41) 0.006  
Trp*  76.07 (7.38) 50.16 (4.57) 0.01  
70 day 
SOD1 
Urea 9447.01 (548.05) 11606.02 (354.13) 0.006 
Gln
†
  646.85 (25.91) 540.98 (29.63) 0.02  
Ala 665.88 (31.81) 521.33 (43.07) 0.02  
Phe*  71.48 (2.11) 61.65 (2.94) 0.02  
Lys*  318.41 (17.80) 242.03 (26.80) 0.04  
His*  81.73 (6.61) 64.16 (2.34) 0.03  
Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L and n values are the same 
as those of Table 3.3.3.2.  * indicates essential amino acids and † indicates conditionally 
essential amino acids.  Amino acids highlighted in red are glucogenic, those in blue are 
ketogenic, and purple indicates amino acids that can be both ketogenic and glucogenic.  
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 When the data from 70 day old saline-treated mice are broken down by genotype and 
examined for gender differences, we see a different plasma metabolite profile than what was 
observed in 50 day old mice, with new metabolite differences appearing.  The bottom portion of 
Table 3.3.3.3 lists the plasma metabolites found to differ significantly between male and female 
70 day old mice treated with saline.  When we compare male and female wild-type mice treated 
with saline, significant gender differences in six plasma metabolites are observed.  Male wild-
type mice in this age group have significantly lower plasma levels of taurine, 
phosphoethanolamine, glutamine, 1-methylhistidine, histidine, and tryptophan.  Of these 
differences, only two are shared with 50 day old wild-type mice – histidine and tryptophan – 
which are also lower in male wild-type mice compared to females.   When we compare 
metabolite levels in plasma from male and female SOD1 mice treated with saline there is very 
little overlap with the profile of wild-type males and females.  In both wild-type and SOD1 mice 
glutamine and histidine levels are found to be significantly higher in females when compared to 
males.  The other plasma metabolites that show gender differences in SOD1 mice at this age – 
urea, alanine, phenylalanine, and lysine – are lower in males than females, with the exception of 
urea which is elevated in male SOD1 mice.  The 50 and 70 day age groups show no similarities 
with respect to gender differences in plasma metabolite levels.   
MSO treatment significantly lowers plasma glutamine levels, increases plasma cystine 
levels, and alters the profile of several other plasma metabolites in SOD1 mice.  The plasma 
metabolite profile of SOD1 mice treated with MSO shows several changes in the levels of a 
variety of chemicals.  We examined plasma metabolite levels in 14 mice treated with saline and 
16 mice treated with MSO and Figure 3.3.3.4 shows the plasma metabolites that are altered 
with MSO treatment in these SOD1 mice.  Phosphoethanolamine, AAAA (α-aminoadipic acid, 
an intermediate in lysine metabolism), and ornithine levels increase, while sarcosine levels 
decrease in MSO-treated SOD1 mice compared to their saline-treated counterparts.  The levels 
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of several glucogenic amino acids are altered with MSO treatment.  Asparagine, alanine, 
arginine, and cystine levels increase significantly with MSO treatment, while glutamine levels 
decrease significantly with treatment.  Interestingly, cystine, which is undetectable in saline-
treated SOD1 mice, becomes detectable with MSO treatment.   Lysine, an essential ketogenic 
amino acid, also increases significantly in SOD1 mice with MSO treatment.  We also compared 
the plasma metabolite profile of wild-type mice treated with saline to that of MSO-treated wild-
type mice and only found one amino acid to change with treatment.  Lysine levels in wild-type 
mice increase significantly from 290.03 ± 18.13 to 352.86 ± 17.99 µmoles/L, with p=0.02.  This is 
similar to the increase in plasma lysine levels seen in SOD1 mice with MSO treatment. 
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Table 3.3.3.4 The effects of MSO treatment on plasma metabolite levels of SOD1 mice. 
 
 
 
Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L. 
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen. 
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or 
acetyl-CoA. 
* indicates essential amino acids. 
† indicates conditionally essential amino acids. 
n (Saline) = 14 
n (MSO) = 16 
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There are several gender-specific changes in plasma metabolites of 70 day old mice 
with MSO treatment.  When the plasma metabolite data are further broken down by gender and 
genotype and examined for changes with MSO treatment, the plasma concentrations of several 
metabolites are altered in a gender-specific fashion.  Table 3.3.3.5 lists the metabolites that 
change significantly with MSO treatment, as well as their concentrations in saline and MSO-
treated animals.  When we compare the concentrations of plasma metabolites of saline-treated 
wild-type female mice to those of MSO-treated wild-type female mice, there are no significant 
changes with MSO treatment.  However, when we look at treatment-related changes in plasma 
metabolites of female SOD1 mice we see that glutamine and sarcosine levels are significantly 
lower, while arginine levels are significantly higher, in MSO-treated mice.  This corresponds to 
the overall changes that were seen when in plasma metabolite levels were examined only by 
genotype (Table 3.3.3.4).  We see a greater number of plasma metabolites change with MSO 
treatment in male wild-type mice.  Male wild-type mice treated with MSO have significantly 
higher levels of phosphoserine, phosphoethanolamine, glutamate, ornithine, and lysine in their 
plasma than their saline-treated counterparts.  Fewer plasma metabolite changes are seen in 
male SOD1 mice that have been treated with MSO.  As with wild-type males, plasma levels of 
phosphoethanolamine increase with MSO treatment in SOD1 males.  This is the only similarity 
between wild-type and SOD1 male mice.   SOD1 males also show significantly increased levels 
of AAAA, alanine, and tryptophan in their plasma with MSO treatment, which are not seen in 
wild-type males.   
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Table 3.3.3.5 Gender-specific changes in plasma metabolites with MSO treatment. 
 
Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L. 
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen. 
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or 
acetyl-CoA. 
Amino acids highlighted in purple can be ketogenic or glucogenic. 
* indicates essential amino acids. 
† indicates conditionally essential amino acids. 
n (F, WT, Saline) = 6 
n (F, WT, MSO) = 6 
n (F, SOD1, Saline) = 7 
n (F, SOD1, MSO) = 8 
n (M, WT, Saline) = 6 
n (M, WT, MSO) = 5 
n (M, SOD1, Saline) = 7 
n (M, SOD1, MSO) = 8 
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To summarize the results of the plasma metabolite analysis, we see that there are a 
variety of differences in SOD1 mice when compared to wild-type mice, some of which are 
gender-specific.  We see that 50 day old untreated SOD1 mice have significantly higher levels 
of plasma ammonia than wild-type mice, but the overall level of ammonia in both groups 
declines with age and these genotype differences disappear in 70 day old saline-treated mice.    
We also see that when plasma ammonia data are broken down by gender and genotype, both 
female and male SOD1 mice have higher plasma ammonia levels, but the differences between 
wild-type and SOD1 females reached significance, while those between males did not.  The 
same trend is seen in 70 day data broken down by gender and genotype, where overall plasma 
ammonia levels decrease in all groups and show no significant gender or genotype differences.  
MSO treatment significantly increases plasma ammonia levels in both wild-type and SOD1 
mice, and no gender differences are seen with treatment.       
With respect to plasma metabolites, 50 day old untreated animals show many more 
genotype differences in metabolites than 70 day old saline-treated mice and several of these 
differences in plasma metabolite levels between wild-type and SOD1 mice show gender-
specificity when data are broken down by both genotype and gender.  For example, significantly 
lower levels of methionine, lysine, and arginine are only seen in 50 day old female SOD1 (when 
compared to female wild-type) mice and significant differences in levels of 
phosphoethanolamine, urea, aspartate, and asparagine are only seen when 50 day old male 
SOD1 and wild-type mice are compared.  When gender is taken into account, genotype 
differences in metabolites from 50 day old mice that are not seen when gender is ignored 
become apparent.  For example, when 50 day old wild-type and SOD1 mice are grouped 
according to gender and examined for genotype differences females show differences in 
ornithine and threonine, while males show differences in alanine, tyrosine, phenylalanine, and 
proline, which are not observed when animals are simply grouped by genotype.  Gender 
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specific differences in plasma metabolites continue to be seen in 70 day old saline-treated mice, 
but there are fewer than what was observed in 50 day old mice.  MSO treatment alters a variety 
of metabolite levels in SOD1 mice, however only lysine levels are altered in wild-type mice.  
When treatment data are broken down by gender and genotype, there are a variety of 
metabolite changes observed but no changes occur in female wild-type mice.   
3.3.4 Nitrogen Metabolism in the Liver 
 Preliminary analysis of plasma metabolite data suggested that several amino acids, 
particularly those involved in urea production, were significantly different in SOD1 mice when 
compared to wild-type animals.  In mammals urea production occurs primarily in the liver (and to 
some extent in the kidney) through the urea cycle, which consists of five reactions that function 
to remove ammonia from the body.  The first two reactions occur in the mitochondria, the first of 
which is catalyzed by carbamoyl phosphate synthetase one (CPSI) and is the rate limiting step 
of the urea cycle.  The mutant SOD1 protein is ubiquitously expressed in the SOD1 G93A 
mouse model of ALS and the protein has been shown to associate with mitochondria isolated 
from spinal cord (Liu et al 2004) and aggregate in brain mitochondria (Vijayvergiya et al 2005) of 
these animals.  In addition, mice expressing mutant SOD1 protein have been found to have 
overall defects energy homeostasis (Dupuis et al 2004) and liver samples collected from ALS 
patients exhibit hepatic ultrastructural changes and abnormal mitochondria, suggestive of liver 
dysfunction (Nakano et al 1987).  As a result, it seems reasonable to believe that the SOD1 
mutation could potentially interact with liver mitochondria in such a way as to impair the urea 
cycle.  We decided to assay CPSI activity to see if SOD1 mice exhibit changes in enzyme 
activity prior to symptom onset.  We also examined the impact of gender and MSO treatment on 
CPSI activity.    
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 The specific activity of CPSI does not differ between wild-type and SOD1 mice.  Figure 
3.3.4.1 compares the specific activity of CPSI in wild-type mice to that of SOD1 mice.  In 50 day 
old untreated mice, both wild-type and SOD1 animals have about the same level of CPSI 
activity, approximately 150 nmoles/min/mg protein (Figure 3.3.4.1A).  At 70 days of age, CPSI 
activity increases significantly in both wild-type (p<0.001) and SOD1 (p<0.05) mice treated with 
saline (Figure 3.3.4.1B).  It also appears as though SOD1 mice may have lower CPSI activity 
than wild-type mice at this age; however this difference did not reach significance. 
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Figure 3.3.4.1 Specific activity of liver CPSI in wild-type and SOD1 mice. 
The data are presented as the average specific activity of CPSI with error bars representing the 
S.E.M.  Green bars indicate data from wild-type mice, while purple bars indicate data from 
SOD1 mice.  A.  The specific activity of CPSI in 50 day old wild-type and SOD1 mice (n=20 
mice/group).  B.  The specific activity of CPSI in saline-treated 70 day old wild-type and SOD1 
mice (n=20 mice/group). 
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 Female mice have higher CPSI activity levels than males, regardless of genotype.  
When the CPSI activity data are broken down by gender and genotype there is a clear 
difference between males and females.  Figure 3.3.4.2 shows the results of the CPSI activity 
assays broken down by gender and genotype.  In 50 day old untreated wild-type and SOD1 
female mice, the average CPSI activity is around 200 nmoles/min/mg protein, almost twice the 
activity of CPSI in wild-type and SOD1 males (Figure 3.3.4.2A).  In 70 day old saline-treated 
mice, CPSI activity is elevated across all groups when compared to 50 day old untreated 
animals (p<0.05).   The gender difference in the specific activity of CPSI remains apparent in 70 
day old mice (Figure 3.3.4.2B).  Saline-treated female wild-type mice show significantly higher 
CPSI activity (280 ± 20 nmoles/min/mg protein) than their male counterparts (210 ± 10 
nmoles/min/mg protein), with p<0.05.  Saline-treated SOD1 female mice also show significantly 
higher CPSI activity (250 ± 10 nmoles/min/mg protein) than their male counterparts (160 ± 10 
nmoles/min/mg protein), with p<0.001.  It is also interesting to point out that in the 70 day age 
group, saline-treated SOD1 males have significantly lower CPSI activity levels than saline-
treated wild-type males (p<0.01), but this difference is not observed when female SOD1 and 
wild-type mice are compared. 
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Figure 3.3.4.2 Specific activity of liver CPSI broken down by gender and genotype. 
The data are presented as the average specific activity of CPSI with error bars representing the 
S.E.M.  Green bars indicate data from male and female wild-type mice, while purple bars 
indicate data from male and female SOD1 mice.  A. Specific activity of CPSI from 50 day old 
untreated mice (n=10 mice/group; *** indicate values are significant with p<0.001).  B.  Specific 
activity of CPSI from 70 day old mice treated with saline (n=10 mice/group; *, **, and *** indicate 
values are significant with p<0.05, 0.01, and 0.001 respectively).   
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MSO treatment does not affect CPSI activity levels in wild-type or SOD1 mice.  Figure 
3.3.4.3 shows the effect of MSO treatment on CPSI activity.  When the data are grouped by 
genotype, 70 day old wild-type animals treated with saline have CPSI activity levels similar to 
those of wild-type animals treated with MSO and the same holds true for SOD1 mice (Figure 
3.3.4.3A).  SOD1 mice in this age group have slightly lower, but not significant, CPSI activity 
levels than wild-type mice for both treatment groups.  When the data are broken down by 
gender and genotype (Figure 3.3.4.3B), we see that MSO-treated wild-type females have 
slightly higher, but not significant, CPSI activity than saline-treated wild-type females.  However, 
female SOD1 mice and male wild-type and SOD1 mice all show slightly lower, but not 
significant, levels of CPSI activity when treated with MSO.   
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Figure 3.3.4.3 The effects of MSO treatment on CPSI activity in presymptomatic wild-type and 
SOD1 mice. 
The data are presented as the average specific activity of CPSI with error bars representing the 
S.E.M.  Blue bars indicate data from both wild-type and SOD1 mice treated with saline while red 
bars indicate data from wild-type and SOD1 mice treated with MSO.  A.  In 70 day old mice, 
MSO treatment has no effect on CPSI activity in wild-type or SOD1 mice (n=20 mice/group).  B.  
When the data depicted in A are broken down by gender and genotype, MSO treatment still has 
no effect on CPSI activity in 70 day old animals (n=10 mice/group). 
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In summary, we see no significant differences in CPSI activity between wild-type and 
SOD1 mice at 50 or 70 days of age.  However, we do see that CPSI activity is significantly 
elevated in 70 day old saline-treated mice of both genotypes when compared to 50 day old 
animals.  When CPSI activity data are further broken down by gender and genotype, we see 
that there is a clear gender difference in 50 day old mice, in which female mice of both 
genotypes have significantly higher CPSI activity levels than their male counterparts.  We 
continue to see significantly elevated CPSI activity in all groups of mice at 70 days of age.  
While we still see a gender difference in this age group (females continue to having significantly 
higher CPSI activity than males), we also start to see changes in CPSI activity in male SOD1 
mice, which have the lowest activity level of all the groups examined.  MSO treatment shows no 
effect on CPSI activity in wild-type and SOD1 mice of both genders. 
 After analyzing CPSI activity levels in the liver of wild-type and SOD1 mice, we assayed 
glutamine synthetase activity levels in the same mice.  In mammals, CPSI and GS protein 
expression are compartmentalized within different cell types.  In the mammalian liver CPSI is 
broadly expressed in most hepatocytes, while glutamine synthetase expression is restricted to 
only a small number of cells which do not express CPSI, specifically those surrounding the 
terminal hepatic venules where GS is found in the cytosol (Smith & Campbell 1988).  Glutamine 
synthetase is also cytosolic in the brain, however it is much more widely expressed within 
astrocytes which can make up about 50% of the volume in certain regions (Squire et al 2008).  
As previously mentioned, a single dose of MSO has been shown to inhibit glutamine synthetase 
activity in the brain for an extended period of time, with brain GS regaining 75% of control 
activity after 90 days.  This same study also showed that a single subconvulsive dose of MSO 
had slightly different effects on the liver.  Maximal inhibition of glutamine synthetase in mouse 
liver was obtained within one hour of injection with MSO and the enzyme regained 70% of 
control activity within 4 days of injection (Rao & Meister 1972).  In an effort to continue the 
166 
 
 
characterization of glutamine metabolism in ALS mice, as well as to examine potential metabolic 
effects of the overexpression of mutant SOD1 protein in liver, we assayed the specific activity of 
liver glutamine synthetase in both wild-type and SOD1 mice and looked at the effects of MSO 
treatment on enzyme activity.       
The SOD1 G93A mutation does not affect the specific activity of glutamine synthetase in 
liver homogenates of presymptomatic mice.  All animals assigned to these experiments were 
given a final injection of MSO within 24 hours prior to euthanasia.  When liver samples were 
processed, a portion of the supernatant from each liver homogenate was desalted for CPSI 
enzyme activity assays, while the remainder was set aside for liver GS activity assays.  The 
activity assays were performed in the same manner as those conducted on brain and spinal 
cord GS, differing only in sample preparation.  The results of liver GS activity assays can be 
seen in Figure 3.3.4.4.  In 50 day old untreated mice, there is no difference in the specific 
activity of GS between wild-type and SOD1 mice (Figure 3.3.4.4A).  The specific activity of liver 
GS in wild-type mice appears to increase slightly by 70 days of age, while that of SOD1 mice 
remains the same as that of 50 day old mice.  In 70 day old saline-treated mice, liver GS activity 
appears to be slightly lower in SOD1 mice than wild-type mice (Figure 3.3.4.4B), but this 
difference was not found to be significant.   
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Figure 3.3.4.4 Specific activity of liver glutamine synthetase in wild-type and SOD1 mice. 
The data are presented as the average specific activity of GS with error bars representing the 
S.E.M.  Green bars indicate data from wild-type mice, while purple bars indicate data from 
SOD1 mice.  A.  The specific activity of liver GS in untreated, 50 day old wild-type and SOD1 
mice (n=20 mice/group).  B.  The specific activity of liver GS in saline-treated, 70 day old wild-
type and SOD1 mice (n=20 mice/group).  
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Male SOD1 mice treated with saline have significantly lower liver GS activity than female 
SOD1 and male wild-type mice.  Figure 3.3.4.5 shows the specific activity of liver GS broken 
down by gender and genotype.  Untreated 50 day old mice have about the same level of GS 
activity across genders and genotypes (Figure 3.3.4.5A).  In 70 day old mice treated with saline, 
we see that the specific activity of liver GS is higher in female mice when compared to male 
mice of both genotypes (Figure 3.3.4.5B).  However, this difference is only significant when 
comparing female SOD1 mice to male SOD1 mice treated with saline.  Saline-treated female 
SOD1 mice have significantly higher liver GS activity (810 ± 30 nmoles/min/mg protein) than 
male SOD1 mice (580 ± 30 nmoles/min/mg protein), with p<0.001.  Saline-treated male SOD1 
mice also have significantly lower GS activity than their wild-type counterparts (580 ± 30 
nmoles/min/mg protein compared to 740 ± 50 nmoles/min/mg protein), with p<0.05.   
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Figure 3.3.4.5 Specific activity of liver GS broken down by gender and genotype. 
The data are presented as the average specific activity of GS with error bars representing the 
S.E.M.  Green bars indicate data from male and female wild-type mice, while purple bars 
indicate data from male and female SOD1 mice.  A.  Specific activity of liver GS from 50 day old 
untreated mice (n=10 mice/group).  B.  Specific activity of liver GS from 70 day old mice treated 
with saline (n=10 mice/group; * and *** indicate values are significant with p<0.05 and 0.001 
respectively).   
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  MSO treatment significantly lowers liver glutamine synthetase activity.  Figure 3.3.4.6 
shows the effects of MSO treatment on the specific activity of liver glutamine synthetase.  Much 
like with brain and spinal cord GS activity, a single weekly injection of 20 mg/kg MSO lowers 
liver glutamine synthetase activity; however the extent of inhibition varies slightly.  Whereas with 
brain and spinal cord, in which MSO treatment lowered GS activity by about 90% in both 
genotypes, we see that liver GS activity at 70 days of age is inhibited by almost 90% in wild-type 
mice, but in SOD1 mice GS activity is only inhibited by approximately 70% (Figure 3.3.4.6A).  
SOD1 mice treated with MSO have significantly higher liver GS activity (200 ± 35 
nmoles/min/mg protein) than wild-type mice treated with MSO (110 ±  10 nmoles/min/mg 
protein), p<0.05.  When these data are broken down by gender and genotype, we see that liver 
GS activity is significantly lowered in all groups (p<0.001).  However, GS activity is clearly 
altered in SOD1 male mice compared to wild-type male and SOD1 female mice (Figure 
3.3.4.6B).  While MSO treatment lowers GS activity by approximately 85% in male and female 
wild-type mice, as well as female SOD1 mice, it only lowers GS activity in male SOD1 mice by 
approximately 55%.  When compared to wild-type male mice treated with MSO (95 ± 10 
nmoles/min/mg protein), male MSO-treated SOD1 mice have significantly higher liver GS 
activity (260 ± 50 nmoles/min/mg protein), with p<0.05.  While female SOD1 mice treated with 
MSO have lower GS activity than their male counterparts, this difference was not found to be 
significant.  Interestingly,  female wild-type mice treated with MSO were found to have 
significantly higher GS activity (120 ± 30 nmoles/min/mg protein) than their male counterparts 
(95 ± 10 nmoles/min/mg protein), with p<0.05.  
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Figure 3.3.4.6 The effects of MSO treatment on liver GS activity in presymptomatic wild-type 
and SOD1 mice. 
The data are presented as the average specific activity of GS with error bars representing the 
S.E.M.  Blue bars indicate data from both wild-type and SOD1 mice treated with saline while red 
bars indicate data from wild-type and SOD1 mice treated with MSO.  A.  MSO treatment 
significantly lowers liver GS activity in 70 day old wild-type and SOD1 mice (n=20 mice/group, 
except for WT mice treated with MSO where n=19 mice/group).  B.  When the data are further 
broken down by gender and genotype, MSO inhibits GS activity by approximately 90% in all 
groups, except male SOD mice where GS activity is only inhibited by 55% (n=10 mice/group, 
except for female WT mice treated with MSO where n=9 mice/group; *** indicates that values 
differ significantly with p<0.001). 
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     In summary, we see that there are no significant differences in liver glutamine 
synthetase activity between wild-type and SOD1 mice at 50 days of age.  The specific activity of 
liver GS is slightly, but not significantly, lower in SOD1 mice treated with saline at 70 days of 
age when compared to saline-treated wild-type mice.  When the data are further broken down 
by gender and genotype, we see no significant gender differences at 50 days of age.  However, 
much like with CPSI activity, we begin to see differences emerging in male SOD1 mice at 70 
days of age.  Liver GS activity in saline-treated male SOD1 mice decreases at 70 days of age 
and is significantly lower than that of female SOD1 mice, as well as wild-type male mice, treated 
with saline.  A similar pattern is seen with the CPSI activity in these animals, but is not reflected 
in the activities of brain or spinal cord GS in animals of the same age.  MSO treatment 
significantly lowers liver glutamine synthetase activity in both wild-type and SOD1 mice, but has 
a much greater impact on GS activity in wild-type mice where activity is decreased by almost 
90%.  MSO treatment impacts liver GS activity in male and female wild-type mice and female 
SOD1 mice similarly, but it does not inhibit liver GS activity in male SOD1 mice to the same 
extent.  Whereas females of both genotypes and male wild-type mice show between 83 and 
85% liver GS inhibition with MSO treatment, male SOD1 mice show only 55% inhibition.     
3.3.5 The Effects of Ovariectomization on Enzyme Activity and Plasma Metabolites 
 In an effort to understand how the removal of sex hormones impacts ammonia and 
amino acid metabolism, we performed glutamine synthetase assays on liver and brain extracts, 
glutaminase assays on brain extracts, ammonia and metabolite analyses on plasma, and CPSI 
activity assays on liver extracts isolated from 70 day old female SOD1 mice that had treated 
with weekly i.p. injections of saline starting at 50 days of age.  We focused on female mice 
because survival experiments and grip assays showed that females benefit more from MSO 
treatment than males.  Obtaining a metabolic profile from these SOD1 female mice might help in 
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understanding how ammonia and amino acid metabolism change when female sex hormones 
are removed, and possibly pinpoint a metabolic pathway that may be responsive to these 
hormones as well as MSO treatment.  For these experiments, female SOD1 mice were 
ovariectomized between 30 and 40 days of age, prior to reaching sexual maturity and 
subsequent exposure to sex hormones.  Intraperitoneal injections of saline were administered 
once a week starting at 50 ± 2 days of age and mice were euthanized at 70 ± 2 days of age.  
Metabolic profiles of these mice were compared to those obtained from SOD1 females treated 
with saline that had not undergone ovariectomy to understand how metabolism was affected by 
removal of sex hormones. 
 Ovariectomized SOD1 females have altered glutamine metabolism when compared to 
SOD1 females with intact ovaries.  Table 3.3.5.1 compares the activity levels of enzymes 
involved in glutamine and ammonia metabolism from 70 day old female SOD1 mice that had 
their ovaries removed to those from female SOD1 mice with intact ovaries.  As shown in 
Chapter 2, SOD1 females that have undergone ovariectomy no longer respond to MSO 
treatment and those treated with saline show no change in lifespan.  When compared to normal 
SOD1 females treated with saline, 70 day old ovariectomized SOD1 females have significantly 
lower levels of brain glutamine synthetase activity and elevated brain glutaminase activity.  
These mice also exhibit significantly lower levels of liver glutamine synthetase activity.  The 
average specific activity of CPSI from ovariectomized female SOD1 mice is lower than that of 
females with intact ovaries, but this difference did not reach significance. 
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Table 3.3.5.1 The effects of ovariectomization on enzyme activity in SOD1 females. 
 
Enzyme activities are expressed as average specific activity (S.E.M.) in nmoles/minute/mg 
protein.  OVR indicates ovariectomized females. 
n (OVR, SOD1) = 7-10 
n (SOD1) = 8-12 
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Ovariectomized female SOD1 mice treated with saline exhibit a different plasma 
metabolite profile than non-ovariectomized female SOD1 mice.  Table 3.3.5.2 lists the plasma 
metabolites that differ significantly between 70 day old ovariectomized and non-ovariectomized 
female SOD1 mice treated with saline.  Ovariectomized female mice have slightly higher levels 
of plasma ammonia than non-ovariectomized female mice however this difference did not reach 
significance.  We do see that there are significant differences in several other plasma 
metabolites in SOD1 females that have had their ovaries removed.  Aspartate, proline, and 
AAAA levels are elevated in plasma from ovariectomized SOD1 females, while threonine, 
serine, sarcosine, lysine, and histidine are all significantly lower in ovariectomized SOD1 
females.  It is interesting to note that SOD1 females treated with saline show elevated levels of 
plasma sarcosine when compared to their wild-type counterparts (Table 3.3.3.2) and that MSO 
treatment lowers plasma sarcosine levels in these mice (Table 3.3.3.5), but ovariectomized 
female SOD1 mice have undetectable levels of sarcosine in their plasma.   
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Table 3.3.5.2 The effects of ovariectomization on plasma metabolite levels in SOD1 female 
mice. 
 
 
Amino acid levels are expressed as the mean (S.E.M.) in µmoles/L with OVR indicating 
ovariectomized female mice. 
Amino acids highlighted in red are glucogenic and can be converted to glucose and glycogen. 
Amino acids highlighted in blue are ketogenic and can be converted to acetoacetyl-CoA and/or 
acetyl-CoA, while those in purple can be glucogenic or ketogenic. 
* indicates essential amino acids. 
† indicates conditionally essential amino acids. 
n (OVR SOD1) = 11 
n (SOD1) = 7 
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In general, we see a variety of changes take place in SOD1 females upon ovariectomy.  
The specific activity of glutamine synthetase from both brain and liver is significantly lower, while 
the specific activity of brain glutaminase is significantly higher, in ovariectomized female SOD1 
mice treated with saline.  In addition, the specific activity of liver CPSI is slightly lower in these 
mice.  Plasma ammonia levels are not significantly different from those of female SOD1 mice 
with intact ovaries; however we do see several plasma metabolite differences in ovariectomized 
female mice.  Threonine, serine, sarcosine, lysine, and histidine levels in the plasma are all 
significantly lower in ovariectomized female SOD1 mice compared to non-ovariectomized 
female SOD1 mice, while aspartate, proline, and AAAA levels are significantly elevated.  
Sarcosine is particularly interesting because it is elevated in SOD1 female mice with intact 
ovaries and MSO treatment significantly lowers plasma levels of this metabolite.  In 
ovariectomized females, sarcosine is undetectable in all of the mice tested.   
3.4 Discussion 
3.4.1 Glutamine Synthetase Activity in the CNS 
 The results obtained from glutamine synthetase activity assays performed on wild-type 
and SOD1 brain and spinal cord homogenates show that there are no genotype-specific 
differences in GS activity in presymptomatic mice.  Untreated, 50 day old mice have brain and 
spinal cord GS activity levels similar to those of saline-treated 70 day old mice, and all age 
groups show that brain homogenates have higher levels of GS activity than spinal cord 
homogenates.  This is probably due to a greater density of astrocytes, the primary GS-
expressing cell type, in the brain than spinal cord.  However, GS activity levels begin to 
decrease after symptom onset in 110 day old saline-treated mice and SOD1 mice show 
significantly lower GS activity levels in brain and spinal cord extracts.  Studies conducted on 
ALS mice show that GS expression does not change over the course of the disease and that 
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enzyme activity is elevated in the lumbar spinal cords of end stage mice (120-150 days of age) 
(Fray et al 2001).  The results obtained from the current study show that GS activity in the whole 
spinal cord of SOD1 mice is lower than that of wild-type mice.  Studies performed on rat primary 
astrocyte cultures have shown that the cytokine, TNFα, (which has been implicated in ALS 
(Hensley et al 2003)) can reduce GS expression and inhibit glutamate-induced activation of the 
enzyme (Zou et al 2010).  In mouse models of ALS, TNFα mRNA expression has been shown 
to increase until the terminal stages of the disease (Elliott 2001) and it is possible that the 
decrease in GS activity seen in 110 day old saline-treated SOD1 mice may be due to gradually 
increasing levels of TNFα production over the course of the disease.  However, cytokine levels 
would have to be measured at the same time intervals at which GS activity levels were 
examined in order to correlate the decrease in GS activity levels to TNFα production.    
When gender differences in GS activity levels were examined, presymptomatic mice (50 
day untreated and 70 day old saline-treated animals) showed similar levels of GS activity in 
males and females.  However, symptomatic 110 day old saline-treated mice, which showed an 
overall decrease in GS activity, also showed some gender-specific changes in GS activity.  Male 
SOD1 mice show significantly lower levels of brain GS activity, while female SOD1 mice show 
significantly lower levels of spinal cord GS activity.  Since studies conducted in other 
laboratories suggested that GS protein levels do not change over the course of the disease in 
ALS mice (Fray et al 2001), GS expression was not examined.  Microarray analysis of estradiol 
treated mice showed that astrocyte-specific genes, including GS, are increased compared to 
vehicle-treated controls (Mong & Blutstein 2006).  Studies conducted on female rats and mice 
show that female hormones increase GS expression in specific brain regions (arcuate nucleus, 
ventromedial nucleus, amygdala, and hippocampus), but these studies did not examine enzyme 
activity levels (Blutstein et al 2009; Blutstein et al 2006).  These results suggest that there could 
be region-specific differences in GS activity in female ALS mice, but since whole tissue 
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homogenates (brain and spinal cord) were used to assay enzyme activity, these potential 
differences were not observed.  It is possible that female hormones that lead to increased levels 
of GS protein expression in certain brain regions, may also lead to a corresponding increases in 
enzyme activity, leading to the normalized levels of whole brain GS activity observed in SOD1 
females.  Low serum levels of free testosterone have been implicated in human ALS (Militello et 
al 2002) and dihydrotestosterone treatment of ALS mice has been shown to increase lifespan 
and ameliorate motor neuron and muscle degeneration that occurs during the disease (Yoo & 
Ko 2012).  However, studies on the developing rat brain showed that testosterone did not have 
an impact on GS activity (Patel et al 1983).  These studies also showed that female hormones 
did not affect GS activity in the developing rat brain, suggesting that hormones may play a 
greater role in the fully developed brain, but no studies examining the effects of testosterone on 
GS activity could be found.   Since ALS targets a subset of neurons, whole brain and spinal cord 
homogenates may not be the best samples to use in order to examine enzyme activity.  In order 
to better understand potential gender-specific alterations in GS activity levels, enzyme activity 
and expression levels should be examined in a region-specific manner.   
Treatment with a single weekly i.p. injection of 20 mg/kg MSO showed that enzyme 
activity was significantly decreased by approximately 90% in both brain and spinal cord 
homogenates from SOD1 mice and their wild-type counterparts.  This observation was 
consistent across age groups and 110 day old mice treated with MSO show the same levels of 
inhibition as 70 day old mice treated with MSO.  When examined for gender-specific changes in 
GS activity with MSO treatment, male and female (wild-type and SOD1) mice show consistent 
levels of GS activity.  These results suggest that the gender-specific effects of MSO treatment 
on survival of these mice observed in Chapter 2 are probably not entirely due to MSO’s ability to 
inhibit glutamine synthetase, but may be due to some other effect of the drug.   
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3.4.2 Glutaminase Activity in the Brain 
 The results obtained from the brain glutaminase activity assays show that there are no 
significant differences in enzyme activity between wild-type and SOD1 mice.  There are also no 
clear gender-specific differences in glutaminase activity.  Saline-treated male SOD1 mice at 70 
days of age show significantly increased glutaminase activity levels when compared to female 
SOD1 mice of the same age, but these differences are not observed in 50 day old mice or 
postsymptomatic 110 day old mice.  By 110 days of age, glutaminase activity in male SOD1 
mice has decreased to levels similar to that of female SOD1 mice.  In addition, MSO treatment 
does not have an impact on glutaminase activity in wild-type or SOD1 mice and there are no 
gender-specific differences in enzyme activity with treatment.  Studies showing that estradiol 
increases levels of GS protein levels in the female rat arcuate nucleus also show that 
glutaminase protein levels increase with estradiol treatment (Blutstein et al 2009), but did not 
examine enzyme activity levels.  The results of these experiments do not show any increase in 
activity in female mice.  The lack of an effect of transgene expression as well as a treatment 
effect on glutaminase activity suggests that glutaminase activity is not affected by mutant SOD1 
protein and glutaminase does not play a role in MSO’s ability to prolong lifespan in this mouse 
model.   
3.4.3 Plasma Metabolite Analysis 
3.4.3.1 Plasma Ammonia Levels 
 The assays measuring plasma ammonia levels show that untreated 50 day old SOD1 
mice have elevated levels of plasma ammonia, suggesting that expression of the mutant 
transgene alters ammonia metabolism in this mouse model.  When gender differences were 
examined, both male and female 50 day old untreated SOD1 mice show elevated average 
181 
 
 
plasma ammonia levels but only female ammonia levels reached significance.  This elevation in 
plasma ammonia disappears in 70 day old mice, as saline-treated SOD1 mice have levels of 
ammonia similar to those of wild-type mice at this age.  Plasma ammonia levels in 70 day old 
saline-treated wild-type and SOD1 mice are also significantly lower than the levels seen in 50 
day untreated mice, suggesting that elevations in ammonia in young animals may have 
something to do with development as mice are just reaching sexual maturity at the 50 day time 
point.  Gender differences in plasma ammonia levels at 50 days of age also disappear in saline-
treated 70 day old animals and all genders show similar levels of plasma ammonia.   
MSO treatment significantly increases plasma ammonia levels in both wild-type and 
SOD1 animals.  When broken down by gender the same trend is observed in all groups 
examined, including male wild-type mice which have lower levels of plasma ammonia than any 
other group, with and without MSO treatment.  Elevations in plasma ammonia with MSO 
treatment were expected since the drug irreversibly inhibits the incorporation of ammonia into 
glutamine, and therefore prevents it from being transported to the liver as glutamine for proper 
removal.   
3.4.1.2 Plasma Metabolites in 50 Day Untreated Mice 
 The plasma metabolite profile of 50 day old untreated animals shows that several 
metabolites differ between wild-type and SOD1 mice.  Most of these metabolite differences are 
due to SOD1 animals having significantly lower levels of various metabolites than wild-type 
mice.  Several of the metabolites that are significantly lower in SOD1 mice are associated with 
the urea cycle, specifically urea, aspartate, citrulline, and arginine.  The fact that urea is 
significantly lower in plasma collected from 50 day untreated SOD1 mice corresponds to the 
observation that ammonia levels in these animals are elevated and suggests that ammonia is 
not being incorporated into urea, implying an underlying defect in the urea cycle.  Plasma 
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glutamine, a precursor of both ammonia and glutamate, is elevated in these mice and could 
indicate an increase in glutamine uptake from the diet, as glutamine synthetase activity was not 
elevated in these animals.  It is interesting to note that the average plasma levels of glutamate 
and ornithine, which are also involved in the urea cycle, are also slightly lower in SOD1 mice, 
but these levels do not reach significance (see Appendix A).   
In addition to urea cycle intermediates, several other plasma metabolites are altered in 
SOD1 mice.  Phosphoserine, phosphoethanolamine, cystine, methionine, and lysine are all 
significantly lower in plasma from SOD1 mice when compared to their wild-type counterparts, 
while asparagine levels are elevated.  Six of the metabolites that are significantly altered 
(aspartate, asparagine, cystine, methionine, and arginine) are glucogenic amino acids that can 
be used as a carbon source to produce glucose.  Since most of these metabolites are 
significantly lower in the plasma of SOD1 mice, this could suggest changes in the rate of 
gluconeogenesis in this model.  Hindlimb suspension loading is a common technique used in 
rats to simulate the weightlessness experienced during space flights (Morey-Holton & Globus 
2002).  This method induces muscular atrophy, as rats are positioned in such a way that their 
hindlimbs no longer support their body weight, and recent research has shown that the rate of 
gluconeogenesis in these rats is elevated in a time-dependent manner (Bederman et al 2012).  
It is possible that SOD1 mice experience an increase in gluconeogenesis associated with 
muscle atrophy, leading to an overall reduction in the levels of certain glucogenic amino acids in 
the plasma.  These animals may experience insulin resistance or some other problem utilizing 
glucose obtained from the diet and may resort to using amino acids as fuel.  Both insulin 
resistance and biomarkers suggestive of insulin resistance have been observed in ALS patients 
(Gonzalez de Aguilar et al 2005; Pradat et al 2010).  ALS mice have been shown to have a 
significantly lower body mass than their wild-type littermates, decreased plasma levels of leptin 
and insulin, and increased plasma levels of corticosterone suggestive of global metabolic 
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defects (Dupuis et al 2004).  Data obtained from human ALS studies suggests that 
hypermetabolism may occur in patients, as a low body-mass is typically observed in patients 
suffering from the disease (Desport et al 1999; Vaisman et al 2009) and worsens with 
progression (Desport et al 2000; Kasarskis et al 1996; Wijesekera & Leigh 2009).  In addition to 
low body-mass, ALS patients also show increased levels of energy expenditure (Desport et al 
2001; Desport et al 2005; Funalot et al 2009) further supporting the idea of impaired metabolism 
as a factor in ALS.     
 One interesting finding from these studies is that SOD1 mice appear to have a cysteine 
deficiency, as cystine levels were undetectable in all but one 50 day old SOD1 plasma sample.  
These results have serious implications for oxidative damage during the disease due to 
impaired glutathione synthesis, as cysteine is one of the three amino acids that make up the 
antioxidant tripeptide.  Oxidative damage has been implicated in the progression of ALS and 
mutant SOD1 mice deficient in a subunit of γ-glutamylcysteine ligase (the first enzyme in 
glutathione synthesis catalyzing the condensation of cysteine and glutamate) show a 55% 
reduction in average lifespan (Vargas et al 2011).  Cell culture models of the disease show that 
motor neurons expressing mutant SOD1 protein under standard culture conditions have 
significantly lower glutathione levels than those expressing wild-type SOD1 protein 
(D'Alessandro et al 2011).  It is possible that SOD1 mice have decreased glutathione levels due 
to a lack of cysteine, which could exacerbate oxidative damage in sensitive neuronal cells.  
Decreased levels of glutathione in SOD1 mice could further exacerbate amino acid uptake by 
inhibiting the γ-glutamyl cycle, which has been shown to play a role in amino acid uptake in cells 
of the intestine (Cornell & Meister 1976).  Follow up experiments to determine if the 
undetectable levels of cystine in the plasma of SOD1 mice correlate with decreased levels of 
glutathione and altered amino acid uptake must be performed.          
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 When plasma metabolite data from 50 day old untreated mice is further broken down 
and analyzed based on gender, a different plasma metabolite profile emerges.  Plasma 
glutamine levels remain elevated in both male and female SOD1 mice when compared to their 
wild-type counterparts, but only female SOD1 mice show significantly lower citrulline, arginine, 
and ornithine levels.  Male SOD1 mice, however, show significantly lower plasma levels of 
aspartate and urea. These gender-specific differences in plasma levels of urea cycle 
intermediates suggest that the expression of the transgene alters the urea cycle differently 
depending upon gender.   Cysteine levels, which are decreased in SOD1 mice, continue to be 
significantly lower in these animals when gender is accounted for.   
 When plasma metabolite data from 50 day old mice are grouped by genotype and 
gender differences are examined, there are several significant differences between males and 
females of both genotypes.  Wild-type animals show a wider range of gender differences in 
plasma metabolites, with males showing significantly lower levels of several metabolites when 
compared to females.  These data suggests that there are basic gender differences in 
metabolism in nontransgenic mice.  SOD1 mice, however, show fewer gender differences in 
plasma metabolites and males show significantly higher levels of the metabolites that differ.  It is 
interesting to note that those metabolites that show gender differences in both wild-type and 
SOD1 mice tend to be increased in wild-type females but decreased in SOD1 females.  For 
example, threonine levels are significantly higher in female wild-type mice compared to male 
wild-type mice but are significantly lower in SOD1 female mice.  The levels of threonine in male 
mice of both genotypes are similar, suggesting that the changes observed are due to an overall 
decrease in female SOD1 mice.  A similar pattern is seen in citrulline levels, which are similar in 
male mice of both genotypes, but lower in female SOD1 mice.  Women have been shown to 
have a lower resting metabolic rate than men (Arciero et al 1993), and as a result one might 
expect to see slightly higher levels of metabolites in the plasma of female animals compared to 
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males.  However, in this SOD1 mouse model of ALS female mice show lower levels of certain 
metabolites, that do not differ between male wild-type and SOD1 mice, suggesting higher rates 
of utilization or impaired uptake of these substances.  A list of all average plasma metabolite 
levels and p values and all of the comparisons made of 50 day old untreated mice can be found 
in Appendix A.     
3.4.1.3 Plasma Metabolites in 70 Day Saline-treated Mice 
 Plasma metabolite levels from 70 day old saline-treated mice were examined to see how 
metabolite profiles from older mice compared to those obtained from young, untreated mice and 
to understand how wild-type and SOD1 mice differ.  When comparing 70 day old saline-treated 
wild-type and SOD1 mice, there are fewer differences in plasma metabolites than what was 
observed in 50 day old mice.  Phosphoethanolamine, aspartate, and cystine levels, which are 
significantly lower in 50 day old SOD1 mice, continue to be low in 70 day old saline-treated 
SOD1 mice.  Cystine is completely undetectable in the plasma of 70 day old SOD1 mice and 
may indicate that cysteine is not being properly absorbed from the diet, or that it is being utilized 
faster than it can be absorbed by these mice.   
Plasma levels of alanine and proline, which were not significantly different in 50 day old 
SOD1 mice, are significantly lower and sarcosine (n-methylglycine) levels are significantly 
higher in SOD1 plasma.  High levels of plasma glutamine and alterations in urea cycle 
intermediates observed in 50 day old untreated mice are no longer seen in 70 day old saline-
treated mice and may indicate the existence of compensatory mechanisms that normalize 
metabolism in these animals.  Alanine, however, can act as a carrier of the carbon skeleton of 
pyruvate and of ammonia from muscle to the liver (Nelson & Cox 2008) and lower levels of 
alanine in the plasma of SOD1 mice may be an early sign of alterations in muscle metabolism 
prior to significant atrophy.  Sarcosine, which is an intermediate in glycine metabolism, is 
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significantly higher in SOD1 plasma, with levels exceeding three times that found in wild-type 
mice.  Sarcosine dehydrogenase is a tetrahydrofolate-binding enzyme responsible for the 
production of glycine from sarcosine found in the matrix of liver mitochondria  (Eschenbrenner & 
Jorns 1999).  Defects in this enzyme cause sarcosinemia and are associated with elevated 
levels of sarcosine in the blood (Eschenbrenner & Jorns 1999).  In the CNS sarcosine acts as a 
natural agonist of glycine transporter 1 which increases the effect of glycine on NMDA receptors 
and has been shown to have beneficial effects in patients suffering from schizophrenia when 
added to antipsychotic treatments for the disorder (Tsai et al 2004).  There are a variety of 
factors that may play a role in elevating sarcosine levels in SOD1 mouse plasma.  These mice 
may have a defect in sarcosine dehydrogenase activity due to the expression of mutant SOD1 
protein expression or due to a deficiency in folate.  Folate deficiencies have been shown to lead 
to increased levels of sarcosine in humans (Allen et al 1993) and treatment of SOD1 mice with 
folate has been shown to delay the onset and progression of the disease (Zhang et al 2008).   
When plasma metabolites were grouped by gender and compared based on genotype, a 
different profile is seen in male and female mice, much like with 50 day old mice.  Alterations in 
phosphoethanolamine and sarcosine are specific to female SOD1 mice, while decreases in 
glycine and alanine levels are specific to male SOD1 mice.  Phosphoethanolamine is used to 
make sphingomyelins, glycolipids involved in the production of membranes (Nelson & Cox 
2008).  Low levels of phosphoethanolamine in plasma may lead to problems in producing cell 
membrane material in female SOD1 mice.  Male SOD1 mice show low levels of glycine, which 
acts as a coagonist of NMDA receptors during glutamatergic signaling, and may impair 
excitatory synaptic signaling.  Although it was not determined to be statistically significant by the 
MANOVA, cystine levels continue to be undetectable in plasma from both male and female 
SOD1 mice and may contribute to reduced glutathione levels and oxidative damage in ALS 
mice.   
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When plasma metabolite data are broken down by genotype and males and females are 
compared, several gender differences in plasma metabolites can be observed in both wild-type 
and SOD1 mice.  Glutamine and histidine levels are similar in wild-type and SOD1 mice, with 
females showing significantly higher plasma levels of glutamine.  In SOD1 mice, urea levels are 
significantly higher in male mice, while females show significantly higher levels of all other 
plasma metabolites.  Much like with 50 day old untreated mice, 70 day old saline-treated mice 
show gender differences in metabolism.  However, the alterations in urea cycle intermediates 
are completely absent, with the exception of urea itself which is elevated in male SOD1 mice.  
Plasma levels of ammonia in these mice show no gender differences and are actually much 
lower than what is observed in 50 day old animals.  These results suggest that between 50 and 
70 days of age, compensatory mechanisms normalize nitrogen metabolism in SOD1 mice.  A 
list of all average plasma metabolite levels and p values and all of the comparisons made of 70 
day old saline-treated mice can be found in Appendix A.    
3.4.1.4 Plasma Metabolites in 70 Day MSO-treated Mice 
 Wild-type and SOD1 mice began a weekly treatment with either saline or MSO at 
approximately 50 days of age and plasma was taken at approximately 70 ± 2 days of age, 
resulting in animals receiving a total of 4 injections.  Plasma metabolite levels were grouped by 
genotype and treatment effects were examined.  Wild-type mice show only one significant 
metabolite alteration with MSO treatment and that is in lysine levels, which increase 
significantly.  This effect is also observed in SOD1 mice treated with MSO.  SOD1 mice, 
however, have similar plasma lysine levels to wild-type mice with and without treatment and this 
effect of MSO is probably not significant to the disease.  SOD1 mice show several other 
changes in plasma metabolite levels with MSO treatment, despite this one similarity.  MSO 
treatment significantly increases the levels of a variety of metabolites including 
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phosphoethanolamine, alanine, cystine, ornithine, and arginine.  Increased levels of 
phosphoethanolamine and cystine in the plasma may allow these substances to be more 
available for use in making membranes and glutathione respectively.  It is important to note that 
previous studies have shown that MSO increases glutathione levels in certain brain regions 
(Ghoddoussi et al 2010), and this may be due to its ability to increase cysteine levels in the 
plasma.  Although the plasma metabolite profile of saline-treated mice did not suggest urea 
cycle defects, MSO treatment increases levels of ornithine and arginine, two urea cycle 
intermediates, and also significantly elevates plasma ammonia levels.  Glutamine levels, which 
were not found to differ in saline-treated SOD1 and wild-type mice, are significantly decreased 
by MSO treatment in SOD1 mice.  Since MSO inhibits the enzyme responsible for the 
production of glutamine, GS, it is not surprising to see a significant decrease in glutamine levels 
in mice treated with MSO.  Lower levels of glutamine may impair the immune response and 
reduce neuroinflammation in ALS mice by starving immune cells of glutamine.  Alanine levels, 
which were found to be significantly lower in saline-treated SOD1 mice, are increased with MSO 
treatment and may indicate a normalization of the alanine-glucose cycle.     
 When 70 day plasma metabolite data are broken down by gender and analyzed by 
treatment, a variety of metabolite changes appear to be gender-specific.  Female wild-type mice 
show no significant alterations in plasma metabolite levels with MSO treatment, while female 
SOD1 mice show decreases in plasma glutamine and sarcosine and increases in plasma 
arginine levels.  All plasma metabolites that are altered with MSO treatment in male wild-type 
mice increase upon treatment.  A similar pattern is observed in male SOD1 mice, but the 
metabolites that increase differ from those that increase in wild-type males.  Although it is not 
clear how all of these treatment-related changes in plasma metabolites impact the disease, it is 
a start to understanding how MSO treatment extends the lifespan of ALS mice.  Since many of 
these metabolites show gender-specific alterations and MSO treatment alters plasma 
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metabolites in a gender-specific fashion, it is possible that sex hormones may modulate 
metabolic pathways affected by the drug therefore producing gender-specific effects in survival 
and neuromuscular function.     
Human and animal studies of circulating metabolite levels associated with ALS have 
been conducted however these studies have not been done in a consistent manner and have 
produced widely conflicting data.  Cerebrospinal fluid (CSF), which circulates through the CNS, 
may provide more information about metabolite changes due to neuroinflammation and 
neurodegeneration in diseases of the CNS.  CSF is difficult to obtain from animals and studies 
of CSF from ALS patients have not provided the best data, as often times controls used in these 
studies are patients with neurological disorders due to the difficulty of obtaining CSF from 
healthy controls (Blin et al 1994; Iijima et al 1978; Patten et al 1978).  As a result, better 
information can be obtained from blood samples, which are easier to obtain from healthy 
controls.  However, many of the studies analyzing plasma or serum also use samples from 
controls with other diseases.  In a study which detected elevated levels of ornithine in the serum 
of ALS patients, some of the controls used suffered from neuropathy and multiple sclerosis 
(Patten et al 1978), diseases which are believed to have underlying mechanisms similar to 
those thought to play a role in ALS.  In another study in which plasma samples were examined, 
patients were not clearly classified as having ALS (Iijima et al 1978) and may have had other 
motor neuron diseases.   In addition to issues with experimental design many studies of ALS 
patients include both genders, which are matched in control groups, but fail to examine gender 
differences in the disease.  As a result, most biochemical data collected on ALS patients comes 
from ambiguous groups composed of both males and females and underlying gender 
differences remain unclear.   
The data presented here show that there are clear differences in plasma metabolites in 
presymptomatic SOD1 mice when compared to their wild-type counterparts, suggesting that 
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early metabolic defects (in 50 day old mice) play a role in, or are related to neurodegeneration in 
this mouse model.    Some of the differences seen in plasma metabolites are gender-specific 
and only appear when comparing wild-type and SOD1 mice by gender, suggesting that 
expression of the transgene alters metabolism differently in male and female mice.   In addition, 
there are several metabolites that differ between male and female SOD1 mice, providing further 
evidence of gender-specific metabolic effects of mutant SOD1 expression.  There are also age-
related changes in plasma metabolites that indicate there may be some ability to compensate 
for metabolic defects, at least in presymptomatic mice.  In order to fully understand metabolic 
abnormalities associated with the disease, these experiments should also be performed in mice 
at the time of symptom onset, as well as in postsymptomatic animals.  MSO’s ability to reverse 
some of the changes in plasma metabolites in a gender-specific manner further supports the 
idea that metabolic defects are involved in the disease progression and that gender is also an 
important factor in the disease.   
Several studies conducted with ALS patients provide evidence of metabolic defects in 
the human disease, but it is unknown as to whether these defects are a direct result of the 
disease itself or are present prior to development of the disease.  Most studies conducted on 
animal models of ALS focus on the central nervous system and there are only a few studies 
available in which metabolism has been the primary focus.  However, those studies that have 
focused on metabolism in mouse models of ALS support the idea of metabolic defects playing a 
role in the disease.  It is important to note that gender is typically not discussed in studies of 
ALS patients and mice, even though both genders have been studied.  Most articles published 
make note that patients and mice have been age and gender-matched, but data are not broken 
down by gender resulting in a missing piece in the puzzle.   
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3.4.1.5 Nitrogen Metabolism in the Liver 
  Carbamoyl phosphate synthetase I (CPSI) activity was measured in desalted liver 
homogenates from both wild-type and SOD1 mice.  At 50 days of age, CPSI activity in SOD1 
mice does not differ significantly from that of wild-type mice, even though plasma metabolite 
analysis shows that SOD1 mice have slightly lower levels of plasma urea and significantly 
higher levels of plasma ammonia.  CPSI is the rate-limiting enzyme in the urea cycle, but the 
decrease in plasma levels of urea cycle intermediates and the finding that CPSI activity is not 
affected by the SOD1 transgene suggests that there may be a problem with one of the other 
enzymes in the cycle.  Decreased citrulline levels could indicate a problem with ornithine 
transcarbamoylase, while decreased levels of arginine could indicate a decrease in activity of 
arginosuccinate synthetase or arginosuccinate lyase.  Although it was not determined to be 
significant, ornithine levels are also slightly lower in these mice and could be an indicator of 
decreased arginase activity.   
 When liver CPSI activity data are broken down by gender, 50 day old untreated females 
of both genotypes have significantly higher activity levels than males.  These results suggest 
that in 50 day old mice, gender is a more important factor in determining CPSI activity than 
transgene expression.  Since CPSI is the rate-determining enzyme in the urea cycle, low activity 
is expected to correlate with low levels of urea and elevated levels of other intermediates that 
are not being consumed in the cycle but this trend is not observed in these mice.  Only wild-type 
mice show a gender difference in plasma urea levels, with males having higher urea levels than 
females.  In addition, wild-type females show elevated levels of citrulline compared to males 
which would not be expected if the overall rate of the cycle is comparable to that of CPSI which 
is high in females.  SOD1 females, however, show decreased levels of ornithine and citrulline 
compared to their male counterparts which would correlate with a higher rate of the urea cycle.  
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More work needs to be done to fully characterize potential urea cycle defects and the role of 
gender in neurodegeneration in this mouse model.   
 CPSI activity levels are significantly increased in 70 day old saline-treated mice 
compared to 50 day old untreated mice of both genotypes, suggesting age-related changes in 
activity occur.  This corresponds to an overall decrease in plasma ammonia levels that are seen 
in both wild-type and SOD1 mice treated with saline at 70 days of age.  Mice in this age group 
also no longer show significant alterations in plasma metabolites associated with the urea cycle.  
Males of both genotypes continue to show significantly lower levels of CPSI activity in 70 day 
old saline-treated mice; however it is at this point that SOD1 males start to show alterations in 
CPSI activity.  Saline-treated 70 day old male SOD1 mice not only have lower activity than 
female SOD1 mice, but also show significantly lower CPSI activity than their wild-type 
counterparts.  The changes in plasma metabolite levels in 70 day old saline-treated male SOD1 
mice do not correlate well with the changes in CPSI activity.  In order to better understand if 
these changes are disease-related, CPSI activity levels at later time points in postsymptomatic 
or end stage animals should be examined.     
It is possible that CPSI activity differences result from gender differences in allosteric 
regulation of the enzyme.  N-acetyl-L glutamate is an allosteric activator of the enzyme (Nelson 
& Cox 2008) but a consistent amount of this activator was added to the reaction mixture and 
should not cause gender-specific differences in activity levels, suggesting the presence of 
another regulator of the enzyme.  Purine nucleotides, ornithine, and increased levels of 
ammonia have been found to activate CPSI, while pyrimidine nucleotides and decreased ATP 
levels have been found to inhibit the enzyme (Meister 1989).  It could be that other gender-
specific cycles that feed into the urea cycle are affected.  MSO treatment has no effect on CPSI 
activity levels, despite its ability to significantly increase plasma ammonia, ornithine, and 
arginine levels.  In addition, CPSI activity in the presence of MSO is unaffected by gender and 
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expression of the transgene.  MSO’s ability to extend the lifespan may be through its effects on 
plasma metabolite levels, but it does not affect the urea cycle. 
Liver glutamine synthetase activity levels were examined using the same samples that 
were used to assay CPSI activity.  The results of these assays in 50 day old untreated mice are 
similar to those of brain GS activity, showing no differences between wild-type and SOD1 mice.  
When broken down by gender, GS activity remains at about the same level across gender and 
genotype.  In 70 day old saline-treated mice, there are still no differences in GS activity between 
wild-type and SOD1 mice, however there appear to be changes in GS activity in SOD1 male 
mice.  When the data are broken down by gender, male SOD1 mice show significantly lower 
activity than female SOD1 mice and male wild-type mice, similar to the results of CPSI activity 
assays in these mice.  This suggests that nitrogen metabolism in the liver of male SOD1 mice 
may start to decline prior to symptom onset.  MSO treatment significantly decreases GS activity 
in both wild-type and SOD1 mice and continues to significantly decrease GS activity when these 
groups are further broken down by gender.  However, MSO does not inhibit GS in male SOD1 
mice to the same extent as the rest of the groups.  MSO inhibits liver GS activity by about 85% 
in all groups, except male SOD1 mice where it only inhibits GS activity by about 55%.  This 
further supports the idea that liver metabolism undergoes changes in presymptomatic male 
SOD1 mice and may partially explain why male SOD1 mice have a shorter lifespan than female 
SOD1 mice, as well as MSO’s reduced effect on increasing lifespan and neuromuscular function 
in these mice.   
Since ALS is a neurodegenerative disease and motor neurons are the primary target, 
most research conducted in animal and human studies revolves around the central nervous 
system.  As a result, there are few studies that actually focus on global metabolism in animal 
models of the disease.  In studying transgenic animal models of disease, especially those that 
ubiquitously express (or overexpress) a transgene throughout the body, it is important to not 
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only study the major organ(s) affected but to also study organs outside of the target system.  
This allows researchers to better understand the disease model and potential effects that can 
occur in other organs upon expression of a transgene.  It also provides researchers with the 
ability to understand shortcomings of the model that may confound the results of studies 
conducted on therapeutic interventions, as expression of transgenes that alter metabolism may 
also impact the pharmacology of a drug.  This being said, it is also important to consider gender 
in these studies as sex hormones have the ability to alter the expression of a wide range of 
genes and may also impact drug metabolism.       
3.4.1.6 The Effects of Ovariectomization on Enzyme Activity and Plasma Metabolites 
 As shown in Chapter 2, removal of sex hormones in female mice through ovariectomy, 
removes the MSO effect on survival.  Ovariectomized SOD1 female mice treated with saline 
have significantly lower levels of brain GS activity with a corresponding increase in brain 
glutaminase activity.  In addition to these changes in the CNS, ovariectomized SOD1 females 
also exhibit significantly lower levels of liver glutamine synthetase activity and lower CPSI 
activity levels.  These results suggest that estrogen has the ability to influence nitrogen 
metabolism and that removing the ovaries, and subsequently estrogen, lowers activities of 
several enzymes involved in nitrogen metabolism.   
 In addition to showing altered activity levels of enzymes involved in nitrogen metabolism, 
ovariectomized female mice treated with saline have a different metabolic profile than their 
normal female counterparts.  Although the results are not considered to be significant, plasma 
ammonia levels in ovariectomized SOD1 females are lower than those in SOD1 females with 
intact ovaries.  There are also no significant alterations in urea cycle intermediates in 
ovariectomized females in this age, which agrees with results obtained from other 70 day old 
SOD1 mice.  It is interesting to note that sarcosine levels, which are significantly increased in 
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SOD1 females with intact ovaries and are lowered with MSO treatment, are completely 
undetectable in ovariectomized mice.  This suggests that changes in sarcosine levels in female 
SOD1 mice may be part of the disease process and enzymes involved in sarcosine production 
and breakdown should be examined in order to better understand its role in disease.   
3.5 Future Experiments 
 The results of these biochemical studies show that the expression of the SOD1 
transgene impacts plasma metabolite levels in this mouse model, but does not have much of an 
impact on the nitrogen handling enzymes examined.  Young presymptomatic SOD1 mice 
appear to have defects in nitrogen metabolism that are no longer observed in 70 day old mice, 
suggesting that there are age related changes in metabolism of these mice.  Gender also plays 
a role in altering plasma metabolites and estrogen impacts nitrogen metabolizing enzymes as 
well as plasma metabolites.  It is not clear how MSO’s impact on plasma metabolites and 
glutamine synthetase activity lead to an increase in lifespan in SOD1 mice, but estrogen 
appears to facilitate its ability to extend the lifespan and suggests that MSO impacts estrogen-
sensitive pathways.    
 GS and glutaminase data from older postsymptomatic mice aid in our understanding of 
defective glutamine metabolism and treatment effects in this disease model, showing that brain 
and spinal cord GS activity levels begin to decline later in the disease.  While glutaminase 
activity does not seem to be important, gender-specific age-related decreases in GS activity 
may be important.  Males show decreased activity in brain, while females show decreased 
activity in spinal cord and these results may be important in explaining why females are able to 
maintain grip strength with MSO treatment.  Presymptomatic male SOD1 mice also show slight 
alterations in liver GS (and CPSI) activity that may indicate the beginning of disease associated 
metabolic perturbations. MSO is able to decrease the glutamine-glutamate cycle, leading to 
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decreased glutamine and glutamate levels in specific brain regions (Ghoddoussi et al 2010), 
and may further decrease levels of these chemicals in the spinal cords of female mice and allow 
them to maintain neuromuscular connections.  NMR examination of gender differences in spinal 
cord chemicals must be done to understand if this may be part of MSO’s gender-specificity.     
 While we have data from the CNS of wild-type and SOD1 mice profiling the course of the 
disease and treatment, we do not have liver enzyme and plasma metabolite data from older 
mice and are missing part of the story.  Since there are age-related changes in plasma 
ammonia and other metabolites, as well as CPSI activity and liver GS activity in SOD1 males, 
these metabolite levels and enzyme activities could further change as the disease progresses.  
For this reason, plasma metabolite profiles and liver enzyme activities should be examined in 
these animals at later time points.  It is possible that male metabolism declines faster than that 
of females and plays a role in MSO’s gender-specific effects on survival.  In addition, obtaining 
these data from MSO-treated mice would provide more information about long-term effects of 
treatment.  Since muscle has been targeted as a major source of glutamine and undergoes 
atrophy as the disease progresses, further studies should consider potential defects in muscle 
metabolism as well.   
 Most of the research on MSO has focused on its ability to inhibit glutamine synthetase, 
but other targets of the drug have been identified, such as alanine aminotransferase (Pace & 
McDermott 1952), ornithine decarboxylase (Di Giacomo et al 1997), and γ-glutamylcysteine 
synthetase (Richman et al 1973).  In order to understand exactly how this drug works in ALS 
mice, these targets should be further characterized.  Further characterization of γ-
glutamylcysteine synthetase is particularly important, as MSO has been shown to inhibit this 
enzyme which catalyzes the first step in glutathione synthesis (Richman et al 1973) and our 
early data shows that MSO treatment increases glutathione levels in specific brain regions 
(Ghoddoussi et al 2010).  Increasing glutathione levels in ALS is important to prevent oxidative 
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damage, but this conflicting data about MSO’s ability to inhibit glutathione synthesis warrants 
further examination. 
MSO has been found to alter cytokine levels in a mouse model of acute liver failure 
(Jambekar et al 2011) and since some immune cells have been shown to lack GS (Ardawi & 
Newsholme 1983; Rohde et al 1996), there may be other potential targets of MSO that have yet 
to be identified.  Since neuroinflammation has been implicated to play a significant role in the 
progression of ALS and peripheral immune cells (which require glutamine) have been found to 
infiltrate the CNS, these cell types should be characterized to understand how MSO affects the 
immune response in these mice.  Basic gender differences in general immune responses have 
been characterized and MSO’s impact on these cells may explain its gender-specific effects in 
ALS mice.   
 There is a need to continue ALS research to better understand how motor neurons are 
selectively killed, identify biomarkers of the disease for early detection, and to discover better 
treatments capable of improving the quality of life of patients.  These studies have shown that 
MSO has the ability to extend the lifespan and alter plasma metabolites in the most common 
mouse model of ALS in a gender-specific manner.  Most research on MSO revolves around its 
ability to inhibit GS, but it is apparent that its effects in the SOD1 G93A mouse model may 
extend beyond its inhibitory effects on GS to other potential targets.  In order to make the most 
of MSO as a tool for elucidating mechanisms of ALS and other diseases, these other targets 
must be identified and better characterized.    
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APPENDIX A 
50 DAY PLASMA METABOLITE COMPARISONS 
Table A-1:  List of all mean 50 day mouse plasma metabolite values grouped by genotype and 
the corresponding p values obtained from the MANOVA. 
 
 
WT SOD1 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 14.43 0.84 6.76 1.24 .000009 
Taur 464.48 33.18 429.15 36.75 .488474 
Pea 11.55 1.27 5.57 2.00 .012771 
Urea 9866.08 358.87 8088.85 696.89 .019385 
Asp 18.03 1.51 11.32 0.87 .001851 
Thr 182.68 8.27 161.74 12.57 .156457 
Ser 150.80 5.09 140.31 7.29 .232226 
Asn 38.98 2.09 47.83 4.03 .041775 
Glu 35.32 4.40 26.26 2.56 .125255 
Gln 560.08 13.21 676.66 37.19 .002029 
Sarc 11.91 4.42 11.81 5.27 .988485 
AAAA 25.83 3.16 21.44 3.73 .378244 
Gly 298.53 7.31 285.10 12.89 .338465 
Ala 577.76 23.95 672.69 66.76 .136491 
Citr 109.36 4.91 87.14 5.46 .005742 
Val 247.16 7.71 237.57 22.61 .648060 
Cys 27.91 2.39 0.36 0.36 .000000 
Met 87.38 5.84 65.47 7.01 .022942 
Ile 87.20 3.50 94.00 5.91 .300051 
Leu 144.72 5.12 153.71 11.28 .426790 
Tyr 71.96 3.57 72.78 5.19 .893887 
Phe 60.28 1.63 64.96 3.13 .158838 
Orn 92.02 6.90 72.35 8.80 .085838 
Lys 319.96 12.69 273.63 16.00 .029437 
1-Mhis 11.18 1.16 11.65 1.17 .787789 
His 70.48 2.22 62.56 3.61 .057402 
Trp 59.16 5.74 53.49 9.04 .581522 
Arg 122.45 8.41 86.84 7.51 .005630 
Hypro 14.10 3.45 23.98 3.68 .065295 
Pro 89.27 3.96 105.51 10.73 .116248 
Amino acid levels are expressed as µmoles/L plasma. 
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Table A-2:  List of all mean 50 day female plasma metabolite values grouped by genotype and 
the corresponding p values obtained from the MANOVA. 
 
 
WT Female SOD1 Female 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 14.45 1.47 8.66 1.54 .020751 
Taur 420.15 21.83 479.74 66.56 .337043 
Pea 12.14 1.07 9.30 3.32 .356879 
Urea 8,708.96 354.88 8,055.03 450.50 .271216 
Asp 15.04 2.19 11.45 1.42 .245272 
Thr 203.07 10.99 131.50 16.26 .002222 
Ser 163.93 7.19 135.88 13.60 .067672 
Asn 42.67 3.37 41.08 5.71 .802155 
Glu 30.56 3.83 26.12 5.18 .493090 
Gln 568.60 16.63 709.78 74.95 .044414 
Sarc 16.02 7.16 11.19 7.43 .659119 
AAAA 23.28 4.64 19.01 6.10 .581708 
Gly 290.37 12.12 258.21 22.06 .188813 
Ala 627.88 40.72 577.55 137.36 .684298 
Citr 119.86 8.34 72.97 7.40 .001715 
Val 247.54 12.37 214.08 18.73 .142795 
Cys 23.32 3.73 0.77 0.77 .000329 
Met 97.45 10.56 47.63 6.17 .003493 
Ile 94.29 5.54 89.33 8.10 .608021 
Leu 152.39 8.36 151.51 14.46 .955598 
Tyr 79.45 5.61 62.43 7.85 .092612 
Phe 62.73 2.19 61.23 5.40 .773206 
Orn 99.00 8.66 53.06 8.53 .003171 
Lys 356.96 17.17 255.59 24.42 .003866 
1-Mhis 11.30 1.50 12.05 2.15 .771866 
His 75.38 2.87 66.22 6.47 .168983 
Trp 76.56 3.39 62.68 13.67 .257627 
Arg 138.40 13.63 76.58 11.60 .006908 
Hypro 9.57 4.81 18.79 6.91 .278058 
Pro 94.27 6.91 77.27 10.86 .187351 
Amino acid levels are expressed as µmoles/L plasma. 
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Table A-3:  List of all mean 50 day male plasma metabolite values grouped by genotype and the 
corresponding p values obtained from the MANOVA. 
 
 
WT Male SOD1 Male 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 14.40 0.96 5.13 1.75 .000158 
Taur 504.37 58.56 385.80 34.25 .140181 
Pea 11.02 2.28 2.37 1.82 .014574 
Urea 10907.49 366.39 8117.83 1287.87 .028406 
Asp 20.73 1.76 11.20 1.15 .000977 
Thr 164.34 9.19 187.67 12.48 .143889 
Ser 138.98 4.92 144.10 7.75 .566131 
Asn 35.65 2.21 53.62 4.98 .002285 
Glu 39.61 7.59 26.38 2.28 .177657 
Gln 552.41 20.70 648.27 28.90 .014115 
Sarc 8.21 5.47 12.33 7.97 .664111 
AAAA 28.13 4.42 23.51 4.85 .499483 
Gly 305.88 8.56 308.14 8.79 .860338 
Ala 532.65 19.39 754.24 26.03 .000004 
Citr 99.90 3.88 99.29 4.30 .919093 
Val 246.82 10.17 257.71 38.76 .754715 
Cys 32.04 2.58 0.00 0.00 .000000 
Met 78.31 4.62 80.77 8.41 .786531 
Ile 80.82 3.51 98.01 8.78 .058409 
Leu 137.81 5.72 155.59 17.94 .293354 
Tyr 65.22 3.55 81.65 5.26 .016576 
Phe 58.07 2.25 68.15 3.44 .021428 
Orn 85.73 10.57 88.89 11.71 .846077 
Lys 286.65 10.76 289.10 20.95 .911321 
1-Mhis 11.08 1.82 11.30 1.31 .929296 
His 66.08 2.76 59.43 3.85 .169528 
Trp 43.50 7.64 45.61 12.15 .879071 
Arg 108.09 8.47 95.65 9.25 .344685 
Hypro 18.17 4.78 28.43 2.98 .122502 
Pro 84.78 4.10 129.72 11.49 .000764 
Amino acid levels are expressed as µmoles/L plasma. 
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Table A-4:  List of all mean 50 day wild-type mouse plasma metabolite values grouped by 
gender and the corresponding p values obtained from the MANOVA. 
 
 
WT Female WT Male 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 14.45 1.47 14.40 0.96 .977777 
Taur 420.15 21.83 504.37 58.56 .214180 
Pea 12.14 1.07 11.02 2.28 .671958 
Urea 8708.96 354.88 10907.49 366.39 .000496 
Asp 15.04 2.19 20.73 1.76 .056956 
Thr 203.07 10.99 164.34 9.19 .014481 
Ser 163.93 7.19 138.98 4.92 .009668 
Asn 42.67 3.37 35.65 2.21 .093654 
Glu 30.56 3.83 39.61 7.59 .318440 
Gln 568.60 16.63 552.41 20.70 .555787 
Sarc 16.02 7.16 8.21 5.47 .392743 
AAAA 23.28 4.64 28.13 4.42 .459507 
Gly 290.37 12.12 305.88 8.56 .302800 
Ala 627.88 40.72 532.65 19.39 .043338 
Citr 119.86 8.34 99.90 3.88 .038316 
Val 247.54 12.37 246.82 10.17 .963949 
Cys 23.32 3.73 32.04 2.58 .067127 
Met 97.45 10.56 78.31 4.62 .103217 
Ile 94.29 5.54 80.82 3.51 .051072 
Leu 152.39 8.36 137.81 5.72 .161014 
Tyr 79.45 5.61 65.22 3.55 .042666 
Phe 62.73 2.19 58.07 2.25 .157474 
Orn 99.00 8.66 85.73 10.57 .351418 
Lys 356.96 17.17 286.65 10.76 .002484 
1-Mhis 11.30 1.50 11.08 1.82 .929766 
His 75.38 2.87 66.08 2.76 .032326 
Trp 76.56 3.39 43.50 7.64 .001420 
Arg 138.40 13.63 108.09 8.47 .070387 
Hypro 9.57 4.81 18.17 4.78 .223317 
Pro 94.27 6.91 84.78 4.10 .242627 
Amino acid levels are expressed as µmoles/L plasma. 
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Table A-5:  List of all mean 50 day SOD1 mouse plasma metabolite values grouped by gender 
and the corresponding p values obtained from the MANOVA. 
 
 
SOD1 Female SOD1 Male 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 8.66 1.54 5.13 1.75 .165966 
Taur 479.74 66.56 385.80 34.25 .216216 
Pea 9.30 3.32 2.37 1.82 .082722 
Urea 8055.03 450.50 8117.83 1287.87 .966461 
Asp 11.45 1.42 11.20 1.15 .891300 
Thr 131.50 16.26 187.67 12.48 .017791 
Ser 135.88 13.60 144.10 7.75 .596319 
Asn 41.08 5.71 53.62 4.98 .124567 
Glu 26.12 5.18 26.38 2.28 .961401 
Gln 709.78 74.95 648.27 28.90 .433670 
Sarc 11.19 7.43 12.33 7.97 .919352 
AAAA 19.01 6.10 23.51 4.85 .570300 
Gly 258.21 22.06 308.14 8.79 .047675 
Ala 577.55 137.36 754.24 26.03 .199172 
Citr 72.97 7.40 99.29 4.30 .008607 
Val 214.08 18.73 257.71 38.76 .358363 
Cys 0.77 0.77 0.00 0.00 .299690 
Met 47.63 6.17 80.77 8.41 .010443 
Ile 89.33 8.10 98.01 8.78 .488275 
Leu 151.51 14.46 155.59 17.94 .865850 
Tyr 62.43 7.85 81.65 5.26 .060810 
Phe 61.23 5.40 68.15 3.44 .288759 
Orn 53.06 8.53 88.89 11.71 .035433 
Lys 255.59 24.42 289.10 20.95 .316951 
1-Mhis 12.05 2.15 11.30 1.31 .765144 
His 66.22 6.47 59.43 3.85 .370413 
Trp 62.68 13.67 45.61 12.15 .369072 
Arg 76.58 11.60 95.65 9.25 .219672 
Hypro 18.79 6.91 28.43 2.98 .203275 
Pro 77.27 10.86 129.72 11.49 .007326 
Amino acid levels are expressed as µmoles/L plasma. 
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APPENDIX B 
70 DAY SALINE TREATMENT PLASMA METABOLITE COMPARISONS 
Table B-1:  List of all mean 70 day saline-treated mouse plasma metabolite values grouped by 
genotype and the corresponding p values obtained from the MANOVA. 
 
 
WT SOD1 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 9.61 2.69 6.09 0.97 .203497 
Taur 328.23 19.93 320.02 26.23 .810515 
Pea 6.11 1.74 1.12 0.61 .008322 
Urea 10638.12 460.47 10526.52 433.47 .861584 
Asp 13.06 1.38 9.15 0.35 .006977 
Thr 200.01 16.49 183.01 7.90 .339951 
Ser 162.33 10.15 144.39 5.37 .116629 
Asn 50.48 5.41 42.92 2.77 .206180 
Glu 14.89 3.65 10.31 3.19 .352352 
Gln 585.30 27.18 593.91 23.94 .813428 
Sarc 9.33 5.38 32.38 5.12 .004920 
AAAA 14.70 2.83 10.63 1.37 .188492 
Gly 314.52 11.57 282.61 19.13 .183576 
Ala 720.05 52.53 593.61 32.61 .045629 
Citr 91.99 6.94 80.81 3.63 .150177 
Val 311.94 24.77 266.01 16.11 .123330 
Cys 13.34 5.45 0.00 0.00 .013968 
Met 98.30 12.32 82.12 6.89 .245710 
Ile 109.92 9.01 97.40 5.14 .222863 
Leu 186.02 15.46 163.87 8.36 .202357 
Tyr 81.54 5.93 73.24 5.06 .293833 
Phe 73.09 4.88 66.56 2.21 .213174 
Orn 87.76 11.50 73.53 5.88 .261826 
Lys 290.03 18.13 280.22 18.74 .712566 
1-Mhis 12.58 1.16 10.91 1.35 .366192 
His 74.71 2.89 72.94 4.16 .738541 
Trp 63.11 5.69 57.25 8.15 .573419 
Arg 108.90 8.30 100.60 7.59 .467178 
Hypro 25.60 6.92 21.00 4.25 .564548 
Pro 116.87 10.32 75.54 11.55 .014711 
Amino acid levels are expressed as µmoles/L plasma. 
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Table B-2:  List of all mean 70 day saline-treated female plasma metabolite values grouped by 
genotype and the corresponding p values obtained from the MANOVA. 
 
 
WT Female SOD1 Female 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 12.69 5.17 5.51 1.32 .176331 
Taur 374.83 20.66 348.69 37.23 .570488 
Pea 11.21 1.40 1.61 1.06 .000168 
Urea 10150.32 674.15 9447.01 548.05 .430534 
Asp 13.26 2.35 9.15 0.60 .095743 
Thr 204.22 30.26 189.55 11.37 .639083 
Ser 173.98 18.82 151.72 6.30 .256377 
Asn 56.77 9.42 47.09 3.20 .321511 
Glu 21.43 5.23 9.55 3.73 .085281 
Gln 638.99 34.74 646.85 25.91 .856985 
Sarc 8.90 5.65 37.80 4.86 .002455 
AAAA 16.12 5.42 11.17 2.71 .410276 
Gly 303.57 18.83 283.98 39.44 .679888 
Ala 766.50 102.31 665.88 31.81 .336704 
Citr 94.21 13.68 84.35 5.54 .494238 
Val 334.47 41.53 256.47 18.31 .097265 
Cys 12.43 7.87 0.00 0.00 .113579 
Met 109.82 18.49 85.19 12.46 .280868 
Ile 123.89 14.72 102.74 5.14 .176130 
Leu 210.02 25.28 170.36 9.44 .146637 
Tyr 84.11 10.23 82.94 6.18 .921283 
Phe 79.47 8.04 71.48 2.11 .323679 
Orn 104.78 18.71 74.15 7.35 .134400 
Lys 317.58 32.62 318.41 17.80 .981690 
1-Mhis 15.07 1.41 12.13 1.58 .198615 
His 81.79 3.31 81.73 6.61 .994224 
Trp 76.07 7.38 71.92 12.69 .792300 
Arg 119.42 14.41 114.79 8.33 .777886 
Hypro 18.35 8.31 13.98 5.14 .653207 
Pro 121.12 20.34 70.32 19.24 .097402 
Amino acid levels are expressed as µmoles/L plasma. 
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Table B-3:  List of all mean 70 day saline-treated male plasma metabolite values grouped by 
genotype and the corresponding p values obtained from the MANOVA. 
 
 
WT Male SOD1 Male 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 6.53 1.14 6.66 1.50 .950618 
Taur 281.63 21.25 291.36 36.36 .829347 
Pea 1.02 1.02 0.63 0.63 .742623 
Urea 11125.92 619.10 11606.02 354.13 .499072 
Asp 12.86 1.68 9.14 0.41 .040910 
Thr 195.79 16.55 176.47 11.26 .343616 
Ser 150.69 6.72 137.06 8.20 .234856 
Asn 44.20 4.91 38.76 4.14 .411383 
Glu 8.34 3.75 11.07 5.48 .699702 
Gln 531.61 29.86 540.98 29.63 .828905 
Sarc 9.77 9.77 26.97 8.95 .220481 
AAAA 13.29 2.27 10.10 0.84 .189239 
Gly 325.48 13.66 281.24 5.40 .008551 
Ala 673.60 28.49 521.33 43.07 .016112 
Citr 89.76 4.80 77.27 4.71 .091535 
Val 289.40 27.79 275.55 27.55 .731536 
Cys 14.25 8.28 0.00 0.00 .087854 
Met 86.78 16.53 79.05 6.87 .656922 
Ile 95.95 7.91 92.07 8.86 .753571 
Leu 162.02 13.50 157.39 14.14 .818810 
Tyr 78.98 6.87 63.54 6.43 .129326 
Phe 66.70 4.90 61.65 2.94 .379318 
Orn 70.73 10.78 72.91 9.78 .883197 
Lys 262.49 8.92 242.03 26.80 .513198 
1-Mhis 10.09 1.22 9.68 2.23 .880259 
His 67.63 2.41 64.16 2.34 .324544 
Trp 50.16 4.57 42.58 7.40 .421331 
Arg 98.38 7.17 86.41 10.63 .387605 
Hypro 32.85 10.99 28.02 5.96 .694851 
Pro 112.63 6.91 80.76 14.11 .081212 
Amino acid levels are expressed as µmoles/L plasma. 
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Table B-4:  List of all mean 70 day saline-treated wild-type mouse plasma metabolite values 
grouped by gender and the corresponding p values obtained from the MANOVA. 
 
 
WT Female WT Male 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 12.69 5.17 6.53 1.14 .272281 
Taur 374.83 20.66 281.63 21.25 .010420 
Pea 11.21 1.40 1.02 1.02 .000153 
Urea 10150.32 674.15 11125.92 619.10 .311531 
Asp 13.26 2.35 12.86 1.68 .892935 
Thr 204.22 30.26 195.79 16.55 .811674 
Ser 173.98 18.82 150.69 6.72 .270784 
Asn 56.77 9.42 44.20 4.91 .263843 
Glu 21.43 5.23 8.34 3.75 .069329 
Gln 638.99 34.74 531.61 29.86 .041048 
Sarc 8.90 5.65 9.77 9.77 .939669 
AAAA 16.12 5.42 13.29 2.27 .640832 
Gly 303.57 18.83 325.48 13.66 .368476 
Ala 766.50 102.31 673.60 28.49 .402286 
Citr 94.21 13.68 89.76 4.80 .765163 
Val 334.47 41.53 289.40 27.79 .388342 
Cys 12.43 7.87 14.25 8.28 .876291 
Met 109.82 18.49 86.78 16.53 .374679 
Ile 123.89 14.72 95.95 7.91 .125514 
Leu 210.02 25.28 162.02 13.50 .124917 
Tyr 84.11 10.23 78.98 6.87 .686404 
Phe 79.47 8.04 66.70 4.90 .205039 
Orn 104.78 18.71 70.73 10.78 .145856 
Lys 317.58 32.62 262.49 8.92 .134341 
1-Mhis 15.07 1.41 10.09 1.22 .023584 
His 81.79 3.31 67.63 2.41 .006124 
Trp 76.07 7.38 50.16 4.57 .013659 
Arg 119.42 14.41 98.38 7.17 .220204 
Hypro 18.35 8.31 32.85 10.99 .317249 
Pro 121.12 20.34 112.63 6.91 .700712 
Amino acid levels are expressed as µmoles/L plasma. 
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Table B-5:  List of all mean 70 day saline-treated SOD1 mouse plasma metabolite values 
grouped by gender and the corresponding p values obtained from the MANOVA. 
 
 
SOD1 Female SOD1 Male 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 5.51 1.32 6.66 1.50 .578220 
Taur 348.69 37.23 291.36 36.36 .292147 
Pea 1.61 1.06 0.63 0.63 .442753 
Urea 9447.01 548.05 11606.02 354.13 .006238 
Asp 9.15 0.60 9.14 0.41 .988134 
Thr 189.55 11.37 176.47 11.26 .429462 
Ser 151.72 6.30 137.06 8.20 .181758 
Asn 47.09 3.20 38.76 4.14 .136933 
Glu 9.55 3.73 11.07 5.48 .822609 
Gln 646.85 25.91 540.98 29.63 .019677 
Sarc 37.80 4.86 26.97 8.95 .308812 
AAAA 11.17 2.71 10.10 0.84 .714570 
Gly 283.98 39.44 281.24 5.40 .946299 
Ala 665.88 31.81 521.33 43.07 .019310 
Citr 84.35 5.54 77.27 4.71 .349278 
Val 256.47 18.31 275.55 27.55 .574656 
Cys 0.00 0.00 0.00 0.00 
 Met 85.19 12.46 79.05 6.87 .673958 
Ile 102.74 5.14 92.07 8.86 .318172 
Leu 170.36 9.44 157.39 14.14 .460239 
Tyr 82.94 6.18 63.54 6.43 .050202 
Phe 71.48 2.11 61.65 2.94 .018749 
Orn 74.15 7.35 72.91 9.78 .921026 
Lys 318.41 17.80 242.03 26.80 .035161 
1-Mhis 12.13 1.58 9.68 2.23 .387300 
His 81.73 6.61 64.16 2.34 .027537 
Trp 71.92 12.69 42.58 7.40 .068969 
Arg 114.79 8.33 86.41 10.63 .057390 
Hypro 13.98 5.14 28.02 5.96 .099441 
Pro 70.32 19.24 80.76 14.11 .669325 
Amino acid levels are expressed as µmoles/L plasma. 
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APPENDIX C 
70 DAY PLASMA MSO-TREATED METABOLITE COMPARISONS 
Table C-1:  List of all mean 70 day wild-type mouse plasma metabolite values grouped by 
treatment and the corresponding p values obtained from the MANOVA. 
 
 
WT Saline WT MSO 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 9.61 2.69 11.43 1.57 .574738 
Taur 328.23 19.93 395.99 41.42 .144739 
Pea 6.11 1.74 9.12 1.82 .246880 
Urea 10638.12 460.47 9146.05 582.81 .055629 
Asp 13.06 1.38 14.83 1.13 .337382 
Thr 200.01 16.49 218.26 13.05 .400963 
Ser 162.33 10.15 176.67 11.16 .351772 
Asn 50.48 5.41 53.13 4.00 .701964 
Glu 14.89 3.65 18.79 4.19 .487941 
Gln 585.30 27.18 557.24 39.21 .557242 
Sarc 9.33 5.38 10.23 5.42 .907711 
AAAA 14.70 2.83 16.05 2.77 .739149 
Gly 314.52 11.57 301.65 19.93 .574421 
Ala 720.05 52.53 844.44 70.01 .165522 
Citr 91.99 6.94 96.57 4.91 .601330 
Val 311.94 24.77 285.58 15.05 .384131 
Cys 13.34 5.45 26.66 5.34 .096435 
Met 98.30 12.32 96.64 8.00 .913104 
Ile 109.92 9.01 107.41 5.43 .817321 
Leu 186.02 15.46 177.73 8.50 .651767 
Tyr 81.54 5.93 89.45 6.28 .369783 
Phe 73.09 4.88 72.20 2.75 .879171 
Orn 87.76 11.50 86.27 7.31 .916251 
Lys 290.03 18.13 352.86 17.99 .022960 
1-Mhis 12.58 1.16 10.83 1.51 .364649 
His 74.71 2.89 77.23 4.06 .613876 
Trp 63.11 5.69 50.43 8.38 .217336 
Arg 108.90 8.30 112.78 7.57 .735051 
Hypro 25.60 6.92 22.87 4.05 .742757 
Pro 116.87 10.32 117.75 9.54 .951244 
Amino acid levels are expressed as µmoles/L plasma. 
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Table C-2:  List of all mean 70 day SOD1 mouse plasma metabolite values grouped by 
treatment and the corresponding p values obtained from the MANOVA. 
 
 
SOD1 Saline SOD1 MSO 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 6.09 0.97 7.09 1.58 .603230 
Taur 320.02 26.23 356.80 17.70 .244954 
Pea 1.12 0.61 4.68 1.16 .014200 
Urea 10526.52 433.47 9882.69 432.57 .304200 
Asp 9.15 0.35 10.40 0.80 .184506 
Thr 183.01 7.90 209.75 13.59 .112417 
Ser 144.39 5.37 153.77 7.17 .315400 
Asn 42.92 2.77 56.49 4.05 .011917 
Glu 10.31 3.19 17.95 3.40 .115627 
Gln 593.91 23.94 449.48 29.23 .000808 
Sarc 32.38 5.12 18.30 3.36 .025673 
AAAA 10.63 1.37 17.60 1.69 .003925 
Gly 282.61 19.13 275.32 10.37 .731411 
Ala 593.61 32.61 743.30 35.23 .004517 
Citr 80.81 3.63 89.36 4.95 .185241 
Val 266.01 16.11 302.59 19.68 .168868 
Cys 0.00 0.00 5.29 2.10 .025781 
Met 82.12 6.89 96.24 6.69 .153442 
Ile 97.40 5.14 105.77 4.69 .238197 
Leu 163.87 8.36 180.33 7.42 .150689 
Tyr 73.24 5.06 80.91 5.05 .294171 
Phe 66.56 2.21 70.29 2.72 .305675 
Orn 73.53 5.88 99.46 7.98 .016463 
Lys 280.22 18.74 358.42 24.71 .020121 
1-Mhis 10.91 1.35 9.47 0.75 .344738 
His 72.94 4.16 73.37 2.40 .927951 
Trp 57.25 8.15 70.90 6.15 .185516 
Arg 100.60 7.59 137.16 10.36 .009664 
Hypro 21.00 4.25 17.40 3.77 .529625 
Pro 75.54 11.55 96.70 11.63 .209456 
Amino acid levels are expressed as µmoles/L plasma. 
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Table C-3:  List of all mean 70 day female wild-type mouse plasma metabolite values grouped 
by treatment and the corresponding p values obtained from the MANOVA. 
 
 
Female Saline Female MSO 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 12.69 5.17 9.70 2.22 .607096 
Taur 374.83 20.66 341.62 18.91 .262994 
Pea 11.21 1.40 9.19 2.39 .483439 
Urea 10150.32 674.15 8484.25 918.68 .174415 
Asp 13.26 2.35 13.28 1.72 .994428 
Thr 204.22 30.26 219.89 24.17 .694414 
Ser 173.98 18.82 185.62 17.78 .662636 
Asn 56.77 9.42 55.01 6.65 .881851 
Glu 21.43 5.23 10.49 3.35 .108579 
Gln 638.99 34.74 587.33 68.26 .515227 
Sarc 8.90 5.65 12.24 8.08 .741493 
AAAA 16.12 5.42 14.28 3.45 .781273 
Gly 303.57 18.83 267.03 26.05 .282248 
Ala 766.50 102.31 888.13 100.72 .416684 
Citr 94.21 13.68 104.92 7.38 .506795 
Val 334.47 41.53 262.41 18.10 .142788 
Cys 12.43 7.87 26.71 8.24 .238523 
Met 109.82 18.49 92.11 14.14 .464140 
Ile 123.89 14.72 106.26 6.78 .302071 
Leu 210.02 25.28 169.97 11.29 .178631 
Tyr 84.11 10.23 89.77 10.82 .711799 
Phe 79.47 8.04 71.71 3.69 .400919 
Orn 104.78 18.71 73.23 9.60 .164447 
Lys 317.58 32.62 377.58 24.88 .174306 
1-Mhis 15.07 1.41 12.52 2.43 .385520 
His 81.79 3.31 83.07 2.54 .764741 
Trp 76.07 7.38 67.40 4.96 .352589 
Arg 119.42 14.41 117.80 9.74 .927223 
Hypro 18.35 8.31 19.72 4.55 .887539 
Pro 121.12 20.34 104.63 11.38 .495285 
Amino acid levels are expressed as µmoles/L plasma. 
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Table C-4:  List of all mean 70 day female SOD1 mouse plasma metabolite values grouped by 
treatment and the corresponding p values obtained from the MANOVA. 
 
 
Female Saline Female MSO 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 5.51 1.32 6.27 1.49 .714939 
Taur 348.69 37.23 382.35 31.45 .498940 
Pea 1.61 1.06 3.63 1.59 .321242 
Urea 9447.01 548.05 9802.29 421.67 .611157 
Asp 9.15 0.60 9.03 0.61 .887741 
Thr 189.55 11.37 221.53 21.19 .225054 
Ser 151.72 6.30 165.77 10.15 .276701 
Asn 47.09 3.20 61.10 6.39 .083888 
Glu 9.55 3.73 13.13 5.43 .606145 
Gln 646.85 25.91 465.34 45.07 .005159 
Sarc 37.80 4.86 20.18 4.86 .024089 
AAAA 11.17 2.71 18.44 2.57 .073518 
Gly 283.98 39.44 260.09 11.90 .549262 
Ala 665.88 31.81 776.21 46.18 .078419 
Citr 84.35 5.54 96.07 6.90 .216917 
Val 256.47 18.31 286.92 19.70 .282501 
Cys 0.00 0.00 3.61 2.89 .265627 
Met 85.19 12.46 100.11 9.14 .343749 
Ile 102.74 5.14 110.23 6.19 .376756 
Leu 170.36 9.44 180.04 9.99 .497543 
Tyr 82.94 6.18 83.05 5.94 .990105 
Phe 71.48 2.11 73.67 3.47 .611836 
Orn 74.15 7.35 101.76 11.42 .071060 
Lys 318.41 17.80 400.52 36.11 .073514 
1-Mhis 12.13 1.58 11.37 0.83 .664781 
His 81.73 6.61 79.65 2.64 .762944 
Trp 71.92 12.69 75.79 11.68 .826045 
Arg 114.79 8.33 152.43 13.55 .039927 
Hypro 13.98 5.14 11.44 4.56 .717204 
Pro 70.32 19.24 81.94 20.17 .685982 
Amino acid levels are expressed as µmoles/L plasma. 
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Table C-5:  List of all mean 70 day male wild-type mouse plasma metabolite values grouped by 
treatment and the corresponding p values obtained from the MANOVA. 
 
 
Male Saline Male MSO 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 6.53 1.14 13.50 2.05 .012415 
Taur 281.63 21.25 461.24 83.37 .048706 
Pea 1.02 1.02 9.02 3.10 .026201 
Urea 11125.92 619.10 9940.21 559.60 .196810 
Asp 12.86 1.68 16.70 1.03 .098440 
Thr 195.79 16.55 216.30 7.62 .321409 
Ser 150.69 6.72 165.93 12.59 .290549 
Asn 44.20 4.91 50.88 4.43 .347640 
Glu 8.34 3.75 28.75 5.84 .013997 
Gln 531.61 29.86 521.15 29.52 .810698 
Sarc 9.77 9.77 7.82 7.82 .883291 
AAAA 13.29 2.27 18.16 4.73 .351081 
Gly 325.48 13.66 343.19 19.40 .463303 
Ala 673.60 28.49 792.01 102.36 .256051 
Citr 89.76 4.80 86.56 2.18 .585681 
Val 289.40 27.79 313.39 20.01 .517898 
Cys 14.25 8.28 26.60 7.41 .304452 
Met 86.78 16.53 102.09 6.17 .443573 
Ile 95.95 7.91 108.78 9.60 .324728 
Leu 162.02 13.50 187.05 12.91 .218733 
Tyr 78.98 6.87 89.07 6.39 .318011 
Phe 66.70 4.90 72.80 4.58 .394486 
Orn 70.73 10.78 101.92 6.61 .044017 
Lys 262.49 8.92 323.20 21.19 .020005 
1-Mhis 10.09 1.22 8.80 1.36 .497626 
His 67.63 2.41 70.22 7.64 .734478 
Trp 50.16 4.57 30.05 12.61 .140806 
Arg 98.38 7.17 106.75 12.49 .558197 
Hypro 32.85 10.99 26.64 7.27 .663518 
Pro 112.63 6.91 133.49 13.89 .188968 
Amino acid levels are expressed as µmoles/L plasma. 
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Table C-6:  List of all mean 70 day male SOD1 mouse plasma metabolite values grouped by 
treatment and the corresponding p values obtained from the MANOVA. 
 
 
Male Saline Male MSO 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 6.66 1.50 7.92 2.87 .715006 
Taur 291.36 36.36 331.25 12.93 .295047 
Pea 0.63 0.63 5.72 1.70 .019937 
Urea 11606.02 354.13 9963.08 788.85 .093929 
Asp 9.14 0.41 11.77 1.36 .105537 
Thr 176.47 11.26 197.97 17.38 .333528 
Ser 137.06 8.20 141.76 8.73 .703881 
Asn 38.76 4.14 51.89 4.82 .062755 
Glu 11.07 5.48 22.76 3.66 .092641 
Gln 540.98 29.63 433.62 39.49 .053598 
Sarc 26.97 8.95 16.41 4.87 .302371 
AAAA 10.10 0.84 16.76 2.33 .024692 
Gly 281.24 5.40 290.55 15.89 .609440 
Ala 521.33 43.07 710.40 53.65 .018407 
Citr 77.27 4.71 82.64 6.67 .533401 
Val 275.55 27.55 318.25 34.68 .362182 
Cys 0.00 0.00 6.96 3.11 .057373 
Met 79.05 6.87 92.37 10.19 .312487 
Ile 92.07 8.86 101.32 7.09 .424863 
Leu 157.39 14.14 180.63 11.67 .223170 
Tyr 63.54 6.43 78.77 8.52 .186732 
Phe 61.65 2.94 66.91 4.05 .324974 
Orn 72.91 9.78 97.17 11.88 .145803 
Lys 242.03 26.80 316.32 28.40 .081930 
1-Mhis 9.68 2.23 7.56 0.84 .365141 
His 64.16 2.34 67.09 2.52 .414048 
Trp 42.58 7.40 66.02 4.31 .014299 
Arg 86.41 10.63 121.90 14.48 .076323 
Hypro 28.02 5.96 23.35 5.47 .572899 
Pro 80.76 14.11 111.47 10.51 .099526 
Amino acid levels are expressed as µmoles/L plasma. 
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APPENDIX D 
THE EFFECTS OF OVARIECTOMIZATION ON PLASMA METABOLITES 
Table D-1:  List of all mean 70 day saline-treated female plasma metabolite values grouped by 
intact or removed gonads and the corresponding p values obtained from the MANOVA. 
 
 
Intact Females OVR Females 
 Metabolite Mean SEM Mean SEM p (MANOVA) 
Phser 5.51 1.32 2.96 0.69 .076841 
Taur 348.69 37.23 270.76 16.02 .034264 
Pea 1.61 1.06 1.39 0.71 .974615 
Urea 9447.01 548.05 8408.40 366.88 .121846 
Asp 9.15 0.60 4.57 1.67 .035407 
Thr 189.55 11.37 153.59 10.79 .056491 
Ser 151.72 6.30 120.88 5.90 .003138 
Asn 47.09 3.20 43.81 3.17 .525487 
Glu 9.55 3.73 14.23 0.97 .184986 
Gln 646.85 25.91 630.12 19.32 .429163 
Sarc 37.80 4.86 0.00 0.00 .000000 
AAAA 11.17 2.71 19.59 1.41 .006611 
Gly 283.98 39.44 253.01 8.86 .375726 
Ala 665.88 31.81 569.99 40.38 .119981 
Citr 84.35 5.54 96.22 6.29 .189837 
Val 256.47 18.31 224.09 17.66 .231240 
Cys 0.00 0.00 0.00 0.00 
 Met 85.19 12.46 64.71 5.39 .171933 
Ile 102.74 5.14 99.05 8.44 .701062 
Leu 170.36 9.44 152.26 9.79 .176260 
Tyr 82.94 6.18 85.56 6.33 .729931 
Phe 71.48 2.11 69.30 3.51 .730354 
Orn 74.15 7.35 65.25 4.66 .292058 
Lys 318.41 17.80 249.69 16.00 .014590 
1-Mhis 12.13 1.58 11.94 1.21 .950118 
His 81.73 6.61 62.77 2.81 .013492 
Trp 71.92 12.69 69.96 4.13 .861269 
Arg 114.79 8.33 101.39 6.38 .230145 
Hypro 13.98 5.14 8.90 2.57 .376231 
Pro 70.32 19.24 113.06 6.48 .017115 
Amino acid levels are expressed as µmoles/L plasma. 
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 Amyotrophic Lateral Sclerosis (ALS) is a devastating neurodegenerative disease 
characterized by motor neuron death and a corresponding loss of neuromuscular connections 
resulting in muscle atrophy.  Patients become paralyzed shortly after symptom onset and 
typically die within one to five years of pulmonary complications.  ALS is a relatively rare 
disease, with an overall incidence of approximately 2 in 100,000 people per year and a 
prevalence of about 5 in 100,000 people.  It is typically associated with increasing age and has 
a slight male prevalence, with a male to female ratio of approximately 3:2.  ALS is classified as 
either familial (the less common form of the disease that has a hereditary component) or 
sporadic (the more common form that has no identifiable genetic component), with both forms of 
the disease exhibiting a great deal of heterogeneity with respect to causes and underlying 
molecular mechanisms.  A wide variety of gene mutations have been associated with both 
forms of ALS, including mutations in superoxide dismutase 1 (SOD1), TDP-43, and FUS, as 
well as several other genes that have yet to be identified.  These genes encode a variety of 
proteins that encompass several processes within the cell, leading to an array of molecular 
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mechanisms that can become dysfunctional during pathogenesis.  These mechanisms include, 
glutamate excitotoxicity, mitochondrial dysfunction and oxidative stress, dysfunctional protein 
quality control, aberrant mRNA processing, neurotrophic factor dysregulation, and 
neuroinflammation.  ALS is difficult to diagnose due to the heterogeneity of symptoms exhibited 
by patients and the lack of reliable biomarkers of the disease.  As a result, a positive diagnosis 
typically takes up to a year from symptom onset, at which time a significant amount of 
irreversible damage has occurred.   
 Since ALS is a neurodegenerative disease, most research focuses on the central 
nervous system, however data obtained from ALS patients and animal models suggests that 
there are metabolic abnormalities associated with the disease.  The experiments conducted in 
this study first examined gender differences in the survival response to an irreversible inhibitor 
of glutamine synthetase, L-methionine sulfoximine (MSO), which targets excitotoxicity using the 
SOD1-G93A transgenic mouse model of ALS.  Human studies have shown that there are 
gender differences in basic metabolism, and studies of drug metabolism in rats and humans 
suggest that males and females may respond differently to treatment.  The results of these 
experiments show that female SOD1 mice respond better to MSO treatment, showing both an 
extension in the average lifespan as well as improved neuromuscular function with MSO 
treatment.   In addition, ovariectomy removes the beneficial effects of MSO treatment on both 
survival and neuromuscular function.  The second portion of this study was designed to test the 
hypothesis that the SOD1 mutation disrupts nitrogen metabolism, specifically the urea cycle.  
The results of these studies show that untreated presymptomatic SOD1 mice have altered 
nitrogen metabolism and show decreased levels of several urea cycle intermediates in the 
plasma compared to their wild-type counterparts.  These plasma metabolites also show gender-
specific differences in wild-type and SOD1 mice, supporting the idea that male and female mice 
have differences in metabolism.  Plasma metabolites change with age and suggest that there 
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are compensatory mechanisms that aid in normalizing plasma metabolites in SOD1 mice.  
Again, these metabolites show gender-specificity and MSO treatment normalizes the levels of 
these metabolites in a gender-specific fashion in SOD1 mice.  Studies of nitrogen handling 
enzymes also show that there are gender-specific differences in CPSI activity levels that are not 
associated with expression of the transgene.  Male SOD1 mice begin to show changes in 
nitrogen handling enzymes in the liver, specifically glutamine synthetase and CPSI, suggesting 
that males may begin to experience alterations in nitrogen metabolism prior to symptom onset 
that may help to explain the gender-specific effects of MSO treatment in this mouse model.       
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